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ABSTRACT 
 
The tumor suppressor DAB2IP is a cytoplasmic signaling protein that modulates the intricate 
network of information established among cancer cells and their microenvironment. Behaving as 
a guardian of signal transduction, DAB2IP modulates pathways activated by several growth 
factors and inflammatory cytokines, including TNFα, thus affecting the cancer cells’ responses 
to extrinsic inputs. The gene is seldom mutated in cancer, but DAB2IP inactivation mediated by 
epigenetic or post-transcriptional means is frequently observed in human malignancies. Since 
DAB2IP inactivation can potentially favor progression of tumors driven by a variety of diverse 
genetic mutations, post-transcriptional inactivation of this protein may be even more diffuse.  
This Thesis describes two different projects aimed to identify additional molecular mechanisms 
to counteract DAB2IP tumor suppressive functions in cancer. 
 
 The first project describes a mechanism of DAB2IP inactivation mediated by physical 
interaction with mutant forms of the p53 tumor suppressor. I demonstrated that mutant p53 binds 
DAB2IP in the cytoplasm, blocking its inhibitory role on NF-κB and counteracting the activation 
of JNK/ASK1 pathway, thus reprogramming the way cancer cells respond to TNF. Importantly, 
through this mechanism, mutant p53 sustains a pro-invasive response to inflammation, also 
restraining apoptosis. Intriguingly, this action is coupled to increased expression of a set of 
chemokines that can expose tumor cells to host immunity, potentially affecting response to 
therapy and patient outcome. 
Finally, I obtained proof-of-concept evidence that overexpression of a decoy protein able to 
displace mutp53-DAB2IP interaction reduces tumor growth and invasion in vivo, suggesting that 
this molecular axis may be a promising therapeutic target. 
 
 The second project is focused on DAB2IP inactivation by microRNAs. Performing a 
high-throughput screen of a large collection of human miRNA mimics, I identified a consistent 
number of miRNAs targeting the DAB2IP mRNA. Among the hits, I demonstrated that two 
different miRNAs can efficiently down-regulate DAB2IP protein in multiple transformed cell 
lines, strongly enhancing cancer cells motility and invasivity. Focusing on the most active 
miRNA isolated, I confirmed that it promotes cancer cell invasivity by reducing DAB2IP levels, 
and this phenotype is likely mediated by sustained activation of NF-κB and increased expression 
of pro-inflammatory cytokines. Importantly, I demonstrated that the use of specific miRNA 
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inhibitors, or target protectors, restores DAB2IP activity and strongly reduces invasiveness of 
PC-3 prostate cancer cells. 
 
Collectively, my results provide additional knowledge on the post-transcriptional mechanisms of 
DAB2IP inactivation in cancer, and offer solid conceptual grounds to hypothesize that 
therapeutic tools able to restore DAB2IP functions in tumor cells, by counteracting the 
mechanisms of its inactivation, would efficiently contrast cancer progression. 
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FOREWORD 
This Thesis is composed of two different projects. Although they concern the analysis of 
mechanisms involved in the inactivation of the tumor suppressor DAB2IP in cancer, they are 
markedly distinct; for this reason I discussed them separately.  
 
In Part 1, I wrote an extensive introduction on the tumor suppressor DAB2IP. 
 
In Part 2, I described studies on the interaction between mutant p53 and DAB2IP in cancer 
progression. Since this work has been recently published, I enclosed the paper reprint, correlated 
with a specific introduction. 
 
Part 3 is relative to unpublished work focused on the identification of microRNAs targeting 
DAB2IP. It includes a specific introduction, results, discussion and description of experimental 
procedures used.  
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PART 1: DAB2IP AS A KEY GUARDIAN OF CYTOPLASMIC SIGNAL 
TRANSDUCTION 
1.1 CANCER: AN OVERVIEW 
Cancer formation, as we currently understand it, involves multiple changes in the regulatory 
circuits that finely modulate proliferation and homeostasis of normal cells. Cancer has 
traditionally been viewed as a set of diseases driven by the activation of proto-oncogenes and by 
the inactivation of tumor suppressor genes (Hanahan and Weinberg, 2000). 
In addition to mutations, the disruption of epigenetic regulatory mechanisms is also prevalent in 
cancer cells, so that genetic and epigenetic alterations interplay and synergize during 
tumorigenesis (You and Jones, 2012). In addition, long non-coding RNAs (ncRNAs) and micro-
RNAs (miRNAs) are emerging as important regulatory molecules in tumor suppressor and 
oncogenic pathways (Huarte and Rinn, 2010), and defects in miRNA activity and processing are 
a common hallmark of the disease (Esteller, 2011).  
As normal cell evolves progressively to a neoplastic state, it acquires a set of common features 
that include self-sufficiency in growth signals, insensitivity to growth inhibition, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (Hanahan and Weinberg, 2000). In addition to these hallmarks of 
cancer, tumors benefit from changes in cell metabolism to sustain increased proliferation 
(Hanahan and Weinberg, 2011) and from the inflammatory microenvironment and the ability to 
avoid immune control (Colotta et al., 2009).  
Notably, tumors are much more than insular masses of proliferating cells; they are complex 
tissues composed by multiple cell types that establish dynamic interactions with one another. 
The complexity of the tumor tissue also resides in the intricate network established between 
tumor cells and the surrounding environment, and the traffic of information shared among 
distinct cells. 
Evidences collected in the last decade have introduced DAB2IP (Disable-2 Interactin Protein) as 
a new tumor suppressor able to modulate different cytoplasmic signaling pathways; this protein 
is frequently down-regulated in tumors, and loss of its oncosuppressive role seems to strongly 
impact tumor progression. 
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1.2 THE TUMOR SUPPRESSOR DAB2IP 
 
DAB2IP was initially identified as a novel member of the RAS GTP-ase (RAS GAP) protein 
family, cloned specifically as a protein interacting with the tumor suppressor DOC-2/DAB2 
(differentially expressed in ovarian carcinoma-2/Disable-2) both in normal tissues and in 
prostate cancer (Chen et al., 2002; Wang et al., 2002). The heterogeneous role of DAB2IP 
emerged immediately: indeed this protein was concomitantly cloned and identified as an ASK1-
interacting protein; hence the alternative name ASK-interacting protein 1 (AIP1) (Zhang et al., 
2003). In the subsequent years a lot of works have explored the important role of DAB2IP as 
modulator of other signaling pathways, pointing out its relevance as guardian of cytoplasmic 
signaling transduction. This protein turned out to be a regulator of cell response to different 
extracellular stimuli, such as TNF (tumor necrosis factor) or EGF (epidermal growth factor), 
affecting cell survival, migration and apoptosis with obvious implications for cancer 
development and progression. 
 
1.2.1 Human DAB2IP gene  
The human DAB2IP gene is located on chromosome 9q33.1-q33.3. It is rather complex, and can 
express multiple transcripts and proteins. Two human transcripts and proteins are annotated in 
RefSeq: hDAB2IP transcript variant 1 (NM_032552.3), and hDAB2IP transcript variant 2 
(NM_138709.1). They are transcribed by different promoters, and encode predicted proteins that 
differ in their N-terminus (variant 1 being 96 amino acids longer) and have an alternative C-
terminal exon (Chen et al., 2006; Chen et al., 2002). 
The hDAB2IP gene is ubiquitously expressed in different tissues and organs. Low levels of its 
transcript are found only in seminal vesicle, ventral prostate, epididymis, and bladder (Wang et 
al., 2002). hDAB2IP transcript variant 1 seems to be the dominant isoform expressed in normal 
tissues (Qiu et al., 2007). During development, hDAB2IP is expressed in most human fetal 
tissues, in a gestational age- and tissue-type specific manner. These data suggest that DAB2IP 
plays a unique physiological role in organogenesis and in regulation of tissues or cells 
differentiation (Liu et al., 2012).   
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1.2.2 DAB2IP protein structure  
DAB2IP can modulate the response of cells to a variety of extracellular signals. Its function 
strongly depends on its complex structure, well conserved in mammalians, which contains 
several domains (Chen et al., 2002). 
 
 
Figure 1.1. DAB2IP functional domains.  
Schematic representation of DAB2IP (isoform 2) domains (see the text for additional details).  	  
 
• Pleckstring homology domain (PH domain): it is an approximately 100-residue protein 
module, localized on the N-terminal of DAB2IP. It characterizes a wide range of proteins 
involved in intracellular signaling. This domain can bind phosphatidylinositol lipids 
within biological membranes, such as phosphatidylinositol (3,4,5)-triphosphate and 
phosphatidylinositol (4,5)-bisphosphate (Musacchio et al., 1993).  
• Protein kinase C conserved region 2 (C2 domain): it is a Ca2+ binding motif, 
approximately 130 residues in length; single and multiple copies of C2 domains have 
been identified in several signaling proteins that mediate a broad array of critical 
intracellular processes. This domain displays the remarkable property of binding a variety 
of different ligand and substrates such as Ca2+, phospholipids, inositol polyphosphates, 
and intracellular proteins (Nalefski and Falke, 1996). 
• Ras GTPase-activator protein (RasGAP domain): it is found in proteins involved in 
protein synthesis and signal transduction. Many of these proteins are much larger and 
more complex than their targets, containing multiple domains capable of interacting with 
an intricate network of cellular enzymes and structures (Boguski and McCormick, 1993).  
• Proline rich domain (PR domain): it is a domain implicated in protein-protein 
interactions, in particular it is a docking site for proteins with SH3 domains (Feller et al., 
1994). 
• Period-like domain (PER domain): a non-described structure, involved in protein-protein 
interaction. 
• Leucine zipper domain: it is a hydrophobic motif, usually found within the DNA-binding 
domain of transcription factors. It is involved in the formation of protein dimers. 
PH C2 GAP PER PR LZ
1 80 186 522 1066
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In humans, there are at least two DAB2IP isoforms, derived from the alternative transcripts 
described above. Human DAB2IP isoform 1 (NP_115941) is composed of 1132 amino acids, 
with a molecular weight of approximately 130kDa.  Human DAB2IP isoform 2 (NP_619723) is 
composed of 1066 amino acids, with a molecular weight of 110 kDa. Both isoforms share the 
same structure (Figure 1.1), but differ at their N- and C-terminal ends. hDAB2IP variant 1 has a 
longer PH domain compared to hDAB2IP variant 2. Variant 2 has an alternative C-terminal 
sequence, encoding a class-I PDZ interacting motif that may allow additional protein-protein 
interactions. However, very little information is currently available on the expression and 
function of the different proteins potentially encoded by this complex gene, with most published 
functional studies performed with isoform 2.  
 
The abundance of DAB2IP’s domains underlies the multiple functions of this protein. First, 
DAB2IP has an enzymatic activity, whose core lies in its RasGAP domain. In addition, through 
its domains specialized in protein-protein binding, DAB2IP can act on one side as an adaptor, or 
scaffold, to promote formation of protein complexes involved in signal transduction, and on the 
other side it can act as a competitor, or scavenger, binding signaling proteins and preventing 
their interaction with upstream activators, or downstream effectors. Table 1.1 summarizes 
currently known interactors of DAB2IP, and the domains involved in the binding. 
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Table 1.1: DAB2IP can interact with several proteins involved in signal transduction, affecting the outcome of 
multiple cellular inputs 
DAB2IP 
domain 
Interacting protein Biological effect of the binding: Ref. 
PH IRE1α 
 
It enhances IRE1α, and ASK1-JNK activation upon ER 
stress 
(Luo et al., 
2008) 
C2 ASK1 
(K154-161 residues-KA2) 
It prevents ASK1 binding to 14-3-3 and enhances TNF- 
induced ASK1-JNK activation 
(Zhang et 
al., 2003) 
GSK3β 
 
It facilitates GSK3β de-phosphorylation and decreases 
transcriptional activity of β-catenin  
(Xie et al., 
2010) 
VEGFR-2 
(K104-106 residues-KA1) 
It inhibits auto-phosphorylation of VEGFR-2 and 
counteracts VEGFR-2 mediated angiogenic signals 
(Zhang et 
al., 2008) 
mutant p53  It counteracts the binding of DAB2IP with ASK1, 
prevents JNK phosphorylation and enhances NF-κB 
activation in response to TNF  
(Di Minin 
et al., 
2014) 
PH-C2  JAK2 It inhibits JAK2, STAT1 and STAT3 phosphorylation 
and activation upon IFN-γ treatment  
(Yu et al., 
2011) 
N-terminal VEGFR-3 It facilitates VEGFR-3 stabilization and activity 
(mechanism not completely understood) 
(Zhou et 
al., 2014b) 
GAP RAS 
 
Inactivates RAS (Wang et 
al., 2002) 
PP2A 
 
DAB2IP facilitates PP2A-ASK1 interaction, and the 
subsequent dephosphorylation and activation of ASK1 
in response to TNF 
(Min et al., 
2008) 
HIPK1 
 
It induces dissociation of ASK1 from its inhibitors 14-
3-3 and thioredoxin, and induces ASK1 activation. 
(Li et al., 
2005) 
RIP-1 
 
It promotes DAB2IP phosphorylation is ser-604 and 
stimulates DAB2IP activation upon TNF treatment 
(Zhang et 
al., 2007) 
PER TRAF2 
 
It enhances TNF- induced JNK activation, while 
counteracts NF-κB cascade 
(Zhang et 
al., 2004) 
14-3-3 It prevents the binding between 14-3-3- and ASK1  (Zhang et 
al., 2007) 
AKT1 It counteracts activation of AKT1 (Xie et al., 
2009) 
PR p85(PI3K) It sequesters p85-p110 complex and inhibits PI3K 
activity and AKT activation 
(Xie et al., 
2009) 
c-Src 
 
It disrupts the interaction between c-Src and AR, and 
blocks AR activation 
(Wu et al., 
2014) 
LZ GATA-1 It regulates CD117 expression (Yun et al., 
2015) 
Undefined DOC/DAB-2 It negatively modulates RAS pathway (Wang et 
al., 2002) 
DAB-1 It negatively modulates RAS pathway (Wang et 
al., 2002) 
FBW7 It promotes the degradation of DAB2IP 
 
(Dai et al., 
2014) 
TNFR-2 TNFR-2 binds to DAB2IP and ASK1 to activate JNK (Ji et al., 
2012) 
Skp2 
(N-term and C-term) 
It mediates DAB2IP ubiquitination and proteasome 
degradation 
(Tsai et al., 
2014) 
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1.2.3 DAB2IP functional activities 
 
DAB2IP as a GTPase Activating Protein     
The RasGAP domain of DAB2IP shows a high degree of amino acids homology (40%-90%) 
with other RasGAPs, such as GAP120 and homo sapiens neurofibrin (NF1) (Chen et al., 2002). 
DAB2IP is able to stimulate in-vitro and in-vivo activity of several RAS protein (i.e. H-Ras, K-
Ras and N-Ras) in prostate and hepatocellular cancer 
cell lines, and in acute myeloid leukemia cells 
(Calvisi et al., 2011; Homayouni et al., 2003; Min et 
al., 2010; von Bergh et al., 2004). In the absence of 
Ras mutations, down-regulation of DAB2IP was 
found in highly proliferative human liver and in 
prostate cancers (Calvisi et al., 2011; Min et al., 
2010). The reactivation of DAB2IP activity, through 
protein overexpression inhibits tumor cells 
proliferation and induced apoptosis (Calvisi et al., 
2011). The GAP domain of DAB2IP is necessary for 
this function: mutation of a key amino acid in this 
domain (R289L) abolishes selectively the Ras-GAP 
activity (Min et al., 2010).  
In Acute Myeloid Leukemia, DAB2IP was 
identified as a novel MLL fusion partner, because of the translocation t(9,11)(q34;q23). The PH 
domain of DAB2IP is disrupted, and the normal function of DAB2IP is aborted; that implies a 
deregulation of RAS activity, which could be involved in leukemia transformations (von Bergh 
et al., 2004).  
In endothelial cells, the GAP activity of DAB2IP may also play an inhibitory role in LPS-
induced NF-κB and MAPK signaling pathways, by acting on the trafficking regulator Arf6, the 
best characterized activator of PIP5K (phosphatidylinositol 4-phosphate 5-kinase) (Wan et al., 
2010). Although the authors could not clearly demonstrate that DAB2IP functions as a GTPase-
activating protein for Arf6, they demonstrated that DAB2IP down-regulates cellular PIP2 
(phosphatidylinositol 4,5-bisphosphate) levels, and inhibits TLR4-dependent activation of NF-
κB and MAPK signaling pathways in a way that requires its Ras GAP domain (Wan et al., 
2010). 
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DAB2IP as a cytoplasmic scaffold or competitor 
DAB2IP was initially identified as an interactor of the adaptor protein DAB2/DOC-2 (Disable-2/ 
differentially express in ovarian carcinoma-2) in human prostate cancer cell (Wang et al., 2002). 
DAB2/DOC2 and DAB2IP appear to form a unique regulatory complex that acts as negative 
feedback machinery for several exogenous stimuli. The protein kinase PKC can phosphorylate 
the N-terminal domain of DAB2/DOC2, which recruits DAB2IP to inactivate Ras protein 
through its Ras GAP activity (Wang et al., 2002). On the other hand, shortly after the stimulation 
with growth factors, DAB2/DOC2 competes with SOS for the binding with Grb2, which leads to 
the inactivation of MAP kinase signaling (Wang et al., 2002). Therefore, the DAB2/DOC2 
binding with DAB2IP has an important role in the control of cell proliferation and 
differentiation. Altered expression of these two proteins is often detected in prostate, ovarian, 
and breast cancer cells, and induces uncontrolled tumor growth and increased tumor 
aggressiveness (Wang et al., 2002). 
Similarly, DAB2IP modulates many cellular pathways, by forming specific and dynamic protein 
complexes with a remarkable number of different signal transducers. 
 
Activation of the ASK1-JNK signaling cascade 
ASK1 (apoptosis signal-regulating kinase 1) is a member of the MAP kinases family (MAP3K) 
and is an upstream activator of JNK (c-Jun N-terminal kinase) and p38 MAPK (Davis, 2000). 
ASK1 can be activated in response to various extracellular signals, including pro-apoptotic 
stimuli such as pro-inflammatory cytokines, and reactive oxygen species; one of the most 
important activator of ASK1 is TNF alpha (tumor necrosis factor alpha) (Davis, 2000). DAB2IP 
carries out a key role in ASK1 activation upon TNFα stimulation. In endothelial and cancer cells, 
TNFα stimulates the activation of two distinct and opposite cytoplasmic pathways: ASK1/JNK 
or NF-κB signaling. The regulation of this cytoplasmic signal transduction is rather complex. 
When TNFα binds its receptor, TNFR1, it induces detachment between TNRF1 and its inhibitor 
SODD (silencer of death-domains). Once activated, TNFR1 can be bound by TRADD (TNFR- 
associated death domain protein), and recruits TRAF2 and RIP1 (receptor-interacting protein-1) 
(Hsu et al., 1995; Jiang et al., 1999). This minimal complex catalyzes the formation of a multi-
proteins complex, recruiting either the IκB kinase complex (IKK) or ASK1, leading to activation 
of the NF-κB and JNK pathways, respectively (Kalliolias and Ivashkiv, 2016). DAB2IP 
functions by specifying TRAF2 towards ASK1-JNK pathway activation, enforcing at different 
levels this signaling cascade. In particular, DAB2IP, through PH/C2 domain, binds the 
cytoplasmic membrane, in a closed and inactive conformation. 
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Upon TNFα stimulation, this protein detaches from plasma membrane and shuttles in the 
cytoplasm, where it binds TRAF2 (Zhang et al., 
2004; Zhang et al., 2003). This interaction 
sequesters TRAF2 from the NF-κB activating 
complex, allowing formation of a complex 
composed of TRADD, TRAF2, RIP1 and DAB2IP 
(the so called AIP1 complex) in the cytoplasm 
(Zhang et al., 2004). In the formation of this 
complex, RIP1 seems to be important to modulate 
DAB2IP activity (Zhang et al., 2007): this kinase 
binds DAB2IP on its GAP domain (Table 1.1), and 
mediates its phosphorylation on Serine 604, 
inducing a conformational change and allowing the 
binding of DAB2IP with the other protein complex 
members, especially with ASK1. Protein 14-3-3, a 
phosphoserine-binding protein, binds to ASK1, 
when phosphorylated on Ser-967 and inhibits its 
function. When phosphorylated on Ser-604, 
DAB2IP binds ASK1 causing the release of 
inhibitory 14-3-3 protein, thus activating ASK1 
(Zhang et al., 2007). Mutation of Ser-604 in 
DAB2IP blocks formation of the AIP1 complex, as 
well as TNF-induced ASK1-JNK activation, 
suggesting that it plays a critical role in this 
mechanism (Zhang et al., 2007). Indeed, in cells 
that express this particular mutant, TNF stimulation 
mainly sustains NF-κB pathway activation, 
promoting EMT and cell invasion (Min et al., 
2010).  
The activation of ASK1 is protracted also by PP2A-
dependent dephosphorylation of Ser-967. DAB2IP 
binds the Ser/Thr phosphatase PP2A through the 
GAP domain (Table 1.1) in resting and TNF-
stimulated cells (Min et al., 2008), and functions as a scaffold in TNF-induced recruitment of 
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PP2A to ASK1, leading to de-phosphorylation of Ser-967 and further activation of ASK1 (Min 
et al., 2008). Notably, PP2A is one of the major Ser/Thr phosphates implicated in the regulation 
of many cellular processes and signal transduction pathways (Sangodkar et al., 2015). Despite 
the high number of signaling kinases, a relatively limited number of Ser/Thr-specific 
phosphatases are known to antagonize them. Therefore, substrate specificity is determined by 
adaptor proteins, such as DAB2IP, which thus play a crucial regulatory role. 
This model is well characterized in endothelial cells (Zhang et al., 2004), but is likely conserved 
in most cell types, including cancer cells, and defines DAB2IP as a determinant in driving the 
response to TNFα toward TRAF2- dependent ASK1/JNK activation, while indirectly inhibiting 
IKK/NF-κB branch (Zhang et al., 2004). 
TNFR2 expression is limited to specific cell types, including endothelial cells, cardiac myocytes 
and hematopoietic cells (Carpentier et al., 2004) and is involved in the activation of canonical, 
and non-canonical NF-κB pathway as well as JNK pathway (Carpentier et al., 2004). Again, 
DAB2IP association with TNFR2 is required for TNFR2-dependent JNK and apoptotic signaling 
in vascular endothelial cells, where it can affect vascular disease progression (Ji et al., 2012). 
 
Notably, DAB2IP can sustain ASK1/JNK pathway activation also acting as a scaffold in another 
protein complex. HIPK1 (Homeodomain-interacting protein kinase 1), a kinase that leads to 
activation of apoptotic pathways upon various stress signals (Isono et al., 2006), was shown to 
form a ternary complex with DAB2IP and ASK1 upon TNF stimulation in endothelial cells 
(Table 1.1) (Li et al., 2005). Under these conditions DAB2IP and HIPK1 synergize to promote 
stress-induced activation of the ASK1-JNK/p38 pathway (Li et al., 2005). 
 
Another condition in which DAB2IP promotes ASK1-JNK/p38 signaling is during the Unfolded 
Protein Response (UPR). In the lumen of the endoplasmic reticulum (ER) maturation of proteins 
requires the coordinated activity of many chaperones and folding enzymes. When unfolded 
proteins accumulate, the cell is said to undergo “ER stress” and elicits a homeostatic UPR 
(Clarke et al., 2014). Three different receptors, localized on the ER membrane, act as sensors of 
ER stress, and induce the activation of various effectors and cellular process. These sensors are 
activating transcription factor (ATF) 6, the trans-membrane kinase PERK (PKR-like ER kinase) 
and the kinase with ribonuclease activity IRE1α (inositol-requiring enzyme-1) (Jager et al., 
2012). 
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Activated IRE1α catalyzes cytoplasmic splicing of 
the mRNA encoding the Xbp1 transcription factor, 
which translates an alternative protein, Xbp1s that 
activates expression of a broad set of UPR 
response genes. In addition, IRE1α also triggers 
the activation of pro-apoptotic JNK signaling 
through recruitment of the TRAF2-ASK1 complex 
(Jager et al., 2012). 
Endothelial cells from DAB2IP knockout (KO) 
mice show dramatic reduction in the response to 
ER-stress mediated by IRE1α/JNK axis (Luo et 
al., 2008). Apparently, the other UPR signaling 
axes are not blunted in DAB2IP KO mice. This 
because DAB2IP binds directly to IRE1α (Table 
1.1), facilitates its dimerization, and behaves as a 
scaffold protein to mediate JNK phosphorylation by the kinase IRE1α (Luo et al., 2008).  
Cancer cells are constantly exposed to ER stress by expression of aberrant proteins, limited 
availability of sugars for protein glycosylation, chronic hypoxia and inflammation in the tumor 
niche, and also the effects of chemotherapeutic drugs (Clarke et al., 2014). The impact of the 
UPR in cancer remains controversial, as it can lead to cell elimination by apoptosis, but also to 
cell survival and adaptation. In this scenario, the role of DAB2IP in promoting ER-stress induced 
activation of the ASK1-JNK axis might have a tumor-suppressive function. 
 
Negative modulation of Androgen receptor signaling 
The androgen receptor (AR) regulates normal prostate development as well as critical growth 
and survival programs in prostate carcinoma. Multiple mechanisms lead to hyperactive AR 
signaling, including AR mutation or amplification, altered expression of AR co-activators and 
co-repressor or presence of androgen regulated promoters fused with ERG and other ETS-family 
transcription factors (Robinson et al., 2015). DAB2IP can inhibit AR-mediated prostate cancer 
cell growth via distinct mechanism (Wu et al., 2014). First, AR activity is inhibited by 
DAB2IP/PP2A complex (Wu et al., 2014). DAB2IP acts as a scaffold protein for PP2A, driving 
this phosphatase to multiple substrates. Phosphorylation in Ser-81 is essential for AR function, 
and appears to mediate chromatin binding and transcriptional activation in response to androgen 
stimulation (Chen et al., 2012). DAB2IP, through the binding with PP2A, is able to suppress 
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DHT-elicited Ser-81 phosphorylation of AR, preventing its nuclear translocation and binding to 
androgen response elements. Notably, DAB2IP can exert this inhibition on different AR splice 
variants (Wu et al., 2014). Moreover, DAB2IP inhibits the non-genomic pathways activated by 
AR, disrupting its binding with c-Src and counteracting AR-induced ERK phosphorylation and 
proliferation of prostate cells (Wu et al., 2014). Taken together, these data demonstrate that 
DAB2IP is a unique intrinsic negative modulator of AR activity in normal and cancer cells, and 
likely can be further developed into a therapeutic agent for PCa. 
 
Activation of GSK3β – βcatenin signaling pathway 
GSK3β is a serine/threonine kinase that phosphorylates numerous substrates, in many cases 
promoting their routing to proteasome degradation. GSK3β is constitutively active under resting 
conditions; different signaling cascades (such as Wnt/βcatenin and PI3K-AKT) promote its 
inactivation through N-terminal Ser-9 phosphorylation. In canonical WNT signaling, in the 
absence of ligand, the serine/threonine kinases 
CK1 and GSK3β phosphorylate βcatenin, rapidly 
stimulating its destruction by the proteasome. 
Upon Wnt stimulation, GSK3β-mediated βcatenin 
degradation is inhibited, leading to the 
stabilization of βcatenin, that shuttles in the 
nucleus to promote gene transcription (Clevers, 
2006). DAB2IP interacts via its C2 domain with 
GSK3β, directing PP2A activities on Ser-9 
dephosphorylation, and leading to GSK3β 
activation (Xie et al., 2010). Loss of DAB2IP 
expression increases inhibitory phosphorylation of 
GSK3β, sustains repression of E-cadherin and up-
regulation of vimentin in both human normal 
epithelial and prostate carcinoma cells, initiating 
epithelial-to-mesenchymal transition (EMT) (Xie et al., 2010). It is tempting to speculate that the 
DAB2IP/PP2A/GSK3β complex may be involved in the regulation of other GSK3β targets, with 
a role in a wide spectrum of cellular processes, including glycogen metabolism (e.g. Inhibitor-2 
Glycogen Synthase), transcription (e.g c-Myc and c-Jun), insulin signaling (e.g. insulin receptor 
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substrate 1), translation, cytoskeletal regulation, intracellular vesicular transport, cell cycle 
progression, and apoptosis (Doble and Woodgett, 2003). 
 
Negative modulation of the PI3K-AKT axis 
DAB2IP can regulate PI3K (phosphoinositide 3-kinase)/PKB (protein kinase B)-Akt, by directly 
acting on the two key factors of the pathway (Xie et al., 2009). This pathway is highly 
conserved, and its activation is tightly controlled via a multistep process. It transmits signals 
from ligand-stimulated receptor kinases (RTKs) to effector molecules that control metabolism, 
proliferation, cell size, survival, and motility (Guertin and Sabatini, 2007). In cancer, this 
pathway is frequently hyperactivated as a result of activation of RTKs by mutation (EGF) or 
gene amplification (HER2), activating mutations of components of the pathway, such as PI3K or 
Akt, and the deletion or decreased function of tumor suppressor PTEN (Fruman and Rommel, 
2014). The PR and PER domains of DAB2IP are important for modulating PI3K-Akt activity 
(Table 1.1); DAB2IP binds p85 and affects PI3K-p85 relocation from the cytoplasm to the 
membrane, a necessary step for PI3K 
activation. Moreover, DAB2IP reinforces 
this inhibitory effect by directly binding 
AKT (Xie et al., 2009). Thus, DAB2IP 
has a key tumor-suppressive function as a 
negative regulator of the PI3K-AKT axis.	  
 
Negative modulation of VEGFR signaling 
Vascular endothelial growth factor 
(VEGF) is a key regulator of angiogenesis 
during embryogenesis, skeletal growth 
and reproductive functions (Ferrara et al., 
2003). The biological effects of VEGF 
are mediated by two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, which differ 
considerably in signaling properties. VEGF primarily utilizes its VEGFR-2 to induce angiogenic 
response by activating a variety of signaling cascades, such as PI3K-Akt, PLC-γ-PKC, and 
MAPK (Ferrara et al., 2003). VEGF is also implicated in pathological angiogenesis associated 
with tumors and other disorders. Importantly, VEGF function in cancer is not limited to 
angiogenesis and vascular permeability; this signaling contributes to key aspects of 
tumorigenesis, such as the function of cancer stem cells, tumor initiation, and metastasis (Goel 
PP2A
PI3K
AKT
DAB2IP
AKT
pathway
VEGF
DAB2IP
VEGF
pathway
VEGFR-2 RTK
IRS
GF GF
JAK
IFNγ
IFNγR
DAB2IPDAB2IP
α α
β β
JAK
STATPI3K
AKT
DAB2IP
JAK/STAT
pathway
AKT
pathway
	   21	  
and Mercurio, 2013). DAB2IP functions as endogenous inhibitor of adaptive angiogenesis, in 
part by binding to the VEGFR-2-PI3K (Zhang et al., 2008). DAB2IP binds VEGFR-2 with its 
C2 domain (Table 1.1), counteracting VEGF-induced activation of PI3K (Zhang et al., 2008). 
DAB2IP-KO mice show normal vascular development, but develop dramatically enhanced 
inflammatory angiogenesis. Consistent with this, VEGF-induced neovascularization is greatly 
increased in these mouse models (Zhang et al., 2008). In in vitro experiments, DAB2IP depletion 
augments VEGF-induced endothelial cells migration (Zhang et al., 2008). Notably, a global or 
vascular endothelial-specific depletion of DAB2IP augments tumor growth and metastasis in 
melanoma and breast cancer mouse models (Ji et al., 2015). A DAB2IP-deficient vascular 
environment not only enhances tumor neovascularization and increases secretion of EMT-
promoting factors, but also increases pre-metastatic niche formation (Ji et al., 2015). These 
effects are associated with augmented VEGFR-2 activity and can be abrogated by systemic 
administration of VEGFR-2 kinase inhibitor (Ji et al., 2015). 
Intriguingly, DAB2IP KO mice exhibit also reduced retinal angiogenesis, delayed developmental 
lymphangiogenesis in neonatal skin, and show weaker VEGF-C-induced corneal 
lymphangiogenesis, correlated with reduced expression of VEGFR-3 (Zhou et al., 2014b). 
Mechanistically, DAB2IP depletion increases the levels of miR-1236, a microRNA known to 
target VEGFR-3 mRNA (Zhou et al., 2014b). The authors reported also that DAB2IP binds 
directly VEGFR-3, modulating its surface expression and facilitating its recycling or/and 
delaying its trafficking to lysosomes. However, 
the mechanism that regulates this process is not 
completely understood (Zhou et al., 2014b). In 
summary, through a direct modulation of VEGF 
signaling, DAB2IP can regulate inflammatory-
induced angiogenesis and the milieu of tumor 
microenvironment, dramatically affecting tumor 
growth and metastasis. 
 
Inhibition of JAK2-STAT1/3 activation  
DAB2IP directly binds to JAK2 through its N-
terminal domain (Table 1.1), and inhibits JAK 
kinase activity, thus limiting JAK-dependent 
STAT1/3 and PI3K/Akt phosphorylation and 
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activation in vascular smooth muscle cells (VSMC). This DAB2IP functions strongly reduces 
proliferation and migration of VSMCs, two critical steps in neo-intima formation (Min and 
Pober, 2011; Yu et al., 2011). Notably, an association of DAB2IP with JAK2 is not detected in 
resting VSMC, but is strongly induced by IFN-γ, underlining again the important role of 
DAB2IP as a modulator of response to extracellular stimuli (Min and Pober, 2011). This 
suggests that DAB2IP may be important to inhibit intimal formation in graft arteriosclerosis, a 
pathological status characterized by diffuse, concentric arterial intimal hyperplasia composed of 
infiltrating host T cells, macrophages, and predominantly graft-derived smooth muscle-like cells 
that proliferate and elaborate extracellular matrix, resulting in luminal obstruction and allograft 
ischemia (Yu et al., 2011). In non-muscle invasive bladder cancer (NMIBC), the DAB2IP-
dependent inhibition of the transactivation of STAT3 suppresses also the expression of Twist1 
and its target gene P-glycoprotein, crucial factors for pirarubicin (THP) chemoresistance (Wu et 
al., 2015a). Accordingly, DAB2IP loss increases STAT3 transcriptional activity and the in vivo 
orthotopic tumor growth after intravescical THP treatment, supporting a role of DAB2IP in 
modulating chemosensitivity and recurrence of high-grade NMIBC (Wu et al., 2015a). It is 
tempting to speculate that DAB2IP might negatively regulate JAK-dependent activation of 
STAT3 in other cell types, including cancer, adding to its tumor-suppressive activities. 
 
1.2.4 DAB2IP inactivation fosters tumor progression 
Different studies describe the important role of DAB2IP in maintaining cell balance upon stress 
in different tissues, in the regulation of cell differentiation and tissue development. For example, 
three recent studies explore DAB2IP role in regulating neurogenesis, where DAB2IP drives 
neuronal differentiation of human mesenchymal stem cells (Chang et al., 2013) (Lee et al., 2012) 
(Qiao et al., 2013). Notably, DAB2IP KO mice are viable, show normal tissue development, but 
exhibit dramatically enhanced ischemia and inflammatory angiogenesis.  
Importantly for this thesis, DAB2IP is a fundamental checkpoint to dampen multiple oncogenic 
pathways. Therefore, it is a bona-fide tumor suppressor and, in agreement with this role, its 
expression is frequently impaired in human tumors. However, loss of DA2IP expression does not 
induce cancer formation per se, since DAB2IP KO mice models do not display increased tumor 
incidence. 
Therefore, DAB2IP inactivation is probably not a driver event in tumorigenesis. Rather, the loss-
of-function of this modulator can strongly support cell transformation induced by several 
different possible driver mutations. Indeed, the role of DAB2IP in the multiple signaling 
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pathways summarized above has strong implications in various aspects of cancer formation and 
progression. 
 
 
Figure 1.2: DAB2IP influences the cancer cell’s response to a plethora of extracellular stimuli. 
DAB2IP protein modulates different cytoplasmic signaling pathways, regulating cancer cell response to 
inflammatory cytokines, growth factors and hormones that are present in the tumor microenvironment and are 
secreted from stromal and immune cells, and the tumor cell itself. DAB2IP sustains cell apoptosis counteracting 
tumor growth and survival, stemness, induction of EMT and cell migration and invasion. Recent evidences 
demonstrate also that this tumor suppressor can impact tumor-related inflammation. See text for details.  
 
DAB2IP and tumor survival and growth 
The most fundamental trait of cancer cells involves their ability to sustain chronic proliferation. 
Normal tissues carefully control the production and release of growth-promoting signals, thereby 
ensuring a homeostasis of cell number, and thus maintenance of normal tissue architecture. 
Cancer cells acquire the capability to escape this control in a number of alternative ways. 
Inactivation of Ras inhibitors, such as in the case of DAB2IP, has been reported to strongly 
sustain tumor growth (Calvisi et al., 2011; Duan et al., 2013; Wang et al., 2002). In the absence 
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of Ras mutation, down-regulation of DAB2IP levels is found in human liver or pancreatic cancer 
cells, and the expression of this protein is lower in patients with more advanced stage of disease 
(Duan et al., 2013). 
Effects of DAB2IP perturbation in Ras-induced tumor growth have been recapitulated elegantly 
by Cichowski and colleagues (Min et al., 2010). They demonstrated that mice injected with 
prostatic cancer cells expressing H-Ras or depleted for DAB2IP develop highly proliferative 
tumors, which grow with similar kinetics and to a similar maximum size (Min et al., 2010). 
Notably, wild-type DAB2IP expression significantly blocked tumor development, whereas 
expression of the catalytically inactive RasGAP mutant (DAB2IP-R289L) was unable to 
suppress tumor growth (Min et al., 2010). 
Similarly to Ras pathway activation, hyper-activation the PI3K/Akt signaling is frequently 
detected in tumors (Hanahan and Weinberg, 2011). Notably, DAB2IP-depleted prostate cells 
injected in mice, develop tumors with strong PI3K/Akt pathway activation (Xie et al., 2009); this 
signaling is also hyper-activated in hyperplastic prostate epithelium of DAB2IP KO mice (Xie et 
al., 2009). Increase in cell proliferation markers (i.e. cyclins and Ki67) in in vitro and in vivo 
models has been correlated to abrogation of DAB2IP inhibitory functions on this pathway (Xie 
et al., 2009). 
Programmed cell death by apoptosis serves as a natural barrier to cancer development. However, 
apoptosis is attenuated in those tumors that progress to high-grade malignancy and develop 
resistance to therapy (Hanahan and Weinberg, 2011). Physiologically, DAB2IP promotes 
apoptosis in response to multiple stimuli, by directly sustaining ASK1/JNK activation. In various 
models of DAB2IP down-regulation, decrease in ASK1 dependent apoptosis has been 
appreciated (Luo et al., 2008; Xie et al., 2009; Zhang et al., 2007; Zhang et al., 2004). 
In conclusion, DAB2IP represents a signaling platform that controls the balance between cell 
growth and apoptosis, which characterizes different types of normal or cancer cells. Based on 
these outcomes, DAB2IP function may dictate the effects of chemotherapy on cancer cell death. 
Therefore restoring DAB2IP expression in target tissue by either a genetic or inductive approach 
is expected to increase the therapeutic index of these agents, concomitantly affecting the 
activation of anti-proliferative and pro-apoptotic pathways. 
 
DAB2IP and cell migration and metastasis 
Metastasis is a multistep process whereby tumor cells disseminate from the primary tumor and 
colonize distant organs. Metastatic disease is the major cause of death from cancer (Bravo-
Cordero et al., 2012; Kitamura et al., 2015). Tumor epithelial cells are converted in migratory 
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and invasive cells by epithelial to mesenchymal transition (EMT), a process controlled by a 
variety of regulatory circuits (De Craene and Berx, 2013). DAB2IP has a heavy impact on EMT; 
DAB2IP levels have been inversely correlated with expression of EMT markers in melanoma, 
bladder, prostate, colorectal and breast cancer. In particular, reduced DAB2IP levels correlate 
with increased vimentin (mesenchymal marker) and reduced E-cadherin (epithelial marker) 
expression (Ji et al., 2015; Marian et al., 2011; Min et al., 2015; Min et al., 2010; Shen et al., 
2014; Wang et al., 2015; Xie et al., 2010). DAB2IP loss or inactivation initiates EMT in both 
human normal prostate epithelial and prostate carcinoma cell lines, inducing changes in cell 
morphology and biomarker expression, including decreased E-cadherin expression and augment 
vimentin, twist and fibronectin levels (Marian et al., 2011; Min et al., 2010; Xie et al., 2010). 
DAB2IP loss affects the migratory and invasive capability of tumor cells: orthotopic prostate and 
colorectal cancer xenografts showed that mice injected with DAB2IP-depleted cells have a 
dramatic increase in the incidence of lymph-node metastases (Min et al., 2015; Min et al., 2010; 
Xie et al., 2010).  
Notably, increased DAB2IP levels revert EMT: overexpression of DAB2IP can restore E-
cadherin levels in metastatic prostate and colorectal cancer cells (Min et al., 2010; Xie et al., 
2010). 
Finally, in bladder cancer, DAB2IP down-regulation promotes cell proliferation, migration and 
invasion together with the activation of ERK and Akt pathways (Shen et al., 2014). 
 
DAB2IP can control EMT and cell migration and invasion by finely coordinating the 
WNT/βcatenin and NF-κB pathways. Cichowski and colleagues demonstrated that a point 
mutation in the period-like domain of DAB2IP, that prevents TRAF2 binding, renders the 
protein defective in suppressing xenograft dissemination in vivo, despite retaining its RasGAP 
activity - thus showing that NF-κB activation has an important role in mediating metastasis (Min 
et al., 2010). Similar results were recently obtained by Xie and colleagues in colorectal cancer 
(Min et al., 2015). In addition to its inhibitory activity on NF-κB, DAB2IP modulates 
GSK3β/βcatenin signaling in EMT; indeed, GSK3β phosphorylation is higher in DAB2IP-/- than 
in DAB2IP+/+ mice, and βcatenin overexpression can reverse DAB2IP-mediated MET 
(mesenchymal-to-epithelial transition) (Xie et al., 2010). 
To conclude, a large part of DAB2IP literature describes its role in modulating EMT and 
metastasis. Therefore, although depletion of this protein does not induce cancer by itself, 
DAB2IP loss can greatly increase cancer cell migration and invasion, especially in response to 
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extracellular inputs. Indeed, DAB2IP knockout mice have aberrantly dilated colonic crypts with 
altered monolayer epithelial arrangement (Min et al., 2015), and exhibit mesenchymal 
characteristic in the prostate gland and prostatic hyperplasia (Xie et al., 2010). 
 
DAB2IP in stemness  
Cancer stem cells (CSCs) are tumor cells that have the principal properties of self-renewal, 
tumor initiation capacity, and clonal long-term repopulation potential. They have been proposed 
as the driving force of tumorigenesis and the seed of metastases (Medema, 2013). A strong 
connection between EMT and CSCs properties exists, as they are sustained in human cancer by 
the same gene expression programs (Brabletz et al., 2005). 
Two recent works describe a role of DAB2IP in modulating CSCs properties. One study reported 
that DAB2IP suppresses transcription of stem cell factor receptor CD117, by interacting with 
GATA-1 on a silencer element on its gene (Yun et al., 2015). Notably, this is the first – and only 
- evidence of a possible nuclear localization for DAB2IP, and of its potential direct role in 
modulating gene transcription. The authors also demonstrate that DAB2IP, through the 
inhibition of PI3K/Akt/mTOR signaling, activates c-myc-dependent ZEB1 expression, leading to 
elevated CSC phenotype (Yun et al., 2015). Indeed, DAB2IP KO prostate cancer cells increase 
sphere-formation activity in vitro, and augment tumorigenic potential in mice (Yun et al., 2015). 
Another study reported that in human colorectal cancer (CRC), DAB2IP inhibition of NF-κB 
pathway can suppress EMT induction and CSC features (Min et al., 2015). The absence of 
DAB2IP in CRC cells increases sphere formation in soft agar, and expression of EMT and stem 
cell markers; reduced DAB2IP levels in CRC patients correlates with increased number of 
CD133+ cells and faster tumor progression (Min et al., 2015).  
 
DAB2IP and cancer-related inflammation 
Inflammation plays a decisive role in cancer development and progression, including metastasis 
formation and response to therapy. Chronic inflammation associated with infection or immune 
diseases increases cancer risk, and can contribute to it by inducing oncogene mutations, genomic 
instability, enhanced angiogenesis, and metastasis (Colotta et al., 2009; Grivennikov et al., 
2010). Later on, in the formed tumor microenvironment, cancer cells engage a continuous 
crosstalk with infiltrating immune and stromal cells; and a variety of cytokines, chemokines, 
prostaglandins, growth factors, and reactive oxygen-species are mediators of this dynamic 
crosstalk (Grivennikov et al., 2010). 
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Given its inhibitory role on NF-κB and STAT3 inflammatory pathways, DAB2IP functions as an 
anti-inflammatory protein, especially in vascular endothelial cells. Indeed, DAB2IP knockout 
mice show dramatically enhanced inflammation in models of ischemic hindlimb, graft 
arteriosclerosis and inflammatory angiogenesis (Huang et al., 2013; Min and Pober, 2011; Yu et 
al., 2011; Zhang et al., 2008). Mechanistically, DAB2IP represents a fundamental modulator of 
signal transduction in response to inflammatory mediators, including TNFα, IFN-γ, TLR4 and 
IL-1β (Di Minin et al., 2014; Wan et al., 2010; Yu et al., 2011; Zhang et al., 2003).  
More importantly, various studies show that DAB2IP modulates secretion of inflammatory 
mediators in endothelial and cancer cells, and the recruitment of immune cells. In hyperlipidemic 
ApoE-/- mice, DAB2IP knockdown increases secretion of inflammatory cytokines (IL-12, IL-6, 
RANTES, TNF, MCP-1 and CX3CL1) and augments macrophage infiltration, thereby 
promoting increased endothelial dysfunction and early phases of atherosclerosis (Huang et al., 
2013). 
Evidences indicate DAB2IP as an important anti-inflammatory molecule, which can strongly 
affect the behavior of immune cells and the response to inflammatory mediators. Nevertheless, 
we still have little information about its potential role in modulating the inflammatory 
component of the tumor microenvironment, and this aspect deserves a deeper investigation. 
 
DAB2IP in chemo- and radio- resistance  
Resistance to chemotherapeutic drugs and radiotherapy is a significant barrier to cure cancer. 
Multiple molecular mechanisms are involved in chemo- and radio-resistance, including 
alteration in drugs metabolisms, the activation of survival signaling pathways, and evasion from 
death signals. Moreover, the tumor microenvironment can also dramatically influence the cancer 
cell response to drugs. DAB2IP has been linked to sensitivity to radiation in prostate tumors: loss 
of DAB2IP sustains more efficient DNA repair, resistance to apoptosis, and robust control of cell 
cycle checkpoint in prostate cancer cells exposed to ionizing radiation (IR) (Kong et al., 2010). 
Similarly, DAB2IP loss in prostate cancer cells was shown to enhance chemoresistance by up-
regulation of the anti-apoptotic protein clusterin (Wu et al., 2013). Accordingly, DAB2IP 
overexpression sensitizes prostate cancer cells to various chemotherapeutic agents (Wu et al., 
2013). Finally, loss of DAB2IP augments STAT3 activation, increasing chemoresistance to 
pirarubicin in bladder cancer (Wu et al., 2015a; Zhou et al., 2015). 
Notably, such evidences suggest that DAB2IP reactivation may be a potential approach for 
developing combined and more efficacious therapy. 
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1.2.5 Escaping DAB2IP mediated control in cancer 
Despite its multiple tumor-suppressive functions, DAB2IP is only rarely mutated in human 
cancers. In contrast, a consistent body of literature reports the epigenetic inactivation of DAB2IP 
by promoter methylation in various tumors and tumor-derived cell lines (see below). More 
recently, alternative mechanisms for DAB2IP inactivation in cancer have been described, or 
suggested, uncovering an interesting scenario where tumor cells arising with very different 
genetic backgrounds may employ different means to disable such a unique “modulator” of 
multiple signaling pathways. 
 
DAB2IP promoter methylation mediated by EZH2 
The best characterized mechanism to inactivate DAB2IP is by epigenetic silencing. As already 
mentioned, the gene is complex and contains multiple CpG islands. A number of studies have 
described aberrant methylation of the gene in lung, breast, prostate, and gastrointestinal cancer 
(Chen et al., 2003; Dote et al., 2005; Dote et al., 2004; Yano et al., 2005). Main factor 
controlling DAB2IP methylation is the complex PRC2 (polycomb-repressive complex-2)/EZH2 
(Enhancer of Zeste homolog)(Chen et al., 2003). The high level of di- and tri- methyl H3-Lys27 
in DAB2IP promoter is modulated by EZH2: EZH2 recognizes and binds specific GpG island in 
DAB2IP promoter, leading the recruitment of the PRC2 protein complex and the histone 
deacetylase HDAC1/2 (Chen et al., 2005) (Wang et al., 2015) (Smits et al., 2012). Recently, it 
has been demonstrated that Snail transcription factor is required for the repressive function of 
EZH2 on DAB2IP in colon cancer. A positive feedback loop established between Snail and 
DAB2IP promotes metastasis in colon-rectal cancer (Wang et al., 2015). 
 
DAB2IP post-transcriptional regulation mediated by microRNAs 
Another mechanism that might contribute to reduce DAB2IP levels in cancer cells is post-
transcriptional silencing by microRNAs (miRNAs). DAB2IP has a relatively long 3’ UTR 
sequence, and is therefore a good candidate for miRNAs activity. Up to now, three studies have 
reported miRNAs able to target DAB2IP. 
miR-338 was reported to reduce DAB2IP levels in neurons (Barik, 2008). miR-338 is located 
within the eighth intron of the Apoptosis-Associated Tyrosine Kinase (AATK) gene. AATK 
protein plays an essential role in promoting neuronal differentiation. miR-338 cooperates with 
AATK through suppression of the translation of a selected group of mRNAs whose protein 
products are negative regulators of neurite growth and neural differentiation - including 
DAB2IP. However, the study does not address the specific role of DAB2IP in this scenario, and 
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does not discuss the potential role of miR-338-dependent DAB2IP down-regulation in tumors 
(Barik, 2008). 
miR-889 targets and down-regulates DAB2IP protein levels in esophageal squamous cell 
carcinoma (ESCC), sustaining cell proliferation in in vitro and in vivo experiments (Xu et al., 
2015b). Notably, DAB2IP overexpression can subvert this phenotype. However, authors do not 
analyze the effects of the miR-889-mediated down-regulation of DAB2IP on other DAB2IP 
dependent phenotypes, including migration or invasion of ESCC cells. The levels of miRNA-889 
and DAB2IP inversely correlated in ESCC tissue samples, where low DAB2IP correlates with 
poor differentiation and high tumor size (Xu et al., 2015b).  
Finally, miR-32 was shown to target DAB2IP in prostate cancer (Liao et al., 2015). The authors 
demonstrated that miR-32, a known onco-miRNA, is well paired with the 3’UTR of DAB2IP. 
They showed that prostate cancer cells depleted for DAB2IP by miR-32 action are more resistant 
to ionizing radiation treatment, with augmented cell proliferation and reduced cell apoptosis 
(Liao et al., 2015).  
These three studies demonstrate that DAB2IP is a target for miRNAs-mediated regulation, and 
give a preliminary hint of the broad potential impact that this regulatory circuit may have in 
cancer, where miRNA expression is often deregulated (see below).  
 
DAB2IP protein degradation mediated by FBW7 and Skp2 
Recently, two studies have analyzed post-translational turnover of the DAB2IP protein, 
identifying two SCF E3 ubiquitin ligases that promote its degradation. 
A recent study demonstrated that FBW7-containing SCF complexes can bind and degrade 
DAB2IP (Dai et al., 2014). A putative phospho-degron motif, commonly recognized by Fbw7 
for substrate recruitment to the SCF protein complex, has been identified in DAB2IP. In line 
with this model, a putative CK1 phosphorylation site controls the efficiency of DAB2IP turnover 
(Dai et al., 2014). 
A second study showed that DAB2IP can be poly-ubiquitinated by Skp2-containing SCF 
complexes. Specifically, the GAP domain of DAB2IP contains three putative sites for Skp2-
elicited ubiquitination (Tsai et al., 2014). Notably, in prostate cancer cells, DAB2IP promotes 
Skp2 degradation, possibly by the inhibition of AKT. This reciprocal interaction may be 
involved in the regulation of cell growth and proliferation; however, an inverse correlation 
between the two proteins has not been clearly demonstrated (Tsai et al., 2014).  
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No studies have carefully analyzed DAB2IP protein stability and turnover under multiple 
different conditions, and it is plausible that other ubiquitin-ligases might be involved in its 
regulation. 
 
Other post-translational modifications: role of Akt 
A recent report suggests that DAB2IP can be phosphorylated by AKT1 (but not AKT2) on Ser-
847, within the proline-rich domain. In transient overexpression experiments, mutation of serine 
847 to Aspartic (to mimic constitutive phosphorylation) moderately reduced DAB2IP interaction 
with Ras and TRAF2; accordingly, mutation to Alanine increased DAB2IP interaction with both 
proteins. These results suggest that phosphorylation by endogenous kinases might interfere with 
DAB2IP activity (Dai et al., 2014). In support of a model whereby phosphorylation at Ser-847 
inhibits DAB2IP functions, authors observed that overexpression of the phospho-mimetic 
DAB2IP (S847D) mutant had no effect on Ras-dependent p-ERK levels (Dai et al., 2014). 
Intriguingly, these data suggest an existing feedback regulatory loop between AKT and DAB2IP. 
Additional studies are required to confirm these observations, and to determine if Ser-847 
phosphorylation might affect other important DAB2IP functions - first of all modulation of 
ASK1 and NF-κB signaling. 
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 AIM OF THE THESIS 
 
An intricate network of signals is continuously established among tumor cells and their 
microenvironment, and the traffic of information among distinct cells within a tumor strongly 
contributes to cancer development and progression. The tumor suppressor DAB2IP plays a 
fundamental role in this context, since it modulates signal transduction by multiple extrinsic 
inputs, including inflammatory cytokines, growth factors and hormones in the tumor 
microenvironment, affecting the behavior of tumor cells. As detailed above, multiple studies 
have begun to uncover molecular mechanisms through which DAB2IP tumor-suppressive 
functions can be inhibited in cancer. The simple block of DAB2IP activity can indeed permit 
tumor cell to simultaneously activate multiple oncogenic signals in response to extracellular 
stimuli, thereby augment tumor transformation and fostering the acquisition of oncogenic 
features. 
Therefore, increasing our knowledge on mechanisms of DAB2IP regulation could strongly 
improve our possibilities to interfere with these cellular processes, eventually developing 
approaches to counteract them, with possible implication for cancer therapy. We think that 
increasing DAB2IP protein levels in tumor cells, or restoring its compromised oncosuppressive 
functions, would coordinately dampen multiple pro-survival pathways and, at the same time, 
activate cell death signaling, effectively reducing tumor growth, metastasis, and resistance to 
therapy. In this Thesis I explored two mechanisms through which tumor cells can counteract 
DAB2IP activity. 
The first one is based on protein-protein interaction (Part 2 of this Thesis). In the host laboratory 
DAB2IP was recently cloned as a novel interactor of p53-family proteins (Lunardi et al., 2010). 
Later, we observed that DAB2IP is efficiently bound by mutant p53 proteins (mutp53). 
Expression of mutant p53 is a significant factor in cancer development and progression (Kim et 
al., 2015). Missense mutations of p53 not only induce loss of its tumor suppressive functions, but 
also confer to the protein new oncogenic properties (as detailed in Chapter 2.1). Notably, mutant 
p53 fosters tumor progression and invasion by reinforcing and up-regulating multiple oncogenic 
pathways including RAS, PI3K-Akt, βcatenin, and NF-κB (Dong et al., 2009; Muller et al., 
2009; Sauer et al., 2010; Weisz et al., 2007). As mentioned above, all these pathways are 
coordinately antagonized by DAB2IP. 
We therefore decided to study the role of mutant p53/DAB2IP interaction in cell transformation. 
Specifically, we hypothesized that some gain-of-function properties of mutant p53 might depend 
on sequestration and functional inactivation of DAB2IP, particularly in the context of TNF-
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induced cell migration and invasion. We demonstrated that, blocking DAB2IP inhibitory activity 
on NF-κB pathway, mutant p53 reprograms TNFα dependent transcriptional response, 
promoting the invasive ability of tumor cells in response to inflammation, and counteracting the 
apoptotic response induced by TNF. Intriguingly, the displacement of mutp53/DAB2IP 
interaction subverts aggressive tumor phenotypes in in vitro and in vivo experiments. 
 
The second mechanism is based on post-transcriptional inhibition by microRNAs (Part 3 of this 
Thesis). 
MicroRNAs are small non-coding RNAs involved in the control of translation of a multitude of 
cellular proteins, and are implicated in the regulation of multiple biological processes, including 
cell proliferation, survival, migration and invasion (detailed in Chapter 3.1). Intriguingly, 
DAB2IP has a long 3’UTR that is heavily conserved among vertebrates, and is therefore a likely 
miRNAs target. Up to now, three miRNAs regulating DAB2IP (miR-32, miR-889 and miR-338) 
have been reported (Barik, 2008; Liao et al., 2015; Xu et al., 2015b). We decided to identify and 
characterize additional miRNAs targeting DAB2IP, and to explore their oncogenic role in 
cancer. Given the moderate reliability of software prediction tools, we decided to perform a 
high-throughput functional screening. 
Considering the fundamental role of DAB2IP as modulator of multiple extrinsic inputs, aim of 
this study was also to characterize the implications of miRNA-mediated down-regulation of 
DAB2IP on the cancer cell’s response to extracellular stimuli, especially inflammatory mediators 
such as TNFα. 
Finally, a long-term aim of this work is the possible development of miRNA inhibitors as 
therapeutics to increase DAB2IP levels and/or restore DAB2IP tumor suppressive functions in 
cancer, with potential clinical impact. 
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PART 2: CYTOPLASMIC GAIN OF FUNCTION MUTANT p53 
CONTRIBUTES TO INFLAMMATION-ASSOCIATED CANCER 
 
In this part I describe studies on the functional aspects of mutant p53/DAB2IP binding in cancer 
progression, especially in the context of tumor inflammation. The interaction with mutant p53 
represents an innovative mechanism of DAB2IP inhibition in tumor cells and exerts a strong 
impact in modulation of cancer cell response to inflammatory stimuli from the tumor 
microenvironment. 
 
2.1 MUTANT p53 AS A DRIVER FORCE IN TRANSFORMATION 
 
Wild type p53 (wt) is a transcription factor (Laptenko and Prives, 2006) with strong tumor 
suppressive activities that identify it as the “guardian of the genome” and label it as one of the 
most important players in cancer biology (Freed-Pastor and Prives, 2012). In normal cells, p53 
activity is low, but in response to numerous stress signals, including DNA damage, oncogenes 
activation and hypoxia, p53 levels rise dramatically and result in the transcription of hundreds of 
genes with important roles in cell cycle arrest, senescence, apoptosis, DNA repair, metabolism, 
autophagy and differentiation (Meek, 2009). Notably, the TP53 gene is the most frequent target 
for mutation in human cancer: 96% in ovarian serous carcinoma, 54% in invasive breast 
carcinoma, and 75% in pancreas cancer (Kim et al., 2015). There are now strong evidences that 
mutation not only abrogates p53 tumor-suppressive functions, but also endows mutant proteins 
with novel oncogenic activities.  
 
2.1.1 Pro-oncogenic roles of mutant p53  
Alterations of p53 have been found in every region of the protein, but only a handful of the most 
frequently occurring mutations have been studied in depth for their contribution to cancer 
progression. Frameshift or nonsense mutations result in the loss of p53 protein expression, as 
seen with other tumor suppressor, including PTEN and Rb (Kim et al., 2015). However, 
approximately 75% of all tumor-associated p53 alterations result in missense mutation, leading 
to the substitution of a single amino acid in the p53 protein that can be stably expressed in the 
tumor cell (Kim et al., 2015; Muller and Vousden, 2014). These substitutions occur throughout 
the p53 protein, but most commonly cluster within the DNA binding region (in about 90% of 
cases) (Kim et al., 2015). Six “hotspot” residues are the most frequently substituted. These 
missense mutations lead to the production of full-length mutant p53 proteins with a prolonged 
half-life (Freed-Pastor and Prives, 2012) (Figure 2.1).  
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Figure 2.1: TP53 mutational spectrum in human cancer. Schematic representation of the p53 protein with 
domains structure illustrated: TAD: transactivation domain; PRD: proline-rich-domain; DBD: DNA-binding 
domain; OD: oligomerization domain (also contains a nuclear export signal); CTD: C-terminal regulatory domain 
(also contains three nuclear localization signals). The six hotspot mutations are highlighted: R175 and R273 are 
DNA-contact mutations, G256 and R249 are locally distorted mutants, R175 and R282 are globally denatured 
mutants. Figure reproduced from (Freed-Pastor and Prives, 2012).  
 
The nature of these mutations provides several clues as to how p53 role is affected. DNA-
binding domain activity is the critical function that is altered, suggesting that changes in 
transcriptional targets could be key to the activity of mutant p53. However, the mutations in the 
structured core of p53 can also have significant consequences to the folding of p53 and to the 
capability to establish new interactions. Therefore, the hotspot changes in p53 are traditionally 
classified as “conformational mutants” (or structural mutants) that can cause unfolding of the 
p53 protein, and “DNA contact mutants” that change amino acid critical for DNA binding 
(Muller and Vousden, 2013). They generally lead to a loss or diminution of the wild-type 
activity of p53, and because p53 normally acts as a tetramer, these mutant proteins may also 
function as dominant negative inhibitor over any remaining allele (Muller and Vousden, 2014). 
More important, the changes in p53 structural stability may be crucial to the acquisition of new 
oncogenic properties, known as Gain of Function or GOF (Muller and Vousden, 2013).  
 
Gain of Function (GOF) 
Single amino acid changes in the p53 gene may result in profound alteration to protein functions, 
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affecting diverse aspects of tumorigenesis. These include DNA synthesis, cell survival and 
proliferation, abnormal centrosomes and spindle checkpoints, somatic cell reprograming and 
stem cell characteristics, disruption of tissue architecture, invasion and metastasis, as well as 
increased angiogenesis, tumor-promoting 
inflammation and Warburg effect (Freed-
Pastor and Prives, 2012; Muller and Vousden, 
2014; Sabapathy, 2015).  
GOF properties were better studied with the 
generation of the p53 mutant knock-in mice. 
The initial data demonstrated that the p53 
R172H mice (equivalent to human R175H) 
were more tumor prone with more carcinomas. 
Further studies have cemented this finding: the 
presence of the R172H mutant p53 protein 
confers significant growth and metastatic 
propensity, compared to the loss of p53, in a 
variety of tumor types such as lung and 
pancreatic ductal adenocarcinomas (Caulin et 
al., 2007; Morton et al., 2010). Moreover, in 
knock-in mice, mutant p53-mediated 
prolonged activation of NF-κB pathway 
increases cytokines expression, inducing 
inflammation and tissue damage that strictly correlates with tumor growth (Cooks et al., 2013). 
Angiogenesis was also shown to be enhanced, through the activation of the DNA-binding protein 
inhibitor ID4 expression in cell culture studies (Fontemaggi et al., 2009).  
Intriguingly, tumor cells carrying mutations of TP53 become addicted to the mutant p53 GOF. 
Indeed in vitro and mice studies demonstrated that tumor cells with accelerated growth and 
acquired migratory/invasive ability are strongly compromised upon mutant p53 abrogation 
(Adorno et al., 2009; Bossi et al., 2006; Bossi et al., 2008; Freed-Pastor et al., 2012; Girardini et 
al., 2011) (Alexandrova et al., 2015). The exact point at which cancer cells get addicted to 
mutant p53 is not understood. It is expected this happens at the point in time of loss of the 
remaining wild type p53 allele; however, it is likely that further events are required for this 
phenomenon (Sabapathy, 2015). 
 
Figure 2.2: The phenotypic effects of TP53 mutations 
can be classified into three non-mutually exclusive 
groups.  First Loss of Function (LOF), that abrogates or 
attenuates the binding of p53 to its consensus DNA 
sequence, and  impedes the transcriptional activation of 
p53 target genes; second, the ability of mutant o53 to 
inhibit the function of the wtp53 proteins, forming a 
heterotetramer (Dominant Negative-DN). Finally, 
mutants p53 can aquire new oncogenic properties 
known as Gain of Function (GOF). Taken from (Brosh 
and Rotter, 2009). 
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2.1.2 Mechanism and mediators of mutant p53 gain of function 
There are multiple proposed mechanisms that account for mutant p53 gain of function. These 
include both transcriptional and non-transcriptional mechanisms. In the first case, they reflect 
alterations in the DNA-binding ability of mutant p53 (Figure 2.3, model 1). In the second case, 
gain of function involves changes in the interaction of mutant p53 with other proteins, including 
transcription factors (Figure 2.3, model 2 and 3) or proteins not directly related to the regulation 
of gene expression (Figure 2.3, model 4) (Freed-Pastor and Prives, 2012; Muller and Vousden, 
2013).  
 
Mutant p53 binds DNA to alter gene expression 
Since tumor-derived mutants p53 retain the N-terminal transcriptional transactivation domains, 
much of the gain of function activity of these proteins has been related to a direct or indirect 
ability to regulate gene expression (Freed-Pastor and Prives, 2012). The amino acid substitutions 
within the DNA-binding domain of the majority of the p53 mutants may change, rather than 
abolish, sequence-specific DNA binding; this aspect mainly characterizes the concept of loss of 
function (Muller and Vousden, 2013). However, it is certainly true that mutant p53 has DNA-
binding activity (Thukral et al., 1995), raising the possibility that some mutant p53 proteins may 
recognize a unique mutant p53 response element (Figure 2.3, model 1). Nevertheless, a 
consensus for mutant p53-specific binding has so far not been identified (Muller and Vousden, 
2013).    
 
Mutant p53 and transcription factor regulation 
The best-characterized transcriptional function of mutant p53 is its ability to interact with other 
transcription factors and modulate the expression of their targets genes (Figure 2.3, model 2 and 
3) (Freed-Pastor and Prives, 2012). In some cases, mutant p53 increases their transcriptional 
activity. p53 mutants have been demonstrated to transactivate MYC, CXCL1, PCNA, CDK1, 
IGF1R and EGFR, all of which can promote proliferation of cancer cells (Deb et al., 1992; Di 
Agostino et al., 2008; Frazier et al., 1998; Ludes-Meyers et al., 1996; Werner et al., 1996; Yan 
and Chen, 2009). 
Additionally, mutant p53 can up-regulate genes that inhibit apoptosis or promote 
chemoresistance. For example, p53 mutants can transactivate BCL2L1 (also known as Bcl-xL) 
to sustain an anti-apoptotic response, and thus favor tumor growth (Bossi et al., 2008).  
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Figure 2.3: Model of mechanisms through which mutant p53 functions.  As part of its gain of function mutant 
p53 interacts with different proteins, to enhance or inhibit their activities. Illustration taken from (Muller and 
Vousden, 2013). See text for the details. 	  
In other cases, mutant p53 increases the activity of other transcription factors, with further 
complexity added by the role of cellular stimuli, transcriptional cofactors, and other proteins. For 
example, the interaction of mutant p53 with the nuclear factor Y (NF-Y) deregulates the cell 
cycle checkpoint following the induction of low levels of DNA damage. Under these conditions, 
DNA topoisomerase 2-binding protein 1 (TopBP1) recruits mutant p53 and the transcriptional 
cofactor p300, to mediate their binding with NF-Y, and induce the transcription of genes 
involved in the regulation of cell proliferation and chemoresistance (Di Agostino et al., 2006; 
Liu et al., 2011). Mutant p53 binding with p300 and NF-Y is also stimulates by mutant p53 
phosphorylation mediated by PLK2 kinase (Valenti et al., 2011).  Additionally, tumor-derived 
mutant p53 can enhance the transcriptional activity of NF-κB in response to TNF, partially 
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through a physical interaction with p65 (Cooks et al., 2013; Dell'Orso et al., 2011; Weisz et al., 
2007).  Mutant p53 has also been shown to transcriptionally regulate the expression of 
mevalonate pathway genes, through an interaction with SREBP family of transcription factors, 
allowing cells to make de novo cholesterol and other key metabolism (Freed-Pastor et al., 2012).  
 
Mutant p53 activity on p63 and p73 
Notably, the interaction of mutant p53 with transcription factors can also be inhibitory (Figure 
2.3, model 3). Probably, the best understood example of this phenomenon is the inhibitory role 
that mutant p53 exerts on the transcriptional activity of the other members of the p53 family, p63 
and p73. (Muller and Vousden, 2013).  
Recent work has found that mutant p53 frequently binds DNA through p63 interaction, even 
though at sites distinct from those that p63 would normally bind, thus preventing normal p63 
functions (Martynova et al., 2012). For example, p63 normally inhibits the activation of RCP 
(Rab coupling protein), through transcriptional targets that are still unknown, to prevent α5β1 
integrin and EGFR recycling to the plasma membrane. Upon expression of mutant p53, p63 
transcriptional activity is suppressed, resulting in enhanced RCP-driven recycling of α5β1 
integrin and EGFR. This activates Rho and PKB/Akt to promote cell migration and invasion 
(Muller et al., 2009). The ability of mutant p53 to bind and inhibit p63 it itself regulated at 
various levels, with the involvement of additional partners, intrinsic and extrinsic signals. For 
example, in response to TGF-β treatment, the protein SMAD2 promotes the interaction between 
mutant p53 and p63, leading to the inhibition of p63-driven gene expression: two important 
suppressor of metastasis, Sharp1 and cyclin G2 are so less expressed, leading to an increased 
invasive capability of tumor cells (Adorno et al., 2009).  
On the other hand, mutant p53 binding of p73 protects cells from chemotherapeutic agents, 
inducing less favorable response to chemo/radio- therapy in patients with head and neck cancer 
(Li and Prives, 2007). A recent work elegantly has showed how mutant p53, through the 
disruption of the p73/NF-Y complex can transcriptionally up-regulate the platelet-derived 
growth factor receptor b (PDGFR b), thus maintain a pro-metastatic phenotype of a murine 
models of pancreatic cancer (Weissmueller et al., 2014). 
The evidence that both p53+/-/p63+/- and p53+/-/p73+/- double-mutant mice display an altered 
tumors spectrum and a more metastatic phenotype, if compared with mutant p53 knock-in 
models is in line with all these study (Flores et al., 2005). 
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Mutant p53 interaction patterns  
Some of the known gain of function activities of mutant p53 are mediated by its ability to form 
aberrant protein complexes with several interacting partners not involved in gene transcription. 
The interaction with mutant p53 can enhance or inhibit their functions (Figure 2.3, model 
4)(Muller and Vousden, 2013). For example, by interacting with MRE11, a DNA nuclease 
required for DNA repair, mutant p53 impairs homologous recombination and causes 
accumulation of unrepaired DNA breaks, thus promoting genetic instability in tumors and pre-
tumorigenic lesions in mouse models (Song et al., 2007). Another example is represented by the 
cytoplasmic interaction between mutant p53 and AMPK (adenosine monophosphate -AMP- 
activated protein kinase), an important energy sensor in cells that regulates the balance between 
anabolism and catabolism. Under stress conditions, mutant p53, but not wild-type p53, 
preferentially binds to the AMPKα subunit and inhibits AMPK activation, leading to impaired 
metabolic checkpoint and increased anabolic tumor growth and progression (Zhou et al., 2014a). 
Other examples of this mechanism of GOF will be described below. 
 
2.1.3 Mutant p53 oncogenic properties 
Regulation of cell fate 
The best-defined feature of mutant p53 is its ability to reprogram cell fate. Indeed, the first 
studies describing mutant p53 GOF, analyzed its role in preventing p53-independent apoptosis, 
especially in response to DNA damaging drugs, including doxorubicin or cisplatin (Li et al., 
1998). Later, it was demonstrated that mutant p53 protects cells from other apoptosis inducers, 
such as TNFα and vitamin D (Stambolsky et al., 2010; Weisz et al., 2007). Mutant p53 has been 
also shown to accelerate cell proliferation by cooperating with Ras, E2F, PCNA and c-myc (Deb 
et al., 1992; Frazier et al., 1998; Sauer et al., 2010; Scian et al., 2005). Finally, numerous recent 
works demonstrated that depletion of mutant p53 strongly reduces proliferation and survival of 
tumor cells in various cellular contexts and under different cell treatments and stimulations, 
suggesting that cancer cells become somehow “addicted” to mutp53 oncogenic properties (Ali et 
al., 2013; Braicu et al., 2013; Zhu et al., 2011; Zhu et al., 2013b). 
 
Genomic instability 
In mutant p53 knock-in mice, several hot spot mutations were reported to disrupt the DNA 
damage response, through different mechanisms, including an inhibitory activity against ATM, 
leading to genomic instability (Liu et al., 2010; Song et al., 2007). In addition, mutant p53 can 
attenuate base excision repair (Offer et al., 1999) and, by binding topoisomerase I, induce 
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aberrant homologous DNA recombination events, and mutagenic DNA rearrangements (Albor et 
al., 1998; Restle et al., 2008). 
Supporting these evidences, mutant p53 was found to induce genomic instability in mouse 
models of breast and prostate cancer (Caulin et al., 2007; Hingorani et al., 2005). 
 
Somatic cell reprogramming and stem cells characteristic 
Mutant p53 can interfere with cell differentiation (Matas et al., 2004), by promoting the reverse 
process of de-differentiation. In 
breast, lung and prostate tumors, 
an ESC (embryonic stem cell) 
gene signature was found to 
correlate with mutant p53 status 
(Markert et al., 2011; Mizuno et 
al., 2010). Moreover, tumors with 
p53 mutation and a stem cells 
transcription signature, and 
phenotype, have the worst 
outcome. Mouse embryonic 
fibroblast (MEF) cells co-
expressing mutant p53 and Oct4 
or Sox2, exhibit an enhanced cell 
reprogramming and a reduced 
differentiation capacity, if 
compared with p53 knockout 
MEF reprogrammed with Oct4 
and Sox2 overexpression alone 
(Sarig et al., 2010). 
 
Disruption of tissue architecture/migration/invasion 
Normally, wt p53 maintains a transcriptional program to prevent EMT, and the loss of this 
suppression may contribute to the induction of an EMT-like phenotype in p53-null cells, 
together with tumor’s invasive and metastatic potential (Muller et al., 2011). However, the novel 
properties acquired by mutant p53 are the main force driving migration and invasion (Solomon 
et al., 2011). The strongest support for the mutp53 GOF role in metastasis formation comes 
Figure 2.4: Mutant oncogenic activities integrated with the 
hallmarks of cancer. The hallmarks of cancer describe the events that 
compromise tumorigenic process. Mutant p53 was found to be 
involved in almost each of the described events (see the text for 
details). Thus, mutant p53 has been proposed has a promising target 
for cancer therapy. Figure taken from  (Solomon et al., 2011). 
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from mouse models (Doyle et al., 2010; Heinlein et al., 2008; Lang et al., 2004; Olive et al., 
2004; Weissmueller et al., 2014). Mutant p53 was found to facilitate tumor cell migration and 
invasion by enhancing the activation of EGFR/integrin signaling by a mechanism involving p63 
inhibition (Muller et al., 2009). In another study, the prolyl-isomerase Pin1 was found to 
transduce oncogenic signals on mutant p53 to activate transcription of a specific set of pro-
invasive and pro-migratory genes (Girardini et al., 2011). 
Intriguingly, mutant p53 can also enhance invasion and metastasis mediating the cancer cells’ 
crosstalk with the tumor microenvironment. This protein can up-regulate platelet-derived 
growth factor receptor b (PDGFR b) expression (Weissmueller et al., 2014), or reprograms the 
response of the cancer to cell to extrinsic inputs (i.e. TGF-β) (Adorno et al., 2009). Moreover a 
mechanistic link between mutant p53 GOF and chemokines secretion was proposed in enhanced 
cell motility (Yeudall et al., 2012). 
 
Tumor microenvironment and tumor –related inflammation  
Normally, wild type p53 protects against multiple inflammatory stress, including reactive 
oxygen and nitrogen species (ROS and RNS), viral infection, and cytokines (Figure 2.5) (Cooks 
et al., 2014). Emerging evidences suggest that mutant p53 oncogenic properties are deeply 
involved in the modulation of cancer cell crosstalk with immune cell population in the tumor 
microenvironment. The most convincing is a study on a mouse model of bowel disease, 
reporting that mutant p53 enhances the cell response to an inflammatory microenvironment and 
amplifies NF-κB activation, leading to an increase in the rate of transformation (Figure 2.5) 
(Cooks et al., 2013). In addition to favoring inflammation-induced transformation, mutant p53 
was found to cooperate with NF-κB and enhance its transcriptional functions in response to 
TNFα in already transformed cancer cells (Weisz et al., 2007). Notably, analysis of human head 
and neck tumors, lung cancer, sporadic colorectal carcinoma, and human colitis-associated 
cancer revealed a close correlation between p53 mutation and activation of NF-κB (Cooks et al., 
2013; Schwitalla et al., 2013; Weisz et al., 2007). Finally, it has been observed that hot-spot 
mutants sustain expression of a transcriptional signature enriched for inflammatory-related genes 
in tumor cells (Solomon et al., 2012; Yeudall et al., 2012).  
Therefore mutant p53 has been shown to cooperate with NF-κB, and to amplify pro-
inflammatory microenvironment. However, data regarding mutant p53 involvement in the 
upstream events of NF-κB pathway activation, and in the response to inflammation, are largely 
incomplete. 
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Figure 2.5: The p53 family in tumor-related inflammation. p53 pathway and other family members display a 
broad interaction with inflammatory elements such as reacitve oxigen and nitrogen species (ROS and RNS), 
cytokines, infection agents and pro-inflammatory NF-κB pathway. This complex crosstalk is higly dependent on 
p53 status, as different p53 isoforms and p53 mutants can mediate different responses and even promote chronic 
inflammation and associated cancer, acting in the tumor cells as well as in the stromal and immune compartments. 
Illustration taken from (Cooks et al., 2014). 
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2.2 CANCER-RELATED INFLAMMATION 
The presence of leukocytes within the tumor, observed in the 19th century by Rudolf Virchow, 
provided the first evidence of a possible 
link between inflammation and cancer 
(Grivennikov et al., 2010). Nowadays, it 
has become clear that an inflammatory 
microenvironment is an essential 
component of all tumors, including those 
not causally related to an obvious 
inflammatory process (Elinav et al., 
2013; Grivennikov et al., 2010).  
Some forms of chronic inflammation 
can be clearly linked to cancer 
susceptibility. For example, persistent 
Helicobacter pylori infection is 
associated with gastric cancer and 
MALT (mucosa-associated lymphoid 
tissue) lymphoma, while infections with 
hepatitis B (HBV) or C (HCV) viruses 
increase risk of hepatocellular 
carcinoma, likewise papilloma virus for 
cervical carcinoma (Grivennikov et al., 
2010). Chronic inflammation can be also 
caused by dietary factors, including 
obesity. Evidences of a relationship 
between obesity and different forms of 
cancer, including lymphoma, prostate, 
breast and endometrial cancer have been 
recently added to the previous evidence 
of a key role of obesity in liver and 
pancreas tumorigenesis (Wolin et al., 
2010). Autoimmune diseases (e.g. 
inflammatory bowel disease for colon 
Figure 2.6: Signaling network that connects inflammation 
and cancer. In the intrinsic pathway, transformed cells 
produce inflammatory mediators, thereby generating an 
inflammatory microenvironment. In the extrinsic pathway 
inflammatory or infectious conditions augment the risk of 
developing cancer. The two pathways converge, resulting in 
the activation of pro-inflammatory ongogenic signaling in 
tumor cells, that coordinates the production of inflammatory 
mediators. These molecules modulate the behaviour of 
immune cells in the tumor microenvironment and activate the 
same  key transcription factors  in inflamamtory, stormal and 
tumor cells, resulting in a more inflammatory milieu. Image 
taken from  (Mantovani et al., 2008). 
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carcinoma) and inflammatory conditions of uncertain origin (e.g. prostatitis for prostate cancer) 
can also promote carcinogenesis (Colotta et al., 2009). 
In summary, inflammation can promote cancer development and progression (Grivennikov et al., 
2010). The identification of molecular and cellular circuits linking inflammation and cancer, 
allowed the description of two distinct paths. In the intrinsic pathway, genetic events causing 
neoplasia initiate the expression of inflammatory-related factors the drive the construction of an 
inflammatory microenvironment within the tumor tissue. In the extrinsic pathway, the 
inflammatory condition associated to a particular disease state or environmental condition 
facilitates cancer development (Colotta et al., 2009) (Figure 2.6). 
 
2.2.1 Inflammation and tumor initiation and promotion 
Inflammation-induced tumor promotion may occur early or late, and can lead to activation of 
pre-malignant lesions that were dormant for many years. The mechanisms through which 
inflammation affects tumor promotion are numerous and in addition to increase proliferation and 
enhanced survival, can also sustain the angiogenic switch, EMT, invasion and metastasis 
(Grivennikov et al., 2010).  
Inflammation may have a prominent role in initiating neoplastic transformation by increasing the 
rate of DNA damage and compromising DNA repair mechanisms (Grivennikov et al., 2010). In 
fact, ROS and RNS that are released by tissue macrophages and neutrophils, or that are induced 
in pre-malignant cells by inflammatory cytokines, cause DNA breaks, single base mutations or 
more complex DNA lesions (Colotta et al., 2009; Elinav et al., 2013; Grivennikov et al., 2010). 
Interestingly, inflammation may also augment cellular susceptibility to mutagenesis and 
indirectly increase genomic destabilization by counteracting DNA repair machinery and 
disrupting cell cycle checkpoints, which leads to the accumulation of random genetic alteration 
(Colotta et al., 2009; Elinav et al., 2013; Grivennikov et al., 2010).  
Another important pathway through which inflammation sustains tumor development and 
progression is NF-κB signaling. Activated NF-κB has been detected in the majority of human 
malignancies (Ben-Neriah and Karin, 2011). It triggers the transcription of genes than control 
cell survival, proliferation, growth, as well as angiogenesis, invasion and chemokine and 
cytokines production, acting as key coordinators of innate immunity and inflammation (Figure 
2.6) (Grivennikov et al., 2010). For example, NF-κB promotes the expression of multiple pro-
survival and anti-apoptotic proteins, such as Bcl-2 and Bcl-xL, as well as c-IAP1 and c-IAP2, 
Mcl-1, c-FLIP, and survivin (Grivennikov et al., 2010). Interestingly, senescence state is 
reinforced by a senescence-associated secretory phenotype, (that include IL-1, IL-6 and 
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chemoattractants, such as IL-8), induced by NF-κB. Intriguingly, recent work demonstrates that 
loss of wt p53 induces a senescence-associated low grade inflammation in stressed colonic 
epithelial cell, promoting tumorigenesis (Pribluda et al., 2013). 
Recent studies observed the involvement of inflammation also in prostate cancer (PCa) (Sfanos 
and De Marzo, 2012). Accordingly, the long-term use of aspirin decreases risk of PCa in men 
(Vidal et al., 2015). 
 
	  	  
	  
Notably, it is well known that besides NF-κB, other inflammatory mediators contribute to 
metastasis of tumor cells. TGFβ, TNF, IL-6 and IL-1 enhance EMT by down-regulating the 
expression of epithelial markers (e.g. E-cadherin) and up-regulating the expression and activity 
of metalloproteins (Adorno et al., 2009; Bates and Mercurio, 2003; Sullivan et al., 2009; 
Voronov et al., 2003; Wu et al., 2009). Myeloid-derived monocytes and macrophages strongly 
facilitate tumor cell invasion, extravasation, and metastatic outgrowth (Elinav et al., 2013).  
Inflammation promotes the intravasation of cancer cells into blood vessel and lymphatics, 
through a crosstalk between tumor-associated macrophages (TAMs) and tumor cells 
(Grivennikov et al., 2006). Inflammatory mediators enhance the survival of circulating 
metastatic cells and promote their extravasation by up-regulating adhesions molecules. For 
example, CC- and CXC-chemokine and their receptors, (e.g. CCR1, CCR4, CCR7, CCR9, 
Figure 2.7: NF-κB regulated processes. NF-κB activation affects six hallmarks of cancer, through the 
transcription of genes involved in proliferation, survival, metastasis and invasion, angiogenesis, cell death and 
inflammation. Taken from (Baud and Karin, 2009). 
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CCR10, CXCR1-5 and CXCR7) are expressed by malignant cells from various tissues in 
response to cytokines; they direct the organ-specific migration of cancer cells (Grivennikov et 
al., 2010). Similarly, CCL18 and CCL2 promote mammary tumor migration by enhancing the 
adherence of metastatic cells to the extracellular matrix (Chen et al., 2011a; Qian et al., 2011; 
Wolf et al., 2012). 
Importantly, inflammatory processes that accompany carcinogenesis can also exert an anti-tumor 
action that can be stimulated by multiple cytokines and accomplished by infiltrating immune 
cells. Indeed, various chemokines are associated with generating an anticancer immune 
contexture in various type of malignances (Bindea et al., 2013; Chew et al., 2012; Hirano et al., 
2007; Kondo et al., 2006; Kunz et al., 1999; Rody et al., 2011). Therefore, a fine balance is 
generated within the tumor microenvironment between inflammatory mediators that are involved 
in attracting immune cells and modulating their activity, and those regulating cancer cell survival 
and acquisition of a more aggressive phenotype. An imbalance in this complex network of 
signals can skew the anti-tumor response of immune system to an anti-inflammatory process that 
sustain and enhance carcinogenesis.  
 
2.2.2 Immune modulation by cancer (crosstalk between cancer and immune system) 
One of the most important aspects of the inflammatory tumor microenvironment is the ability of 
cancer cells to interfere with every step of the antitumor inflammation response. Tumor cells act 
both in the recruitment and in the activation of adaptive and innate immunity. 
They can reprogram the acquired T cells response from the pro-inflammatory and anti-tumoral 
Th1 cell subset, to the pro-tumorigenic Th2 type. Moreover, they can skew the phenotype of 
macrophages and neutrophils to a type 2 differentiation state through the secretion of IL-4, IL-
13, TGFβ and IL-10, and sustain induction of myeloid-derived suppressor cells (MDSCs) 
(Elinav et al., 2013; Grivennikov et al., 2010). For example, in a mouse model of pancreatic 
ductal adenocarcinoma, it was recently shown that tumor-derived GM-CSF (granulocyte-
macrophage colony stimulating factor) promotes the recruitment of  (GR1)+CD11b+ myeloid 
cells that suppress antigen-specific T cells activity at the site of the tumor (Bayne et al., 2012). 
Moreover cancer cells actively recruit Treg in the site of tumor (Facciabene et al., 2011). 
However, cancer cells can also secrete mediators that are associated with an anti-tumor immune 
response. For example, in large cohorts of colorectal tumors, high expression of CX3CL1 (also 
known as fractalkine), CXCL9 and CXCL10, was associated with the infiltration of memory and 
effector T cells, particularly Th1 cells - and was strongly correlated with prolonged disease-free 
survival (Mlecnik et al., 2010). 
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A complex interplay of immune and tumor cells, both of which express inflammatory mediators 
and growth factors, builds the architecture on the immune context in tumors. The coordination of 
this complex network of information is essential to control a tumor. Subtle modification of this 
architecture, provoked by changes in the tumor cells or in the host immune system, or in the 
chemokine milieu of the local microenvironment, may weaken immune control of the tumor, 
with a good opportunity to augment tumor aggressiveness. 
 
 
	  
Figure 2.8: Cells and chemokines that coordinate the cancer cell-mediated immune modulation. The tumor 
microenvironment is characterized by the recruitment of multiple immune cells through the secretion of cytokines 
and chemokines by tumor cells and other infiltrating  immune cells. CTL: cytotoxic T lymphocyte; FDC: follicular 
dendritic cell; MDSC: myeloid-derived suppressor cell; NK: natural killer; Tfhcell: T follicular helper cell; Th:T 
helper; Treg:  regulatory T cell . Image taken from (Fridman et al., 2012). 	  
 
2.2.3 TNFα signaling  
The principal sources of TNF are activated immune cells, especially macrophages and T-cells, 
but TNF can be efficiently produced by other cell types, including fibroblasts and tumor cells 
(Wajant et al., 2003). TNF binds two distinct receptors, TNFR1 e TNFR2. This interaction 
results in the recruitment of the death domain-containing serine-threonine kinase RIP and the 
death-domain-containing adapter protein TRADD that, in turn, mediates the recruitment of 
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TRAF2 (Complex I). This protein complex recruits and activates the multi-protein cytoplasmic 
IKK, responsible for the inhibitory phosphorylation of IκB at two conserved serine residues in 
N-terminal regulatory domain. Once phosphorylated, IκB almost immediately undergoes 
polyubiquitination and degradation by proteasome, releasing p65/p50 from the inhibitory 
binding and leading to NF-κB activation (Figure 2.9) (Perkins, 2007; Wajant et al., 2003). 
Activation of NF-κB, mediates pro-tumorigenic activities of TNF. 
TRAF2 and RIP also mediate activation of JNK and p38 MAP kinase cascade, stimulating 
programed cell death (Figure 2.9) (Wajant et al., 2003). TNFR1 can induce cell death by other 
two distinct processes. First, it induces necrosis, which is mediated by RIP- and TRAF2- driven 
excessive generation of ROS and subsequent prolonged JNK signaling (Lin et al., 2004). 
Second, TNRF1 induces caspase-mediated apoptosis, which involves the death domain 
contained in TRADD and FADD (Fas-associated death domain) and activation of the initiator 
caspase-8 (Complex II- Figure 2.9) (Wajant, 2009). 
Notably, in some cases, TNF secretion in the microenvironment can exert an anti-tumor effect, 
inducing hyper-permeability in tumor-associated vessels, thus facilitating tumor entry of blood 
cells, and their cytotoxic properties. TNF can also stimulate the activity of antigen presenting 
cells (APC), promoting the immune response (Wajant, 2009). 
However the finding that TNF depletion in mice protects from skin cancer development offered 
incontrovertible genetic evidence of its pro-tumor function (Moore et al., 1999).  
In fact, tumor promotion mediated by TNF involves different strategies: TNF enhances tumor 
growth and invasion, leukocyte recruitment, especially those not related with cytotoxic activity, 
angiogenesis and facilitates EMT (Colotta et al., 2009; Wajant, 2009).  TNF secreted by TAMs 
promotes Wnt/βcatenin signaling, through the inhibition of GSK3β, contributing to tumor 
development in gastric mucosa (Oguma et al., 2008). In breast cancer cells, TNF secretion in the 
tumor microenvironment establishes a crosstalk between tumor cells, immune cells and CAF, 
strongly sustaining invasiveness of breast cancer cells (Hagemann et al., 2004; Stuelten et al., 
2005; Wang et al., 2005). Finally, TNF, together with IL-1 and IL-8 (also known as CXC-
chemokine ligand 8), is also involved in prostate cancer initiation and progression, where its 
expression is also an indicator of worst prognosis, increased bone metastasis and shorter time to 
castration resistance and overall survival (Kea et al., 2013; Sharma et al., 2014; Wang et al., 
2013). 
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Figure 2.9: TNFR1 induces TNF signaling activation by protein complex I and II. TNFR1 is obquitiosly 
expressed in all cell types and can sustain directly the activation of pro-apototic pathways (JNK/p38MAP kinase and 
caspase 8 signaling) and pro-survival and pro-cell motility signals (NF-κB). Illustration taken from (Wullaert et al., 
2006) (see the text for details).  	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SUMMARY
Inflammation is a significant factor in cancer develop-
ment, and a molecular understanding of the parame-
ters dictating the impact of inflammation on cancers
could significantly improve treatment. The tumor
suppressor p53 is frequently mutated in cancer, and
p53 missense mutants (mutp53) can acquire onco-
genic properties. We report that cancer cells with
mutp53 respond to inflammatory cytokines increas-
ing their invasive behavior. Notably, this action is
coupled to expression of chemokines that can ex-
pose the tumor to host immunity, potentially affecting
response to therapy. Mechanistically, mutp53 fuels
NF-kB activation while it dampens activation of
ASK1/JNK by TNFa, and this action depends on
mutp53 binding and inhibiting the tumor suppressor
DAB2IP in the cytoplasm. Interfering with such
interaction reduced aggressiveness of cancer cells
in xenografts. This interaction is anunexploredmech-
anism by which mutant p53 can influence tumor
evolution, with implications for our understanding of
the complex role of inflammation in cancer.
INTRODUCTION
Inflammation is tightly linked to cancer, but a mechanistic
comprehension of this complex relationship remains elusive. In
the tumor stroma inflammatory chemokines and cytokines, such
as Tumor Necrosis Factor alpha (TNFa), modulate the activity of
infiltrating immune cells and also the behavior of cancer cells,
influencing tumor growth, dissemination, and response to
therapy (Grivennikov et al., 2010). Molecular studies aimed at
defining the impact of inflammation on specific tumors could
thusprovidenovelprognosticmarkersand therapeutic strategies.
Expression of mutant p53 isoforms (mutp53) is another
significant factor in cancer development, since tumor-asso-
ciated p53 mutants can actively promote transformation
through oncogenic gain-of-function (GOF) activities (Muller
and Vousden, 2013; Oren and Rotter, 2010; Walerych et al.,
2012).
Various evidences suggest that mutp53 oncogenic properties
are deeply connected to tumor inflammation (Solomon et al.,
2011, 2012; Yeudall et al., 2012). Perhaps the most convincing
is a recent study on a mouse model of inflammatory bowel
disease, reporting that mutp53 amplifies and sustains the proin-
flammatory microenvironment, leading to an increase in the rate
of transformation (Cooks et al., 2013).
In addition to favoring inflammation-induced cell transfor-
mation, mutp53 may have an unexplored role in shaping
the response to inflammation of already transformed cancer
cells. In fact, a large proportion of tumors undergo p53
mutation at a later stage of transformation, when an inflam-
matory microenvironment has been established within the
growing tumor mass. The recognition and molecular under-
standing of a potential mutp53 GOF in inflammation-driven
tumor progression and metastasis is therefore of primary
interest.
In the recent past, we identified 37 novel interactors of p53
family members (Lunardi et al., 2010). Among them, the RasGAP
Disabled2 Interacting Protein (DAB2IP), also called ASK1 Inter-
acting Protein (AIP1), stands out for its role in signaling by
growth factors and inflammatory cytokines. Modulating the cell
response to multiple potentially oncogenic signals, DAB2IP is a
bona fide tumor suppressor and is frequently silenced by pro-
moter methylation in aggressive human tumors (Dote et al.,
2004; Qiu et al., 2007). Nonetheless, in many tumors DAB2IP
is not methylated, and alternative mechanisms might exist to
interfere with its functions.
In the present study, we find that DAB2IP can be functionally
inactivated by physical interaction with mutant p53 proteins,
with implications for the response of cancer cells to inflammatory
cytokines.
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RESULTS
Mutant p53 Increases the Invasive Behavior of Cancer
Cells Exposed to Inflammatory Cytokines and
Specifically TNFa
To explore the role of p53 mutation in the response of cancer
cells to inflammation, we performed invasion assays with human
breast cancer cell lines bearing mutant p53. To mimic the cyto-
kine milieu of the tumor microenvironment, we used culture
medium conditioned by LPS-activated murine dendritic cells
(dendritic cell-conditioned medium [DCCM]). The cell lines
used are metastatic and thus penetrate matrigel, but DCCM
caused a significant increase in such behavior. Under these con-
ditions, p53 depletion abrogated the effect of DCCM, indicating
that mutp53 is required for this phenotype (Figures 1A, S1A, and
S1B available online).
We performed the same experiments with Ras-trasformed
embryonic fibroblasts (MEFs) derived from p53 knockout or
p53(R172H) knockin mice; DCCM triggered a greater increase
in invasion in mutp53 than in p53 null MEFs (Figure S1D),
indicating that this phenotype represents a mutp53 gain of
function.
Activated dendritic cells secrete a variety of cytokines and
growth factors, including TNFa and TGFb (Moustakas et al.,
2002). Mutant p53 can form a complex with activated Smad2
and p63 in cancer cells, driving metastasis in response to
TGFb (Adorno et al., 2009); a specific TGFb inhibitor had no
impact on the proinvasive response to DCCM, thus excluding
this aspect of the mutp53/p63 axis in the phenotype. In contrast,
a TNFa blocking antibody efficiently suppressed the increase
in invasion induced by DCCM (Figure 1B), indicating that TNFa
is the main mediator of this effect.
Mutant p53 Increases Cell Invasion and Protects
from Apoptosis in Response to TNFa
We thus repeated the above experiments using recombinant
human TNFa, confirming that TNFa increases cell invasion in
a mutp53-dependent manner (Figures 1C and S1C). This result
was confirmed in a pancreatic cancer cell line with the
p53(R273H) mutation (PANC-1), so it is not restricted to mam-
mary cells (Figure S7A).
To verify whether mutp53 is sufficient for this phenotype, we
introduced mutant p53 in a nontransformed mammary epithelial
cell line. We used MCF-10A stably silenced for endogenous
wild-type (WT) p53 (MCF-10A shp53) to generate a panel of
mutp53 knockin cell lines (Figure 1D). Notably, TNFa treatment
rendered mutp53 knockin cells significantly more invasive than
p53 knockdown cells (Figures 1E and S1E). We conclude that
mutp53 is sufficient to mediate this response in nontransformed
cells.
We also analyzed the death-inducing effects of TNFa on
breast cancer cell lines before and after mutant p53 knockdown.
With the exception of MDA-MB-231, which underwent a partial
G2 arrest (Figure S1F), mutp53 depletion sensitized cells to
TNF-induced cell death (Figures 1F and 1G), indicating that
mutant p53 restrains TNF-induced activation of proapoptotic
pathways. This effect was confirmed also in PANC-1 cells
(Figure S7B).
Mutant p53 Modulates TNF-Induced Transcription
toward a Proinvasive and Immunogenic Gene
Expression Program
To gain a molecular insight on this phenotype, we used micro-
arrays to analyze the transcriptional profile of MDA-MB-231
treated with TNFa for 20 hr, with or without mutp53 silencing.
Mutp53 depletion had a broad impact on transcription, indepen-
dently of TNFa (Figure S2A), so we examined TNF-responsive
genes, defined as the union of genes up- or downregulated by
TNFa in control and/or mutp53-depleted cells (Table S1). Gene
ontology (GO) enrichment analysis revealed that TNF-repress-
ible genes are mostly related to the mitotic cell cycle. In contrast,
TNF-inducible genes display a much broader spectrum of bio-
logical functions, including cell migration, apoptosis, and inflam-
matory and immune response (Table S2). Since in our cell
models mutant p53 sustains invasion and survival, we focused
our analysis on TNF-inducible genes and identified those less
expressed (TNF-upsiC) or more expressed (TNF-upsip53) after
mutp53 knockdown (Figure 2A).
Microarrays were validated by RT-qPCR on a selection of
genes belonging to the TNF-upsiC and TNF-upsip53 groups,
confirming their mutp53-dependent regulation (Figures 2C–2D
and S2B). We also analyzed public breast cancer data sets
with information on p53 status (Curtis et al., 2012; Miller et al.,
2011) and verified that the TNF-upsiC metagene is more ex-
pressed in tumors with mutp53 (Figure S2C).
We noticed a specific enrichment for the processes ‘‘immune
response,’’ ‘‘cytokine production,’’ and ‘‘positive regulation
of cell migration’’ in TNF-upsiC genes (Figure 2B), suggesting
that mutp53 modulates a transcriptional response to TNFa that
can be proinvasive but also immunogenic. Indeed, TNF-upsiC
genes include secreted proteins that can stimulate cell migra-
tion and metastasis (e.g., CA12, MMP9, and CXCL10) (Bjordahl
et al., 2013; Muthuswamy et al., 2012; Xin et al., 2005), but also
chemokines that may control recruitment of lymphocytes (e.g.,
CXCL10, CX3CL1, and LTB) (Duffy et al., 2000; Hsieh et al.,
2010; Shin et al., 2010). To verify this last point, we asked
whether medium conditioned by TNFa-treated MDA-MB-231
cells could attract lymphocytes from peripheral blood. We
observed chemotaxis of T lymphocytes, cytotoxic T lympho-
cytes (CTL), and Natural Killer cells. Importantly, this activity
was reduced by mutp53 knockdown (Figure S2D). Therefore,
mutp53 can affect both cell-autonomous and non-cell-autono-
mous responses to TNFa.
Mutant p53 Coordinately Modulates TNF-Dependent
Activation of Both NF-kB and JNK Pathways
Many of the genes identified are direct NF-kB targets (Table S1),
yet they display a striking difference in mutp53 dependency. In
addition to NF-kB, TNFa can trigger activation of ASK1/JNK
kinases, and these two signaling axes have a complex reciprocal
interaction that can affect gene expression (Wajant et al.,
2003). We used inhibitors to selectively block either branch of
the pathway and analyzed TNF-responsive genes differently
affected by mutp53: MMP9 (TNF-upsiC group) and IL1B (TNF-
upsip53 group). Not surprisingly, induction of both genes was
impaired by the NF-kB inhibitor BAY (BAY11-7082), confirming
that they are NF-kB targets (Figure 2E). However, there were
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Figure 1. Mutant p53 Amplifies the Aggressive Behavior of Cancer Cells Exposed to Inflammatory Cytokines and TNFa
(A) Mutp53 drives inflammation-induced invasion. MDA-MB-231 cells were transfected with control (siC) or p53 (sip53) siRNAs; invasion assays were performed
with medium conditioned by activated dendritic cells (DCCM). Graph summarizes migrated cells per area (mean ± SD; n = 3; **p < 0.01). Mutp53 depletion
was checked by western blot. Representative images of migrated cells are shown in Figure S1A.
(B) Invasion assays with MDA-MB-231 were performed as in (A). Rabbit IgG (10 mg/ml), TNFa blocking antibody (10 mg/ml), or TGFb inhibitor SB431542 (10 mM)
were added to the medium as indicated (mean ± SD; n = 3; *p < 0.05).
(C) Invasion assays with indicated cell lines were performed in low serum plus 10 ng/ml TNFa (mean ± SD; n = 3; ***p < 0.001). Representative images of migrated
cells are shown in Figure S1C.
(D and E) Mutp53 is sufficient for TNF-induced invasion. MCF-10A cells stably silenced for endogenous WT p53 (shp53) were infected with retroviruses ex-
pressing shRNA-resistant (*) p53 mutants. (D) Immunofluorescence of exogenous p53 mutants. Immunoblots are shown in Figure S1E. (E) Transwell migration
assays (mean ± SD; n = 3; ***p < 0.001).
(F and G) Mutp53 depletion sensitizes cancer cells to TNF-induced cell death. (F) Indicated cells were treated with TNFa (10 ng/ml) for 48 hr. DNA content was
analyzed by flow cytometry (mean ± SD; n = 3; **p < 0.01). Mutp53 depletion was checked by immunoblotting (bottom). (G) SUM-149 cells were treated with TNFa
for 24 hr and analyzed by western blot to detect cleaved PARP and CASP-3.
See also Figure S1.
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interesting differences in the response to the JNK inhibitor SP
(SP600125). TNF-dependent induction of IL1B was reduced by
SP treatment, indicating that both NF-kB and JNK positively
regulate this gene. In contrast, induction of MMP9 was
unaffected by SP in control cells but was amplified by SP in
p53-depleted cells, suggesting that JNK represses this gene in
the absence of mutp53. Identical results were obtained with
CXCL10 and PTGS2 (Figure S2E). Transient knockdown of p65
RelA or JNK by siRNA produced similar outcomes (Figure S2F),
confirming the direct involvement of these factors.
Together, the data are consistent with a model in which
mutp53 sustains activation of NF-kB while counteracts activa-
tion of JNK in response to TNFa (Figure S2G). In line with this
concept, predicted JUN/AP-1 consensus elements are enriched
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Figure 2. Mutant p53 Modulates the TNF-
Induced Transcriptional Landscape
(A) MDA-MB-231 cells were treated with TNFa
for 20 hr and analyzed by Illumina microarray.
TNF-inducible genes less expressed (TNF-upsiC,
black) or more expressed (TNF-upsip53, gray) in
mutp53-depleted cells were selected. See also
Table S1.
(B) Representative Gene Ontology terms specif-
ically enriched in TNF-upsiC or TNF-upsip53
genes. See also Table S2.
(C) Expression of selected TNF-upsiC (black)
or TNF-upsip53 (gray) genes was validated by
RT-qPCR. Bars indicate differential expression in
sip53_TNF versus siC_TNF samples (mean ± SD;
n = 3). Values are normalized to histone H3 and
compared to untreated siC-transfected samples.
(D) Expression of selected genes at 6 hr or 20 hr of
TNFa treatment. Corresponding p53 immunoblot
is shown in Figure S2B.
(E) Mutp53 sustains NF-kB and counteracts JNK-
dependent transcription. MDA-MB-231 cells were
stimulated with TNFa for 20 hr and treated with the
NF-kB inhibitor BAY11-7082 (1 mM) or the JNK
inhibitor SP600125 (10 mM) as indicated. Expres-
sion of MMP9 and IL1B mRNAs was measured
by RT-qPCR as in (C). Dashed lines mark TNF-
induced expression levels without inhibitors.
See also Figure S2.
in the promoters of genes selectively up-
regulated by TNFa in mutp53-depleted
cells (Figure S2H).
Mutant p53 Interacts with the
Tumor Suppressor DAB2IP in the
Cytoplasm
To unveil the mechanism of this mutp53
action, we searched for a potential target
with a role in TNF signaling. We focused
onthe tumorsuppressorDAB2IP,aprotein
that promotes activation of ASK1/JNKand
inhibits activation of NF-kB in response to
TNFa (Zhang et al., 2003, 2004).
We had previously found that DAB2IP
can bind p53 family proteins (Lunardi
et al., 2010); using coaffinity purification assays, we verified
that DAB2IP can interact with hot-spot missense p53 mutants,
with no evident bias for contact or conformational alterations
(Figure 3A). Using deletion constructs, wemapped the reciprocal
binding to the C2 domain of DAB2IP and the core domain of
different p53 mutants (Figures 3B–3C and Figures S3A and
S3B). This suggests that interaction does not involve p53 struc-
tural elements required for binding to DNA. This also implies that
most p53 mutants can potentially bind DAB2IP.
DAB2IP is a cytoplasmic protein, so interaction with mutp53
must occur in the cytosol. Using fractionation, we verified that
mutp53 is present in sizeable amounts in the cytoplasm of met-
astatic breast cancer cell lines (Figures 3D and S3F). The same
was observed with p53 mutants expressed in nontransformed
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cells (Figure S3D). Using coimmunoprecipitation, we proved
interaction between endogenous DAB2IP and mutp53 in the
cytosolic fraction of MDA-MB-231, SUM-149, and PANC-1 cell
lines (Figures 3E, S3F, and S7C), with different p53 mutants.
No interaction was detected between endogenous DAB2IP
and p53 in the cytosolic fraction of cells with wild-type p53 (Fig-
ure S3E). Thus, mutant p53 could affect TNF-induced activation
of NF-kB and JNK by binding DAB2IP and interfering with its
functions.
Inhibition of DAB2IP Defines a Cytoplasmic Gain of
Function of mutp53
The above hypothesis implies that mutp53 should affect up-
stream events of the TNFa transduction cascade (Zhang et al.,
2004). We analyzed TNF-induced IKBa and JNK phosphoryla-
tion as readouts of NF-kB and ASK1 signaling branches, respec-
tively. In the absence ofmutp53, phosphorylation and turnover of
IKBa were significantly reduced, indicating less efficient activa-
tion (Figures 4A and S7D). Accordingly, nuclear translocation
and activation of p65 RelA was also reduced (Figures 4C–4D
and S3G).
Depletion of WT p53 had no impact on TNF-induced IKBa
phosphorylation and p65 nuclear translocation in HCT116 cells
(Figures S3H and S3I), supporting the notion that this phenotype
is specific for mutant p53.
Oppositely, phosphorylation of JNK was increased and longer
lasting in the absence of mutp53 (Figure 4B), as was phosphor-
ylation of p38 MAPK, another ASK1 downstream kinase (Fig-
ure S3J). Together, these effects are consistent with mutp53
inhibiting DAB2IP and provide a mechanistic explanation for
the coordinated impact of mutp53 on TNF-induced NF-kB and
JNK activation.
The above hypothesis also implies that mutant p53 nuclear
activities should not be required for the phenotype. To test
this, we replaced the endogenous mutp53 of MDA-MB-231 cells
with the same p53 mutant (R280K) deprived of nuclear locali-
zation signals (NLSs). Strikingly, expression of mutp53(DNLS)
efficiently restored TNF-induced invasion in mutp53-depleted
MDA-MB-231 cells (Figure 4E). The same was recapitulated in
MCF-10A nontransformed cells; replacement of endogenous
WT p53 with a cytoplasmic p53 mutant was sufficient to amplify
TNF-induced migration (Figure 4F).
We conclude that this specific GOF of mutant p53, i.e.,
increased invasion triggered by inflammatory cytokines, is
largely mediated by its cytoplasmic fraction.
The Effects of mutp53 in Modifying the Response
to TNFa Depend on Its Binding to DAB2IP
To assess their functional relationship, we tested whether deple-
tion of DAB2IP could rescue the effects of mutp53 knockdown
in our cell models.
Silencing of DAB2IP restored TNF-induced invasion in
mutp53-depletedMDA-MB-231 cells (Figures 5AandS4A). Simi-
larly, DAB2IP knockdown protected mutp53-depleted SUM-
149 cells from TNF-induced apoptosis (Figure 5B). The same
relationship was confirmed in modulation of TNF-dependent
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Figure 3. Mutant p53 Interacts with DAB2IP
in the Cytoplasm
(A) DAB2IP binds hot-spot p53 mutants. We co-
transfected 293T cells with HA-DAB2IP together
with plasmids expressing p53 mutants fused to
MBP. After purification on amylose resin, HA-
DAB2IP bound to mutp53 was detected by west-
ern blot (top). Middle: DAB2IP in the lysate (1/40
inputs). Both panels are from the same autoradi-
ography film (i.e., have the same exposure).
Bottom: MBP-p53 fusion proteins (baits) after
affinity purification.
(B) DAB2IP binds mutp53 through the C2
domain. Schematic representation of DAB2IP
deletions used (PH, pleckstrin homology domain;
C2, synGAP-like C2 domain; GAP, Ras-GTPase
activating domain; DUF3498, domain of un-
known function). Binding to MBP-p53(R175H)
is indicated.
(C) p53 mutants bind DAB2IP through the DNA
binding domain (DBD). Schematic represen-
tation of mutant p53 deletions used (TA, trans-
activation; Ct, oligomerization/C-terminal regula-
tory). Their interaction with HA-DAB2IP(1-186) is
indicated.
(D) Cytoplasmic localization of mutant p53. MDA-
MB-231 cells were subjected to fractionation to
separate cytoplasm and nuclei. Equal fractions of
each sample were analyzed by western blot. Tubulin (cytoplasmic) and Lamin C (nuclear) were blotted as controls.
(E) Endogenous p53(K280R) and p53(M237I) mutants were immunoprecipitated respectively from the cytoplasmic fraction of MDA-MB-231 and SUM-149 cells.
Coprecipitated endogenous DAB2IP was detected by western blot. Sp1 was blotted to confirm cytoplasm purity. Input is 1/100 of the cytoplasmic fraction.
See also Figure S3.
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transcription, whereby knockdown of DAB2IP strikingly reverted
the effects of mutp53 depletion (Figures 5C, S4B, and S7E).
Finally, depletion of DAB2IP restored to normal the kinetics of
TNF-induced IKBa, JNK, and p38 phosphorylation (Figures 5D–
5F and S4C), as well as p65 nuclear translocation (Figure 5E), in
mutp53 knockdown cells. In all these experiments, depletion of
DAB2IP had a negligible impact on TNF-induced phenotypes
in the presence of mutp53, strongly supporting an epistatic rela-
tionship between the two proteins.
Consistently, DAB2IP overexpression abolished the proinva-
sive behavior of MDA-MB-231 cells in response to inflammatory
cytokines. Of note, escalating mutp53 levels in the cytoplasm,
by overexpression of p53(R280K)DNLS, fully restored inflam-
mation-induced invasion in DAB2IP-overexpressing cells (Fig-
ure 6A), strongly suggesting that mutp53 interferes with DAB2IP
metastasis-suppressive functions.
DAB2IP interaction with the protein kinase ASK1 is required to
funnel TNF-signaling toward the JNK pathway (Min et al., 2008;
Zhang et al., 2003, 2004). In transient overexpression, we verified
that increasing amounts of p53(R280K) caused a progressive
reduction in the fraction of DAB2IP bound to ASK1 (Figures 6B
and S5A). Analyzing endogenous proteins, we observed that
depletion of mutant p53 in MDA-MB-231 cells increased the
fraction of DAB2IP coimmunoprecipitatedwith ASK1 (Figure 6C).
Together, these data indicate thatmutp53 can compete with DA-
B2IP physiological interactors and in particular ASK1.
Disruption of the mutp53-DAB2IP Interaction Reduces
the Invasive Behavior of Cancer Cells Exposed to
Inflammation
We found that mutp53 binds to the N terminus of DAB2IP. To
interfere with this interaction, we constructed a chimeric protein
in which the first 186 amino acids of DAB2IP are fused to GFP.
Since the C2 domain of DAB2IP is also involved in interaction
with ASK1, we introduced a mutation that specifically prevents
ASK1 binding (KA2, Figures S5B and S5C) (Zhang et al., 2003).
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Figure 4. Cytoplasmic Gain of Function of
Mutant p53 in the Response to TNFa
(A) Mutant p53 sustains TNF-induced phosphory-
lation and degradation of IKBa. MDA-MB-231
cells were silenced with indicated siRNAs, serum
starved, and treated with TNFa (10 ng/ml). Phos-
phorylated and total IKBa were measured by
immunoblotting. Bottom: the ratio of phosphory-
lated over total IKBameasured by densitometry on
autoradiography films (mean ± SD; n = 3).
(B) Depletion of mutant p53 increases JNK acti-
vation by TNFa. Cells were treated as in (A).
Phosphorylated and total JNK were analyzed by
immunoblotting.
(C and D) Mutant p53 sustains TNF-induced nu-
clear translocation and activation of p65 RelA. (C)
Cells were treated as in (A). At the indicated times
cells were subjected to biochemical fractionation
to separate cytoplasm and nuclei. Tubulin (cyto-
plasmic) and Lamin C (nuclear) were blotted as
controls. (D) Sequence-specific DNA binding of
p65 RelA was measured by ELISA in cells treated
as in (A) (mean ± SEM; n = 4; *p < 0.02). Control
immunoblots are shown in Figure S3G.
(E and F) Cytoplasmic mutant p53 promotes
inflammation-driven invasion. (E) MDA-MB-231
cells stably silenced for mutp53 (shp53) were in-
fected with retroviruses encoding shRNA-resistant
(*) versions of p53(R280K) or its cytoplasmic
variant p53(R280K)DNLS. Matrigel invasion as-
says with DCCM were done as in Figure 1A. Bars
indicate the fold increase in migrated cells in
DCCM versus Ctrl medium (mean ± SD; n = 3; **p <
0.01). Localization of mutp53 proteins (red) was
verified by immunofluorescence. Expression
levels were checked by western blot (bottom). (F)
MCF-10A cells stably silenced for WT p53 (shp53)
were infected with p53(R280K)DNLS retrovirus as
in (E). Transwell migration assays with TNFa were
performed as in Figure 1E (mean ± SD; n = 3; **p <
0.01). Expression of p53 was checked by western
blot (bottom).
See also Figure S3.
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Figure 5. Functional Interaction between Mutant p53 and DAB2IP in the Response of Cancer Cells to Inflammatory Cytokines
(A) MDA-MB-231were silenced for DAB2IP and/or mutp53 as indicated. Invasion assays were performedwith DCCMas in Figure 1A (mean ± SD; n = 2; *p < 0.05;
***p < 0.001). Control immunoblot in Figure S4A.
(B) SUM-149 were silenced for DAB2IP and/or mutp53, serum starved, and treated with TNFa (10 ng/ml) for 24 hr. The fraction of cells in SubG1 was measured
by flow cytometry (mean ± SD; n = 3; **p < 0.01; ***p < 0.001). The same cells were analyzed by western blot to detect cleaved PARP and CASP-3 (bottom).
(C) MDA-MB-231 were silenced for DAB2IP and/or mutp53. Expression of MMP9 and IL1B was measured by RT-qPCR after 20 hr of TNFa as in Figure 2
(mean ± SD; n = 3; *p < 0.05; ***p < 0.001). Control immunoblot in Figure S4B.
(D) MDA-MB-231 were silenced for DAB2IP and/or mutp53, and treated with TNFa as in Figure 4A. Phosphorylated and total IKBa were detected by immu-
noblotting.
(E) Cells treated as in (D) were subjected to biochemical fractionation to separate cytoplasm and nuclei. Tubulin (cytoplasmic) and Lamin C (nuclear) were blotted
as controls.
(F) MDA-MB-231 were silenced for DAB2IP and/or mutp53 and treated with TNFa as in (D). Phosphorylated and total JNK were analyzed by immunoblotting.
See also Figure S4.
Molecular Cell
A mutp53/DAB2IP Axis in Inflammation and Cancer
Molecular Cell 56, 617–629, December 4, 2014 ª2014 Elsevier Inc. 623
A B C
E
– –
+ + + + +
+ + + +–
DAB2IP :
ASK1 :
mutp53 :
ASK1
ASK1
p53
IP: ASK1
Input
DAB2IP
DAB2IP
e
G
FP
ve
ct
GFP
input
IP
eGFP-KA2
IgG p53
DAB2IP
DAB2IP
p53
p53
0
25
50
75
100
eGFP eGFP-KA2
%
 D
AB
2I
P 
bi
nd
in
g 
IP:
eGFP
eGFP-KA2
F G
I
H
D
ASK1
DAB2IP
p53
ASK1
DAB2IP
Ig
G
siC
ASK1
sip
53
IP
In
pu
t
IP:
DAB2IP
mutp53 (HA)
Actin
0
1
2
3
4
– + +–
– + +–
Fo
ld
 in
va
sio
n
(D
CC
M/
Ct
rl)
p53 R280K(ΔNLS)
DAB2IP
Fo
ld
 in
va
sio
n
(D
CC
M/
Ct
rl)
Actin
GFP
eGFP
0
1
2
3
siDAB2IP + +– –
eGFP-KA2
DAB2IP
**
**
Ly
m
ph
no
de
 m
as
s 
(m
g)
eGFP eGFP-KA2
0.000
0.002
0.004
0.006
0.008 P < 0.0001
Ly
m
ph
no
de
 
%
 m
et
as
ta
tic
 a
re
a
eGFP eGFP-KA2
0
20
40
60
80 P = 0.013
2 3 4 5
0
100
200
300
Tu
m
o
r 
si
ze
 (m
m3
)
Weeks after injection
eGFP
eGFP-KA2
P < 0.0001
Figure 6. The mutp53-DAB2IP Interaction Is Required for the Invasive Response of Cancer Cells to Inflammation
(A) MDA-MB-231 cells stably overexpressing DAB2IP were infected with a retrovirus expressing HA-p53(R280K)DNLS or an empty retrovirus as a control.
Invasion assays with DCCMwere done as in Figure 1A; bars indicate the increase in cells migrated in DCCM versus Ctrl medium (mean ± SD; n = 3). Protein levels
were checked by western blot (bottom).
(B) H1299 cells were cotransfected with plasmids expressing DAB2IP, HA-ASK1, and increasing amounts of p53(R280K). The fraction of DAB2IP bound to ASK1
was analyzed by western blot of ASK1 immunoprecipitates. Quantification is reported in Figure S5A.
(C) MDA-MB-231 cells were transfected with control or p53 siRNA. Endogenous DAB2IP bound to ASK1 was analyzed by coimmunoprecipitation with anti-ASK1
antibody.
(D) MDA-MB-231 cells were stably transduced with retroviruses expressing eGFP-DAB2IP1-186KA2 fusion protein (eGFP-KA2) or eGFP alone, with or without
DAB2IP siRNA as indicated. Invasion assays were performed as in (A) (**p < 0.01). Expression of eGFP proteins and endogenous DAB2IP was analyzed by
western blot (bottom).
(E) Endogenous mutp53was immunoprecipitated fromMDA-MB-231 cells stably expressing eGFP or eGFP-KA2 (two lines derived from independent infections);
coprecipitated endogenous DAB2IPwas analyzed bywestern blot. Specificity was checked using unrelated IgG (panels are from the same autoradiography). The
fraction of DAB2IP bound to mutp53 was quantified by densitometry; bars represents the DAB2IP(co-IP)/DAB2IP(input) ratio, normalized to the eGFP sample
(mean ± SD; n = 3).
(F–I) Expression of DAB2IP1-186KA2 reduces growth and dissemination of cancer cells in immunocompromisedmice.MDA-MB-231 cells stably expressing eGFP
or eGFP-KA2 were injected in the mammary fat pad of SCID mice and different parameters of tumor progression were evaluated. (F) Kinetics of primary tumor
(legend continued on next page)
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Invasion assays were performed with MDA-MB-231 express-
ing the eGFP-DAB2IP(1-186)KA2 fusion protein. The KA2 decoy
protein had no obvious effects on cell growth and motility, but
clearly reduced invasion triggered by inflammatory cytokines;
notably, this effect requires DAB2IP (Figures 6D and S5D). The
inhibitory action of the KA2 peptide was also verified in PANC-
1 cells (Figure S7F).
Mechanistically, overexpression of the KA2 decoy signifi-
cantly diminished the amount of endogenous DAB2IP coim-
munoprecipitated with mutp53 (Figure 6E), confirming that
reduced invasion might be due to an increase in ‘‘free’’ DAB2IP
protein.
We next extended these experiments to an in vivo model.
When injected orthotopically in the fat pad of nude mice, MDA-
MB-231 cells expressing the KA2 fusion protein formed smaller
tumors than control eGFP-expressing cells (Figure 6F), indi-
cating reduced aggressiveness. To evaluate metastatic dissem-
ination, homolateral axillary lymph nodes were collected and
screened for invading human cells when the primary tumors
reached a similar size. Gross weight and immunohistochemistry
(Figures 6G–6I and S5E) confirmed that KA2-expressing cells
were less abundant in lymph nodes than eGFP-expressing
controls, clearly indicating reduced metastasis. Importantly,
analysis of primary tumors confirmed that mutp53 levels were
not affected (Figure S5F).
Implications of the mutp53/DAB2IP Interaction
in Breast Cancer: A Meta-analysis
To explore the potential clinical impact of this molecular axis, we
analyzed public gene expression data sets. We focused on
basal-like triple negative breast cancers (TNBCs) that have a
high frequency of p53mutation and are an outstanding challenge
for clinical management (Carey et al., 2010; Foulkes et al., 2010;
Walerych et al., 2012).
We used a large metadata set of 19 independent studies, con-
sisting of 3,254 individuals (see Supplemental Information) (Rus-
tighi et al., 2014), and stratified patients based on expression
of the mutp53-dependent TNF-inducible genes that were identi-
fied in MDA-MB-231 cells (Figure 2). To minimize cell line bias,
we selected a subset of these genes consistently coexpressed
in mutp53-enriched breast cancers (upsiC10, Figure S6A). The
upsiC10 signature was not prognostic on the entire data set,
but correlated with prolonged disease-free survival (DFS) in
basal/TNBC patients (Figure 7A). We next restricted our analysis
to data sets with information on p53 status. Notably, the upsiC10
metagene was predictive of survival specifically in patients with
mutant p53 (Figure 7B). Similar results were obtained using all
genes in the TNF-upsiC group (Figure S6B and Table S3).
Since mutp53 makes cancer cells more invasive in response
to inflammation in vitro, the improved patients’ survival suggests
a host interaction effect. We noticed that genes associated to
the TNFa/mutp53 axis include powerful chemokines that can
promote recruitment of immune cells (Figures 2 and S2D), and
an increased B and T cell infiltrate has been correlated to
prolonged DFS in breast cancer (Finak et al., 2008; Fridman
et al., 2012). We thus analyzed expression of immune-specific
gene signatures as a proxy to infer amount and composition of
infiltrating lymphocytes in tumor samples. We used previously
published metagenes already validated in colon (Bindea et al.,
2013) and breast cancer (Rody et al., 2009, 2011).
Within our cohort of basal breast cancers, lymphocyte meta-
genes were significantly more expressed in tumors with higher
expression of the upsiC10 signature (Figures 7C and S6C),
indicative of increased infiltration. Intriguingly, we found higher
expression of cytotoxic (CTL+NK) and Th1, but not Th2, meta-
genes, suggesting that infiltrating T cells might be preferentially
polarized toward a proinflammatory phenotype.
In line with studies by others (Rody et al., 2009, 2011), high
expression of immune metagenes (with the remarkable excep-
tion of Th2 cells) correlated with prolonged DFS in basal/TNBC
patients (Figures 7D and S6D). Strikingly, expression of immune
metagenes correlated with better DFS specifically in tumors with
mutant p53 (Figure 7E and Table S3).
Together, these observations suggest that mutp53 repro-
grams inflammatory signaling toward a gene expression profile
that increases cell motility and survival but also promotes activa-
tion of tumor immune cells, potentially affecting clinical outcome.
DISCUSSION
Various evidences, including our work, indicate that mutation
of p53 plays a primary role in the relationship between inflamma-
tion and cancer, suggesting that mutp53 may shift the effects
of inflammation toward oncogenic outcomes. A recent study
showed that p53 missense mutation can be a driver in inflam-
mation-induced cancer formation (Cooks et al., 2013). Here,
we demonstrate that mutp53 can also drive inflammation-
induced cancer progression.
We observed that mutant p53 can influence multiple down-
streammolecular pathways activated by the TNF receptor.While
confirming that mutp53 sustains TNF-induced activation of
NF-kB, as previously reported by others (Cooks et al., 2013;
Schneider et al., 2010; Weisz et al., 2007), we demonstrated
that mutp53 also dims TNF-induced activation of ASK1/JNK.
This dual effect is translated in a characteristic gene expression
profile, with strong activation of a group of NF-kB target genes,
but reduced or no activation of another group of NF-kB target
genes.
Previous studies reported that mutp53 is recruited to kB sites
on the promoters of inflammatory genes in response to TNFa
(Cooks et al., 2013; Schneider et al., 2010; Weisz et al., 2007).
We discovered that mutp53 also acts upstream, shifting the
balance between activation of the NF-kB and ASK1/JNK
pathways in response to TNFa. Mechanistically, a fraction of
growth. eGFP, black (n = 10); eGFP-KA2, red (n = 10). (G) Weight of homolateral lymph nodes when primary tumors reached similar size. eGFP, black, 4 weeks
(n = 9); eGFP-KA2, red, 5 weeks (n = 10). (H) Percentage of area occupied by invading cells in lymph nodes, quantified by immunohistochemistry of human
cytokeratin. (I) Representative sections of lymph nodes stained for human cytokeratin (bar = 1 mm).
See also Figure S5.
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mutp53 binds DAB2IP in the cytoplasm, interfering with forma-
tion of TNF-induced signaling complexes that activate the
ASK1/JNK axis, thereby promoting activation of NF-kB.
DAB2IP is a tumor suppressor protein that is rarely mutated
in cancer but is often silenced by promoter methylation (Dote
et al., 2004; Qiu et al., 2007). Our data indicate that binding by
mutp53 is an alternative means to inactivate DAB2IP functions
in cancer. Notably, experiments with nuclear-excluded p53
mutants indicate that this activity may be sufficient to mediate
the invasive response triggered by inflammatory cytokines in
cancer cells. So, this is a bona fide cytoplasmic gain of function
of mutp53.
In addition to funneling TNFa signals toward growth-restrain-
ing activation of ASK1, DAB2IP negatively modulates multiple
oncogenic signaling pathways: most notably Ras and Akt
(Min et al., 2010; Xie et al., 2009, 2010). It is quite possible
that the mutp53/DAB2IP interaction in cancer cells may have
broader effects than promoting inflammation-induced invasion.
For instance, a role of mutant p53 has been described in sustain-
ing Ras (Sauer et al., 2010) as well as Akt activation (Dong et al.,
2009), but a convincing mechanism has not been described. It
is possible that the mutp53/DAB2IP interaction might partially
explain those observations as well.
DAB2IP can bind also WT p53, at least in vitro and in transient
overexpression (Lunardi et al., 2010), raising interesting ques-
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Figure 7. In Silico Analysis Reveals a Poten-
tial Impact of the TNF/mutp53 Axis in the
Clinical Outcome of Breast Cancer
(A) Kaplan-Meier (K-M) survival curves for high or
low expression of the upsiC10 signature in a large
breast cancer metadata set and basal-like/TNBC
samples (see Supplemental Information for de-
tails).
(B) K-M survival curves for high or low expression
of the upsiC10 signature in breast cancers with
known p53 status.
(C) Expression of metagenes identifying specific
immune cell populations (Bindea et al., 2013) in
basal-like/TNBC breast cancers divided accord-
ing to high or low expression of the upsiC10
signature (***p < 0.0001).
(D) K-M survival curves for high or low expression
of immune metagenes in basal-like/TNBC breast
cancers.
(E) K-M survival curves for high or low expression
of T cell and cytotoxic cell metagenes in breast
cancers with known p53 status.
See also Figure S6 and Table S3.
tions on whether such interaction can
occur physiologically. In normal condi-
tions, WT p53 concentration in the cyto-
plasm is very low, and we could not
detect binding of the endogenous pro-
teins. Accordingly, WT p53 depletion
had no impact on DAB2IP-dependent
TNF signaling steps (Figure S3), strongly
indicating that the phenotypes described
here are peculiar tomutant p53. Nonethe-
less, it is tempting to speculate that binding with DAB2IP can
occur upon specific stress conditions that increase cytoplasmic
p53, thus potentially linking p53 to nontranscriptional modulation
of multiple signaling pathways. Additional work will be required
to explore this possibility and its implications.
Our finding that tumor-derived p53 mutants can bind DAB2IP
in the cytoplasm, competing with functionally relevant DAB2IP
protein partners, provides striking evidence that mutant p53
can gain oncogenic functions by making nonphysiological
interactions with other proteins—not necessarily transcription
factors—and interfering with their function (Muller and Vousden,
2013; Oren and Rotter, 2010).
We tested the above principle by designing a fusion protein
that can interfere withmutp53-DAB2IP binding. Notably, expres-
sion of such decoy abolished TNF-induced invasion in vitro, and
xenograft growth and dissemination in vivo, confirming that
this interaction is functionally relevant. These results provide a
crucial proof of principle that peptide or nucleotide aptamers
designed to interfere with the mutp53/DAB2IP interaction might
have a potential application in targeted therapy of mutp53 can-
cers. Future work in this direction is warranted.
Various studies described WT p53 as an important mediator
in the crosstalk between inflammatory microenvironment and
cell behavior. In a complex interplay with NF-kB, p53 modulates
expression of immune-response and inflammation genes; such
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secretory phenotypes can contribute to tumor suppression in
a non-cell-autonomous manner, for instance, controlling the
inflammatory microenvironment and promoting macrophage
M1- versus M2-type polarization (Lowe et al., 2013; Lujambio
et al., 2013; Schwitalla et al., 2013). Loss of p53 can thus
affect inflammatory pathways, eventually contributing to tumor
formation.
In this study, we provide compelling evidence that mutation
of p53, compared to its loss, confers additional properties to
cancer cells, making them more aggressive in response to
inflammatory cytokines and in particular TNFa. Intriguingly, our
data also indicate that cancer cells with mutant p53 respond
to TNFa by expressing secreted molecules that promote recruit-
ment of immune cells, a phenomenon that can be tumor restrain-
ing (Fridman et al., 2012; Galon et al., 2013). We think this is
a sort of ‘‘Achilles’ heel’’ of mutp53 cancers; in response to
inflammation, mutp53-modulated activation of NF-kB conveys
powerful proinvasive and prosurvival activities but, at the same
time, triggers expression of chemokines that can recruit leuko-
cytes and modulate their functions within the tumor. Increased
recruitment of B and T cells is associated with longer relapse-
free survival in breast and other cancers (Fridman et al., 2012;
Lee et al., 2013; Schmidt et al., 2008). Accordingly, our in silico
studies indicate that cancers with mutant p53 have a better
outcome if they express a gene signature linked to the
mutp53/TNFa axis. These observations suggest that a relatively
simple standard clinical-pathological parameter such as
quantity and quality of infiltrating immune cells—i.e., the immu-
noscore (Galon et al., 2013)—may improve prediction of the
clinical outcome of mammary tumors with mutant p53.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments
The following human cell lines were used: MDA-MB-231 (p53R280K), MDA-
MB-468 (p53R273H), SUM-149 (p53M237I), PANC-1 (p53R273H), MCF-10A
(p53 wild-type), HCT116 (p53 wild-type), and U2OS (p53 wild-type).
For gene expression analysis, cells were treated with recombinant human
TNFa (10 ng/ml) in low serum (0.1% FBS) for the indicated times. When neces-
sary, JNK (SP600125) and NF-kB (BAY11-7082) inhibitors were added to the
medium 2 hr before TNFa. For analysis of IKBa, p38, and JNKphosphorylation,
cells were serum starved for 24 hr before TNFa (10 ng/ml) addition.
Migration and Invasion Assays
For transwell migration assays, cells (0.5–13 105) were plated on 24-well PET
inserts (8.0 mmpore size, Falcon). For invasion assays, cells (0.5–13 105) were
plated on 24-well PET inserts (8.0 mm pore size, Falcon) coated with BD
Matrigel (BD Bioscience). Cells that passed through the filter were fixed,
stained, and counted after 16 hr or 18 hr, respectively. For invasion assays
using DCCM, cells were seeded in 10% FBS on the upper chamber, while
the lower chamber was filled with DCCM or control medium.
For invasion or transwell assays using recombinant TNFa, cells were pre-
treated with the cytokine; specifically, cells were kept in low (0.1%) serum
with or without TNFa (10 ng/ml) for 24 hr. Subsequently, cells were trypsinized,
counted, and reseeded on filters in low serum, with or without TNFa. The lower
chamber was filled with high serum medium without TNFa.
Gene Expression Analysis
Total RNA was extracted with QIAzol (QIAGEN). For RT-qPCR, 1 mg of total
RNA was reverse transcribed with QuantiTect Reverse Transcription kit
(QIAGEN). Real-time PCR was performed using SsoAdvanced SYBR Green
Master Mix (Biorad) on a CFX96 Real-Time PCR System (Biorad). Primer
sequences are listed in Supplemental Experimental Procedures.
For microarrays, three biological replicates for each group (siC, siC_TNF,
sip53, sip53_TNF) were hybridized on HumanHT-12-v4-BeadChip (Illumina).
Processing and analysis of the data are described in detail in Supplemental
Experimental Procedures.
In Vivo Tumorigenicity and Metastasis Assays
For xenografts, cells (1 3 106) were resuspended in 100 ml of DMEM and
injected into the mammary fat pad of previously anesthetized 6-week-old
SCID female mice. Tumor growth at the injection site was monitored by caliper
measurements. For metastasis evaluation, animals were anesthetized and
sacrificed at times when tumors were of similar size. Primary tumors were
extracted and directly frozen in liquid nitrogen for molecular analyses. Lymph
nodes were excised, weighted, formalin fixed, and paraffin embedded for
hematoxylin-eosin staining and Cytokeratin 7 immunohistochemistry.
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SUPPLEMENTAL FIGURE LEGENDS 
 
Figure S1 (related to Figure 1): Mutant p53 promotes cell invasion and protects 
from apoptosis in response to TNFα . 
(A) Mutp53 drives inflammation-induced invasion. Representative images of migrated 
MDA-MB-231 and MDA-MB-468 cells from the experiment described in Figure 1A and 
Figure S1B. Cells were fixed and detected by Crystal Violet staining. 
(B) Mutp53 drives inflammation-induced invasion. MDA-MB-468 were transfected with 
control (siC) or p53 (sip53) siRNAs; invasion assays were performed in the presence of 
medium conditioned by activated dendritic cells (DCCM) or control medium (Ctrl). Bars 
indicate the average number of migrated cells per area. Mutp53 depletion was checked by 
western blot of the same cells. 
(C) Mutp53 is necessary for TNF-induced invasion. Representative images of migrated 
cells from TNF invasion experiments in Fig 1C. 
(D) Mutp53 drives inflammation-induced invasion. Ras-transformed mouse embryo 
fibroblasts (MEF) derived from p53-null (-/-) or p53R172H knock-in (m/m) mice were 
used for invasion assays as in B. Migrated cells were fixed and detected by Hoechst 
staining. Bars indicate the average fold increase in cells migrated in DCCM vs Ctrl 
medium (mean ± SD; n=3). Representative images of migrated cells are shown. 
Endogenous p53 was checked by western blot (bottom panels). 
(E) Mutp53 is sufficient for TNF-induced invasion. Representative immunoblots of 
mutp53 expression in the cell lines used for the transwell experiments reported in Fig 1E. 
 
!!
(F) Depletion of mutant p53 sensitizes cancer cells to the cytotoxic effect of TNFα. 
MDA-MB-231, SUM-149, and MDA-MB-468 cell lines were transfected with control 
(siC) or p53 (sip53) siRNAs and treated with TNFα (10 ng/ml) for 48 hr. DNA content 
was analyzed by flow cytometry after Propidium Iodide (PI) staining. Graphs summarize 
percent distribution of the cells in various phases of the cell cycle, as well as cells with 
sub-G1 DNA content (mean of 3 independent experiments). p53 was blotted in the same 
cells to control knockdown efficiency. !!!
Figure S2 (related to Figure 2): Mutant p53 modulates the TNF-induced 
transcriptional landscape of MDA-MB-231 cells 
(A) Unsupervised hierarchical clustering of all genes of the filtered microarray expression 
matrix, excluding features with low standard deviations (<0.4). Red - increased 
expression, green - decreased expression relative to average levels of signals (log 2 scale). 
Genes differentially regulated by TNFα in control vs sip53 treated cells are boxed. 
(B) Validation of microarray results. Expression of ICAM1 (belonging to the TNF-upsiC 
group) and IL1A (belonging to the TNF-upsip53 group) were measured by RT-qPCR at 6 
or 20 hr of TNFα treatment in MDA-MB-231 cells. Data are normalized to H3 gene, and 
compared to expression levels of untreated cells transfected with siC. Depletion of 
endogenous mutant p53 was checked by immunoblotting (panel on the right). 
 
 
!!
(C) The mutp53-dependent TNF-inducible genes identified by microarray in MDA-MB-
231 cells are more expressed in primary breast cancers with mutant p53. 
Expression of the TNF-upsiC metagene in tumors with wild-type or mutant (missense) 
p53 from the Uppsala (Miller et al., 2011) and Metabric (Curtis et al., 2012) datasets. 
Significance was calculated by unpaired t-test (*** P<0.0001). 
(D) Mutp53 sustains a secretory phenotype that stimulates lymphocyte chemotaxis. 
Peripheral blood mononuclear cells (PBMCs) from anonymous healthy blood donors 
were isolated from buffy coats. Transwell migration assays were performed for 45 min in 
the presence or absence of conditioned medium from mutant (siC) or p53 silenced (sip53) 
MDA-MB-231 cells treated with TNFα for 20 hr in low serum. The total number of cells 
migrated to the lower side of the inserts was counted, and differences in population 
distribution were evaluated by flow cytometry after labeling with specific fluorescent 
antibody. The histogram summarizes the number of migrated cells accordingly to the 
different immune subtypes analyzed (mean ± SD; n=4; * P<0.05): Total (Lympho-
monocytes: CD45+), T-cell (T lymphocytes: CD45+/CD3+), CTL (Cytotoxic T 
Lymphocytes: CD45+/CD8+), NK cell (Natural Killer cells: CD3-/CD56+). Efficiency of 
mutant p53 depletion was controlled by immunoblotting (bottom panel). 
(E) Mutp53 sustains NF-κB and counteracts JNK-dependent transcription. MDA-MB-
231 cells were silenced with control (siC) or p53 (sip53) siRNAs, and treated with TNFα 
for 20 hr. Cells were also treated with the NF-κB inhibitor BAY11-7082 (1µM) or the 
JNK inhibitor SP600125 (10µM). Expression of CXCL10 and PTGS2 was measured by 
RT-qPCR as in B (mean ± SD; n=3). Dashed lines provide a reference for TNF-induced 
expression of each gene - with or without mutp53 silencing - in the absence of inhibitors. 
!!
(F) MDA-MB-231 cells were silenced with control (siC) or p53 (sip53) siRNAs. Where 
indicated, cells were also transfected with siRNA against p65 (sip65) and JNK (siJNK). 
Subsequently, cells were treated with TNFα (10ng/ml) for 20 hr. Expression of MMP9, 
CXCL10, IL1B and PTGS2 mRNA was measured by RT-qPCR. Efficiency of p53, p65 
and JNK knockdown was confirmed by western blot (panel on the right). 
(G) A model derived from the observed impact of mutp53 depletion on TNF-induced 
transcription of different NF-κB target genes. 
(H) In silico analysis reveals enrichment of predicted JUN/AP1 transcription factor 
binding sites in the promoters of TNF-inducible genes upregulated by depletion of mutant 
p53 in our microarray. Genes induced by TNFα by at least two-fold were divided in three 
groups: those induced only in the presence of mutant p53 (siC only, black) those induced 
only after mutant p53 knockdown (sip53 only, grey), and those that are induced in either 
condition (common, white). The genes were analyzed using ExPlain 
(http://www.biobase-international.com) to identify enrichment for predicted transcription 
factor binding sites in their upstream genomic sequences. The table summarizes the top 
scoring results. In the tables are indicated the transcription factor (Gene symbol), the 
binding site code (Matrix name), the frequency of the binding site in the promoter of 
analyzed genes (Yes-sites/1000bp), the enrichment with respect to the background 
(Yes/No), and the significance of this enrichment (P-value); data are sorted according to 
P-value. 
 
 
!!
Figure S3 (related to Figures 3 and 4): Physical and functional interaction between 
DAB2IP and mutant or wild-type p53 
(A) Mutp53 binds the C2 domain of DAB2IP. HEK-293T cells were co-transfected with 
the indicated HA-tagged DAB2IP deletion constructs, together with a plasmid expressing 
the p53(R175H) hot-spot mutant fused to MBP. After purification with amylose resin, 
samples were analyzed by western blot. Input lanes correspond to 1/40 of the lysate used 
for Co-AP. Bottom panels show the MBP-fusion proteins (baits) after purification.!
(B) Mutp53 binds to DAB2IP through the DNA binding (DBD) domain. Interaction 
between the DAB2IP 1-186 fragment and various mutp53 deletions fused to MBP was 
analyzed by Co-AP as above. The input is 1/40 of the lysate. The two upper panels are 
from the same autoradiography (i.e. have the same exposure). The bottom panels show 
MBP-fusion proteins (baits) after purification.!
(C) Mutp53 and DAB2IP interact in the cytoplasm. MDA-MB-231 cells were silenced 
with control (siC) or p53 (sip53) siRNAs. Endogenous mutp53 was immunoprecipitated 
from the cytoplasmic fraction of transfected cells. Co-precipitated endogenous DAB2IP 
was detected by western blot. Sp1 was blotted to confirm cytoplasm purity. Input 
corresponds to 1/100 of the cytoplasmic fraction used for immunoprecipitation. 
(D) Cytoplasmic localization of exogenous p53 mutants in infected MCF-10A cells. 
MCF-10A cell lines used in Figure 1D-E were subjected to biochemical fractionation to 
separate cytoplasm and nuclei. Equal fractions of each sample were analyzed by western 
blot. Tubulin (cytoplasmic) and Sp1 (nuclear) were blotted as controls. 
 
!!
(E) Wild-type p53 and DAB2IP do not interact in the cytoplasm. Endogenous mutant p53 
and wt p53 were immunoprecipitated respectively from the cytoplasmic fraction of 
HCT116 and U2OS cells. Co-precipitated endogenous DAB2IP was detected by western 
blot. Lamin C was blotted to confirm cytoplasm purity (absence of nuclei). Input 
corresponds to 1/100 of the cytoplasmic fraction used for immunoprecipitation. 
(F) Cytoplasmic localization of endogenous mutant p53 in SUM-149 breast cancer cells. 
Cells were fractionated and analyzed as in D. 
(G) Mutant p53 sustains TNF-induced activation of p65 RelA. Representative western 
blot of nuclear fractions of MDA-MB-231 cells used for the ELISA experiments in 
Figure 4D. 
(H) Wild-type p53 has no impact on TNF-induced phosphorylation and degradation of 
IKBα. HCT116 cells were silenced with control (siC) or p53 siRNAs (sip53), serum 
starved, and treated with TNFα (10ng/ml) for the indicated times. Phosphorylated and 
total IKBα were detected by immunoblotting. Lower panel shows the ratio of 
phosphorylated IKBα over IKBα in this representative experiment, measured by 
densitometry on autoradiographic films. 
(I) Wild-type p53 has no impact on TNF-induced nuclear translocation of p65 RelA. 
HCT116 cells were treated as in H. At the indicated time-points cells were subjected to 
biochemical fractionation to separate cytoplasm and nuclei. Total cell lysate and purified 
nuclei were analyzed by western blot. Tubulin (cytoplasmic) and Lamin C (nuclear) were 
blotted as controls. 
 
 
!!
(J) Depletion of mutant p53 increases p38 MAPK activation by TNFα. MDA-MB-231 
cells were silenced with control (siC) or p53 siRNAs (sip53), serum starved, and treated 
with TNFα (10ng/ml) for the indicated times. Phosphorylated and total p38 were 
analyzed by immunoblotting. 
 
 
 
Figure S4 (related to Figure 5): Functional interaction between mutant p53 and 
DAB2IP in the response of cancer cells to inflammatory cytokines 
(A) DAB2IP knockdown restores inflammation-driven invasion in mutp53-depleted 
cancer cells. MDA-MB-231 were treated with siRNAs against p53 or DAB2IP, alone or 
in combination, as indicated. Shown is a representative western blot of cells used for 
invasion assays in Figure 5A. 
(B) DAB2IP knockdown restores the transcriptional response to TNFα in mutp53-
depleted cancer cells. MDA-MB-231 cells were silenced for DAB2IP and/or mutp53 as 
indicated. Expression of ICAM1 and PTGS2 was measured by RT-qPCR after 20 hr of 
TNFα (10 ng/ml) treatment as in Figure 5C. DAB2IP and/or mutp53 depletion was 
checked by western blot (bottom panel). 
(C) DAB2IP knockdown counteracts increased TNF-induced phosphorylation of p38 
MAPK in mutp53-depleted cancer cells. MDA-MB-231 cells were silenced for DAB2IP 
and/or mutp53, and treated with TNFα as in Figure 5F. Phosphorylated and total p38 
were analyzed by immunoblotting. 
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Figure S5 (related to Figure 6): The mutp53-DAB2IP interaction is required for the 
invasive response of cancer cells to inflammation. 
(A) Overexpression of mutp53 interferes with DAB2IP binding to ASK1. H1299 cells 
were co-transfected with plasmids expressing DAB2IP, HA-ASK1, and increasing 
amounts of p53(R280K), as indicated. The fraction of DAB2IP bound to ASK1 was 
analyzed by western blotting of ASK1 immunoprecipitates, and quantified by 
densitometry on autoradiography films; bars represent the DAB2IP(co-IP)/DAB2IP(input) 
ratio, normalized to the sample without mutp53 (mean ± SD; n=3). 
(B) The DAB2IP1-186 KA2 peptide binds mutp53. MDA-MB-231 cells were stably 
transduced with retroviruses expressing GFP-DAB2IP1-186 wt, GFP-DAB2IP1-186 KA2 or 
with an empty vector. Cell lysates were immunoprecipitated with an anti-GFP antibody, 
and endogenous mutp53 associated to DAB2IP1-186 variants was analyzed by western blot. 
(C) The DAB2IP1-186 KA2 peptide has negligible binding to ASK1. Cells transduced as 
above were subjected to biochemical fractionation to separate the cytoplasmic and 
nuclear proteins. GFP-fusion proteins were immunoprecipitated from the cytoplasmic 
fraction, and co-immunoprecipitated endogenous ASK1 was analyzed by western blot. 
Input and IP panels are from the same film (i.e. have the same exposure). 
(D) Overexpression of the p53-binding domain of DAB2IP reduces inflammation-driven 
invasion. MDA-MB-231 cells were stably transduced with retroviruses expressing the 
eGFP-DAB2IP1-186KA2 fusion protein (eGFP-KA2), eGFP alone, or an empty vector as 
further control. Invasion assays were performed as in Fig. 6D. Expression of eGFP 
proteins and endogenous DAB2IP was checked by western blot (bottom). 
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(E) Expression of DAB2IP1-186KA2 reduces the metastatic potential of cancer cells 
injected in the fat pad of immunocompromised mice. Representative sections of lymph 
nodes from mice injected with eGFP or eGFP-KA2 expressing cells, stained with 
Hematoxylin and Eosin. 
(F) Primary tumors generated by MDA-MB-231 cells stably expressing eGFP or eGFP-
KA2 were collected from the mammary pads, snap-forzen in liquid nitrogen, and stored 
at -80°C. Tumors were mechanically disrupted, homogenized in lysis buffer, and 
analyzed by western blot for expression of eGFP fusion proteins and endogenous mutant 
p53. 
 
 
 
Figure S6 (related to Figure 7): In silico analysis reveals a potential impact of the 
TNF/mutp53 axis in the clinical outcome of breast cancer 
(A) A subset of genes correlated to the TNFα/mutp53 axis is reproducibly co-expressed 
in breast cancers with mutp53. Heat maps of 1-Pearson correlation coefficients of the 29 
mutp53-dependent TNF-inducible genes derived from our microarray in MDA-MB-231 
cells. Two independent sets of tumors were analyzed: the basal/TNBC samples of the 
Affymetrix breast cancer metadataset (left) and the mutant p53 samples of the Metabric 
breast cancer dataset (right). Genes robustly co-regulated in both sets of tumors (black 
bar) define the upsiC10 signature. 
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(B) Genes linked to the TNFα/mutp53 axis correlate with prolonged metastasis-free 
survival in basal/TNBC breast cancer patients. Kaplan-Meier survival curves for high or 
low expression of the TNF-upsiC signature in the entire breast cancer metadataset, or in 
the basal/TNBC subset. 
(C) Expression of metagenes identifying specific immune cells subpopulations (Rody et 
al., 2009; Rody et al., 2011) in basal-like/TNBC breast cancer samples stratified 
according to high or low expression of the upsiC10 signature. 
(D) Higher expression of lymphocyte markers correlates with prolonged metastasis-free 
survival in basal/TNBC breast cancer patients. Kaplan-Meier survival curves for high 
(red) or low (blue) expression of immune metagenes from Rody et al. (2009) and Rody et 
al. (2011) in basal-like/TNBC breast cancer patients. 
 
 
 
Figure S7 (related to Figures 1, 3, 4, 5 and 6): The mutp53/DAB2IP axis modulates 
the response to TNFα  in the pancreatic cancer cell line PANC-1. 
(A) Mutp53 drives TNF-induced invasion. PANC-1 cells were transfected with control 
(siC) or p53 (sip53) siRNAs. Invasion assays were performed in low serum plus TNFα 
(10ng/ml). Mutp53 depletion was checked by western blot of the same cells (lower panel). 
Representative images of migrated cells are also shown. Bars indicate the average 
number of cells per area (mean ± SD; n=3). 
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(B) Mutp53 depletion sensitizes cells to TNF-induced cell death. PANC-1 cells were 
transfected with control (siC) or p53 (sip53) siRNAs and treated with TNFα (10ng/ml) 
for 48 hr. DNA content was analyzed by flow cytometry after Propidium Iodide (PI) 
staining. The histogram summarizes the fraction of cells in SubG1 (mean ± SD; n=3). 
Mutp53 depletion was checked by western blot of the same cells (left panel). 
(C) Mutp53 and DAB2IP interact in the cytoplasm. Endogenous mutp53 was 
immunoprecipitated from the cytoplasmic fraction of PANC-1 cells. Co-precipitated 
endogenous DAB2IP was detected by western blot. Sp1 was blotted to confirm cytoplasm 
purity. Input corresponds to 1/100 of the cytoplasmic fraction used for 
immunoprecipitation. 
(D) Mutp53 depletion reduces TNF-induced phosphorylation and degradation of IKBα. 
PANC-1 cells were silenced with control (siC) or p53 siRNAs (sip53), serum starved, and 
treated with TNFα (10ng/ml) for the indicated times. Phosphorylated and total IKBα 
were measured by immunoblotting. Lower panel shows the ratio of phosphorylated IKBα 
over IKBα in this representative experiment, measured by densitometry on 
autoradiographic films. 
(E) DAB2IP knockdown restores the transcriptional response to TNFα in mutp53-
depleted cancer cells. PANC-1 cells were silenced for DAB2IP and/or mutp53 as 
indicated. Expression of ICAM1 and IL8 was measured by RT-qPCR after 20 hr of 
TNFα (10 ng/ml) treatment. DAB2IP and/or mutp53 depletion was checked by western 
blot (bottom panel). 
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(F) Overexpression of the p53-binding domain of DAB2IP reduces TNF-driven invasion. 
PANC-1 cells were stably transduced with retroviruses expressing the eGFP-DAB2IP1-
186KA2 fusion protein (eGFP-KA2), or eGFP alone. Invasion assays were performed in 
low serum plus TNFα (10ng/ml). Graph shows the increase in invasion triggered by TNF 
(mean ± SD; n=3; ** P < 0.005). Expression of eGFP proteins was analyzed by western 
blot (bottom panel). 
 
 
 
Table S1. Listing of TNF-responsive genes differentially expressed in sip53 versus siC 
transfected MDA-MB-231 cells. 
 
 
 
Table S2. Output of GO term enrichment analysis performed using the DAVID 6.7 
release (http://david.abcc.ncifcrf.gov/sevice) on the indicated groups of TNF-responsive 
genes identified in MDA-MB-231 cells. 
 
 
Table S3. Univariate Cox regression analysis of the expression of various metagenes in relation to 
disease free survival (DFS) in breast cancer patients stratified according to the status of p53. 
 
Metagene Tumor samples§ Hazard Ratio (95% CI) P-value 
    
Upsic10 TP53 wt 1 (0.7982, 1.253) 0.999 
 TP53 mut 0.575 (0.3697, 0.895) 0.0141 * 
    
TNF-upsiC TP53 wt 0.911 (0.589, 1.407) 0.673 
 TP53 mut 0.333 (0.164, 0.676) 0.0023 ** 
Bindea et al., 2013 
B_cells TP53 wt 0.9103 (0.7565, 1.095) 0.32 
 TP53 mut 0.7228 (0.5229, 0.9992) 0.0494 * 
    
T_cells TP53 wt 0.9709 (0.8062, 1.169) 0.775 
 TP53 mut 0.6612 (0.4708, 0.9287) 0.017 * 
    
CTL TP53 wt 0.9665 (0.8189, 1.141) 0.687 
 TP53 mut 0.6286 (0.4343, 0.9098) 0.0138 * 
    
NK TP53 wt 0.9605 (0.8073, 1.143) 0.649 
 TP53 mut 0.675 (0.4578, 0.9952) 0.0472 * 
    
Th1 TP53 wt 0.9271 (0.7436, 1.156) 0.501 
 TP53 mut 0.6461 (0.448, 0.9318) 0.0194 * 
    
Th2 TP53 wt 0.765 (0.5082, 1.152) 0.199 
 TP53 mut 0.8319 (0.442, 1.566) 0.568 
Rody et al., 2011 
B_cells TP53 wt 0.8935 (0.7084, 1.127) 0.342 
 TP53 mut 0.6798 (0.4626, 0.999) 0.0494 * 
    
T_cells TP53 wt 0.9704 (0.8091, 1.164) 0.746 
 TP53 mut 0.5585 (0.3854, 0.8094) 0.0021 ** 
Rody et al., 2009 
Lck TP53 wt 0.9566 (0.7941, 1.152) 0.64 
 TP53 mut 0.5349 (0.3642, 0.7855) 0.0014 ** 
    
§ Samples from the CRCM cohort (Sabatier et al., 2011): p53wt (n=125), p53 mutant (n=68); and the Uppsala 
cohort (Miller et al., 2005): p53wt (n=189), p53 missense (n=47). 
 
* P<0.05;  ** P<0.01 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Cell Culture, Transfections, Retroviral Transductions and treatments. MDA-MB-
231 (p53R280K), MDA-MB-468 (p53R273H), PANC-1 (p53R273H), 293T, 293GP, 
HCT116 (wt-p53), U2OS (wt-p53) and MEF (Mouse Embryonic Fibroblasts) were 
cultured in DMEM medium (Sigma) supplemented with 10% FCS (ECS0180L, 
Euroclone), and antibiotics (DE17-602E, Lonza). H1299 cells were cultured in RPMI 
medium (Sigma) supplemented with 10% FBS and antibiotics. SUM-149 (p53M237I) 
cells were cultured in DMEM:F12 Ham’s medium 1:1, supplemented with 10% FCS and 
antibiotics. MCF10A cells were maintained in DMEM:F12 Ham’s medium 1:1, 
supplemented with 5% horse serum, insulin (10 µg/ml), hydrocortisone (0.5 µg/ml) and 
epidermal growth factor (EGF 20 ng/ml). 
All human mammary cell lines were subjected to STR genotyping with PowerPlex 18D 
System and confirmed in their identity comparing the results to reference cell databases 
(DMSZ, ATCC, and JCRB databases), where possible. 
MEFs were generated by crossing mice of the appropriate genotype, and collecting cells 
from 13.5 d.p.c. embryos. MEF p53KO and MEF KI p53R172H were immortalized 
through retroviral transduction of H-RasV12 (Girardini et al., 2011). 
HEK293T or 293GP were transfected using calcium-phosphate. Transfections of H1299 
were performed with Lipofectamine 2000 (Invitrogen), following manufacturer’s 
instructions. For siRNA transfections, cells were transfected with 50 nM siRNA 
oligonucleotides using Lipofectamine RNAiMax (Invitrogen), following manufacturer’s 
instructions. After 48 hr of silencing, cells were subsequently processed.  
siRNAs used in this work are listed in the following table: 
 
siRNA Sequence Purchase from/  
Reference 
Control siRNA  
(siC) 
Unknown All star negative control 
(1027281,Qiagen) 
sip53 ORF GACUCCAGUGGUAAUCUAC Eurofins MWG 
siDAB2IP A GGAGCGCAACAGUUACCUG Eurofins MWG 
siDAB2IP B GGUGAAGGACUUCCUGACA Eurofins MWG 
siDAB2IP 3’UTR GUAAUGUAACUAUCUCACC Eurofins MWG 
siJNK1/2 A AAAGAAUGUCCUACCUUCU Eurofins MWG 
!!
siJNK1/2 B AGAAGGUAGGACAUUCUUU Eurofins MWG 
sip65 GCCCUAUCCCUUUACGUCA Eurofins MWG 
 
For retroviruses production, low confluent HEK 293GP packaging cells were transfected 
by calcium phosphate precipitation. After 48–72 hr the virus-containing medium was 
filtered and added to target cells. Cells were selected with blasticidin (2 µg/ml) and/or 
puromycin (0.5 µg/ml) and kept under selection for the entire experiment.  
Human TNFα was purchased from Invitrogen (PHC3015); TGF-β inhibitor SB431542 
(S4317), JNK inhibitor SP600125 (S5567), and NF-κB inhibitor BAY11-7082 (B556) 
were purchased from Sigma. Mouse TNFα blocking antibody was purchased from BD 
Pharmigen (#558415). 
For gene expression analysis, cells were treated with recombinant TNFα (10ng/ml) in 
low serum (0.1% FBS) for the indicated times. When necessary, JNK (SP600125) and 
NF-κB (BAY11-7082) inhibitors were added to low serum medium 2 hr before addition 
of TNFα. For analysis of p-IKBα and p-JNK, cells were serum starved for 24 hr and 
subsequently TNFα (10ng/ml) was added for the indicated times. 
 
Plasmids.  
pCS2-HA-DAB2IP FL and deletions were generated by cloning PCR products generated 
using specific primers; mouse DAB2IP was amplified from pLENTI-DAB2IP (kindly 
provided by K. Cichowski) with AccuPrime™ Taq DNA Polymerase High Fidelity 
(Invitrogen), following manufacturer’s instructions. pLPC-DAB2IP and pLPC-
p53R175H, -p53R273H, -p53R280K were obtained by cloning respectively DAB2IP and 
p53R175H, p53R273H, p53R280K coding region into pLPC empty vector. pLPC-
p53*R175H, -p53*R273H, -p53*R280K were generated introducing silent mutations in 
the region targeted by p53 siRNA by site directed mutagenesis in pLPC-p53R175H, -
p53R273H, -p53R280K respectively. pLPC-p53*R280K ΔNLS was obtained starting 
from pcDNA3-p53 ΔNLS (kindly provided by U. Moll): R280K mutation and 
subsequently silent mutations in the region targeted by p53 siRNA were introduced by 
site directed mutagenesis and then subcloned in pLPC vector.  
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pLPC-DAB2IP1-186wt was obtained by cloning DAB2IP1-186 coding region from pCS2-
DAB2IP1-186 to pLPC; pLPC-DAB2IP1-186KA2 was generated mutating lysine residues by 
site directed mutagenesis (Zhang et al., 2003). 
pcDNA3-MBP and MBP-p53 wt were described previously (Lunardi et al., 2010); the 
full-length coding sequences and various deletions of p53 hot-spot mutants were PCR 
amplified from corresponding expression plasmids and cloned in frame with MBP in the 
pcDNA3-MBP vector. pcDNA3HA-ASK1 was kindly provided by L. Schmitz. pSR-
shp53 plasmid was previously described (Drost et al., 2010). pLKO-shDAB2IP plasmid 
was generated by cloning in the pLKO lentiviral vector a double stranded oligo 
corresponding to siDAB2IP A (described above). 
 
Cell manipulation and Western blot analysis. Total cell extracts were prepared in 
RIPA buffer without SDS (150mM NaCl, 50mM Tris-HCl pH8, 1mM EDTA, 1% NP-40, 
0.5% Na-deoxycholate) supplemented with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 
10µg/ml CLAP, 1µM TSA and 5µM nicotinamide. Protein concentration was determined 
with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Lysates were resolved by 
SDS/PAGE and transferred to nitrocellulose (Millipore). 
Nucleus-cytoplasm fractionation. Cells were scraped in PBS and washed two times. The 
pellet obtained after the last centrifugation was resuspended in Cytoplasmic-buffer 
(10mM HEPES pH7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.1% NP-40) 
supplemented with inhibitors (1mM PMSF, 5mM NaF, 10mg/ml CLAP, 1mM Na3VO4); 
lysis was obtained gently pipetting a couple of times. After 3’ in ice, lysates were 
centrifuged at 2500g for 5’ at 4°C; the supernatant was collected as the cytoplasmic 
fraction. The pellet was washed twice in Wash-buffer (10mM HEPES pH7.9, 1.5mM 
MgCl2, 10mM KCl, 0.5mM DTT) and then Nuclei in the pellet were resuspended in 
Nuclear-buffer (20mM HEPES pH7.9, 1.5mM MgCl2, 420mM NaCl, 0.2mM EGTA, 
0.5mM DTT, 25% glycerol) supplemented with inhibitors (1mM PMSF, 5mM NaF, 
10mg/ml CLAP, 1mM Na3VO4); nuclear extract was recovered by centrifugation at 
15000g for 15’ at 4°C. To evaluate DAB2IP and p53 cellular localization, nuclear and 
cytosolic fractions were also prepared using the ProteoExtract® Subcellular Proteome 
Extraction Kit, following the manufacturer’s instructions. 
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Western blot analysis was performed according to standard procedures using the 
following primary antibodies: 
 
 
 
 
Protein Interaction studies 
Coaffinity purification. Co-AP experiments were performed as described in Lunardi et al. 
(2010), with minor changes. Plasmids were transfected in human 293T cells. 48 hr after 
transfection cells were lysed in coaffinity purification buffer (50 mM Tris·HCl pH8, 150 
mM NaCl, 1 mM EDTA pH8, 1 mM DTT, 5% glycerol, protease inhibitors (Sigma), 1 
mM PMSF, 5 mM NaF, 1 mM beta-glycerolphosphate) for 30 min on ice and cleared by 
centrifugation for 30 min at 13000g at 4 °C, and protein complexes were collected on 
amylose beads. After extensive washes, purified complexes were separated by 
SDS/PAGE, detected by immunoblotting, and visualized by ECL (Amersham). Purified 
MBP baits were visualized by DAB staining (Sigma). 
Target Antibody 
p-JNK (Thr183/Tyr185) #9251 (Cell Signaling) 
JNK sc-571 (Santa Cruz) 
HA 12CA5 hybridome 
p-IKBα (Ser32/36) #9246 (Cell Signaling) 
IKBα #9242 (Cell Signaling) 
HSP90 sc-13119 (Santa Cruz) 
Actin #A9718 (Sigma) 
Cleaved Caspase-3 #9664 (Cell Signaling) 
PARP p85 fragment TB273 (Promega) 
p53 (DO1) sc-126 (Santa Cruz) 
DAB2IP  A302-440A (Bethyl) 
Tubulin T5168 (Sigma) 
SP1 sc-59 (Santa Cruz) 
MBP home-made rabbit polyclonal  
ASK1 (F-9) sc-5294 (Santa Cruz) 
ASK1 (H-300) sc-7931 (Santa Cruz) 
GFP home-made rabbit polyclonal  
p65 RelA sc-372X (Santa Cruz) 
Lamin A/C sc-6215 (Santa Cruz) 
p-p38 MAPK 
(Thr180/Tyr182) 
#9216 (Cell Signaling) 
p38 MAPK #9212 (Cell Signaling) 
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Co-immuno precipitation. Co-IP experiments with endogenous proteins were performed 
using Co-IP buffer (NaCl 120mM, Tris-HCl pH8 20mM, EDTA 1mM, NP40 0.5%) with 
protease inhibitors. Samples were cleared by centrifugation for 30 min at 13000g at 4 °C 
and incubated for 2 hr at 4 °C with specific antibody. After 1 hr incubation with protein 
G-Sepharose (GE Healthcare), immunoprecipitates were washed three times in Co-IP 
buffer, resuspended in sample buffer, and analyzed by immunoblotting. For Co-IP of 
endogenous DAB2IP and mutp53, p53DO1 (sc-126) was used for immunoprecipitation, 
and mouse purified IgGs as negative control. For Co-IP of endogenous DAB2IP and 
ASK1, anti-ASK1 (sc-7931) was used for immunoprecipitation, and mouse IgGs as 
negative control. Anti-GFP antibody (home-made rabbit polyclonal) was used to 
immunoprecipitate GFP-DAB2IP1-186KA2 to study differential interaction with 
endogenous p53 and ASK1 proteins. Anti-HA (12CA5) was used to immunoprecipitate 
ASK1 in transfected H1299 cells.  
 
Immunofluorescence. Cells were fixed in 4% paraformaldehyde at room temperature, 
and permeabilized in PBS plus 0.1% Triton X-100. Permeabilized cells were incubated 
with primary antibodies, followed by Alexa Flour® 568, 488 conjugated secondary 
antibodies (Life Technologies). Images were captured using a Leica DM4000B 
epifluorescence microscope. 
 
Nuclear extract preparation and NF-κB transcription factor activation assay. 
Nuclear protein extract from MDA-MB-231 were prepared using Active Motif Nuclear 
Extract Kit. NF-κB p65 activation was measured through its ability to bind a specific 
DNA consensus site with TransAM Chemi NF-κB p65 ELISA (Active Motif) according 
to the manufacture’s instructions. 2ug of nuclear protein extract were analyzed in each 
point. The chemiluminescent signal was read on an EnSpire Multimode Plate Reader 
(PerkinElmer). 
 
RNA extraction and RT-qPCR. Total RNA was extracted with QIAzol (Qiagen) 
following manufacturer’s instructions. 1µg of total RNA was reverse-transcribed with 
QuantiTect Reverse Transcription (Qiagen). Real-time qPCR was performed using 
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SsoAdvancedTMSYBR® Green Master Mix (Biorad) on a CFX96™ Real-Time PCR 
System (Biorad). List of primers used: 
 
Target Sequence 
DAB2IP Fw: 5’CACATCACCAACCACTAC3’ 
Rev: 5’TCCACCTCTGACATCATC3’ 
p53 Fw: 5’CTCCTCTCCCCAGCCAAAGA3’ 
Rev: 5’GGAACATCTCGAAGCGCTCA3’ 
CA12 Fw: 5’CAGTTTTCCGAAACCCCGTG3’ 
Rev: 5’TGCCGCAGTACAGACTTGC3’ 
MMP9 Fw: 5’GCCTTTGGACACGCACGACGT3’ 
Rev: 5’GCAGGACGGGAGCCCTAGTC3’ 
LTB Fw: 5’AGGGAGGACTGGTAACGGAG3’ 
Rev: 5’GAAACGCCTGTTCCTTCGTC3’ 
CXCL10 Fw: 5’TGGCATTCAAGGAGTACCTCTC3’ 
Rev: 5’TGATGGCCTTCGATTCTGGA3’ 
SERPINE1 Fw: 5’GACCGCAACGTGGTTTTCTC3’ 
Rev: 5’GCCATGCCCTTGTCATCAAT3’ 
CX3CL1 Fw: 5’ACGGTGTGACGAAATGCAAC3’ 
Rev: 5’TTGACCCATTGCTCCTTCGG3’ 
CSF2 Fw: 5’AATGTTTGACCTCCAGGAGCC3’ 
Rev: 5’TCTGGGTTGCACAGGAAGTT3’ 
IDO-1 Fw: 5’GCAAGAACGGGACACTTTGC3’ 
Rev: 5’GCCTTTCCAGCCAGACAAAT3’ 
ICAM1 Fw: 5’GGGCATAGAGACCCCGTTGCCT3’ 
Rev: 5’ GGGTGCCAGTTCCACCCGTTC3’ 
CXCL1 Fw: 5’TTGCCTCAATCCTGCATCCC3’ 
Rev: 5’TTGGATTTGTCACTGTTCAGCA3’ 
CSF1 Fw: 5’TCCAGCCAAGATGTGGTGAC3’ 
Rev: 5’AGTTCCCTCAGAGTCCTCCC3’ 
IL1B Fw: 5’GCCTGAAGCCCTTGCTGTAGT3’ 
Rev: 5’GCGGCATCCAGCTACGAA3’ 
BMP-2 Fw: 5’AGACCTGTATCGCAGGCACT3’ 
Rev: 5’CGGGTTGTTTTCCCACTCGT3’ 
CXCL2 Fw: 5’TCACAGTGTGTGGTCAACAT3’ 
Rev: 5’ACACAGAGGGAAACACTGCAT3’ 
IL1A Fw: 5’TAAGCTGCCAGCCAGAGAGGGA3’ 
Rev: 5’AGCCTTCATGGAGTGGGCCATAGC3’ 
IL8 Fw: 5’GGCAGCCTTCCTGATTTCTG3’ 
Rev: 5’CTTGCCAAAACTGCACCTTCA3’ 
PTGS2 Fw: 5’GTTCCACCCGCAGTACAGAA3’ 
Rev: 5’AGGGCTTCAGCATAAAGCGT3’ 
Actin Fw: 5’CGCCGCCAGCTCACCATG3’ 
Rev: 5’CACGATGGAGGGGAAGACGG3’ 
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H3 Fw: 5’GAAGAAACCTCATCGTTACAGGCCTGGT3’ 
Rev: 5’CTGCAAAGCACCAATAGCTGCACTCTGGAA 3’ 
GAPDH Fw: 5'CATGCCATCACTGCCACCC3' 
Rev: 5'ACCTGGTCCTCAGTGTAGC 3' 
18S Fw: 5’GTAACCCGTTGAACCCCATT3’ 
Rev: 5’CCATCCAATCGGTAGTAGCG3’ 
 
Cell cycle and FACS analysis. For FACS analysis, adherent and floating cells were 
harvested, permeabilized with 0.1% NP-40 in PBS containing RNase A (200 µg/ml) and 
then stained with 50 µg/ml Propidium Iodide (#P4865, Sigma). At least 2x104 cells were 
counted in each experiment, using a FACSCalibur flow cytometer (Becton-Dickinson). 
Cell cycle analysis was performed with FlowJo software (http://www.flowjo.com/). 
 
Migration and invasion assays. For transwell migration assays, cells (0.5-1x105) were 
plated on 24 well PET inserts (8.0 µm pore size, Falcon). After 16 hr, cells that passed 
through the filter were fixed in 4% PFA, stained with 0.05% crystal violet (or Hoechst, as 
indicated) and counted. 
For invasion assays, cells (0.5-1x105) were plated on 24 well PET inserts (8.0 µm pore 
size, Falcon) coated with BD MatrigelTM (BD Bioscience). Cells that passed through the 
matrigel-coated filter were fixed, stained, and counted after 18 hr. 
 For invasion assays using DCCM, cells were seeded in 10% FBS on the upper chamber, 
while the lower chamber was filled with DCCM or control medium. After 18 hr cells 
were fixed as previously described. For invasion or transwell assays using recombinant 
TNFα, cells were pre-treated with the cytokine; specifically, cells were kept in low 
(0.1%) serum with or without TNFα (10ng/ml) for 24 hr. Subsequently, cells were 
trypsinized, counted, and re-seeded on filters in low serum, with or without TNFα. The 
lower chamber was filled with high serum medium without TNFα. Cells were fixed as 
previously described. 
 
DCCM media preparation. Precursor cells were extracted from C57BL/6 mice bone 
marrow and grown in IMDM (Iscove’s Modified Dulbecco’s Medium, GIBCO) 
supplemented with 10% fetal bovine serum (FBS, GIBCO), primocin (Invivogen), and 
beta-mercaptoethanol 50µM (Sigma-Aldrich). The cells were induced to differentiate 
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through addiction of 30% GM-CSF (Granulocyte-macrophage colony-stimulating factor), 
produced harvesting the conditioned culture media of J558 cells. Dendritic cells were 
maintained in IMDM medium for 7-8 days. Subsequently, they were stimulated O/N with 
LPS (1µg/ml). The supernatant was then harvested and centrifuged to remove cells in 
suspension. DCCM was aliquoted and stored at -80°C.  
 
In vivo Tumorigenicity and Metastasis assays. For xenograft studies, 1x106 of MDA-
MB-231_GFP or MDAMB231_eGFP-DAB2IP1-186KA2 were resuspended in 100 µl of 
DMEM, injected into the mammary fat of previously anesthetized 6 weeks old SCID 
female mice (1-3% isoflurane, Merial). The mice were used and housed in a specific 
pathogen-free (SPF) animal facility. Procedures involving animals and their care were in 
conformity with institutional guidelines (D.L. 116/92 and subsequent complementing 
circulars) and all experimental protocols were approved by the ethical Committee of the 
University of Padua (CEASA). Tumor growth at the injection site was monitored by 
repeated caliper measurements. Tumor volume was calculated using the formula: tumor 
volume (mm3) = D × d2/2, where D and d are the longest and the shortest diameters, 
respectively. After 21 days the animals from MDA-MB-231_GFP group were 
anesthetized and the primary tumors were extracted and directly frozen in liquid nitrogen 
to perform molecular analyses. The mice from MDAMB231_eGFP-DAB2IP1-186KA2 
group were sacrificed when the tumor reached the same volume of the control group, at 
day 25. For metastasis studies the lymph nodes were excised and formalin-fixed and 
paraffin-embedded (Diapth) for hematoxylin-eosin staining and human Cytokeratin 7 
(Cell Marque, OV-TL12/30) staining. 
All in vivo tumor growth experiments were conducted according to the UK Coordinating 
Committee on Cancer Research (UKCCCR) guidelines 1989 for the welfare of animals in 
experimental neoplasia. During in vivo experiments, animals in all experimental groups 
were examined daily for a decrease in physical activity and other signs of disease. 
 
Peripheral blood mononuclear cells (PBMCs) chemoattractant assay. 
Peripheral blood mononuclear cells (PBMCs) from healthy blood donors were isolated 
from anonymous buffy coats, kindly provided by the local blood bank (Dipartimento 
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Immunotrasfusionale, Ospedale Maggiore, Trieste, Italy) using Ficoll-PaqueTM PLUS 
density gradient (GE Healthcare) as previously described (Spessotto et al., 1995). PBMCs 
(9 x 105 cells/ml), resuspended in DMEM with 0.1% FBS, were added to the upper 
compartment of the polycarbonate insert of a 6-well Transwell system (24 mm diameter, 
8µm pores; Corning Costar). PBMCs were left to migrate for 45 min at 37°C and 5% CO2 
in MDA-MB-231 cells conditioned medium (CM), added to the lower chamber as a 
chemoattractant for PBMCs. The number of cells transmigrated to the lower side of the 
insert was evaluated by Coulter Counter® Analyzers (Coulter Electronics). PBMCs 
migrated were fixed with FIX & PERM® cell fixation and permeabilization kit (Società 
Italiana Chimici) according to the manufacturer’s instructions. A total number of 5×105 
cells were incubated on shaking at 800 rpm O/N at 4°C with PE- or FITC-conjugated 
mouse monoclonal antibody (mAb) specific to human CD3 (clone MEM-57), CD8 (clone 
MEM-31), CD45 (clone MEM-28), CD56 (clone MEM-188) (ImmunoTools GmbH) and 
IgG1 and IgG2a (ImmunoTools GmbH) isotype controls. Cells were fixed with 1% PFA 
(Sigma-Aldrich) and analyzed for fluorescence with a FACSCalibur flow cytometer (BD 
Falcon) using CellQuest software. 
 
Statistical Analysis 
In all graphs data are expressed as mean ± SD of three independent experiments, except 
when otherwise indicated. Differences were analyzed by Student’s t test using Prism 5 
(GraphPad). P-values < 0.05 were considered significant. 
 
Microarray Hybridization and Analysis 
For gene profiling, we used the Illumina HumanHT-12-v4-BeadChip (Illumina), which 
includes a bead pool of more than 48,000 unique bead types corresponding to 40,876 
transcripts. Total RNA (2µg) isolated from MDA-MB-231 cells expressing siRNA 
control (siC) and siRNA for TP53 (sip53), treated with or without TNFα were reverse 
transcribed and amplified according to standard protocols and in vitro transcription was 
then carried out to generate cRNA. cRNA was hybridized onto each array (three 
replicates for each condition) and then labeled with Cy3-streptavidin (Amersham 
Biosciences). The array was then scanned using a BeadStation 500 system (Illumina). 
!!
The full data set was submitted to Gene Expression Omnibus under accession number 
GSE53153. The probe intensities were calculated and normalized using GenomeStudio 
Data Analysis Software’s Gene Expression Module (GSGX) Version 1.9 (Illumina). 
Further data processing was performed in the R computing environment (http://www.r-
project.org/) version 2.15, with BioConductor packages (http://www.bioconductor.org/). 
Statistical analysis for differentially expressed genes was performed with limma (Smyth, 
2004). P-values were adjusted for multiple testing using Benjamini and Hochberg's 
method to control the false discovery rate (Hochberg and Benjamini, 1990). 
 
Cluster analysis 
Starting from the normalized annotated expression matrix, after gene mean centering, 
features whose standard deviation was less than 0.5 were filtered out. Unsupervised 
hierarchical cluster analysis (average-linkage method) was performed using Cluster 
software (EisenLab). Cluster results were then visualized using Java TreeView software. 
 
Definition of TNF-inducible genes 
We selected differentially expressed probes with greater than 1.5 fold change in siC_TNF 
vs siC and/or in sip53_TNF vs sip53 contrasts. One of the 3 replicates of sip53 untreated 
cells was slightly more variable than the others, so we used a less selective P value cutoff 
in sip53-transfected samples (adjusted P value < 0.05 in sip53 versus adjusted P value 
<0.005 in siC transfected samples). We defined TNF-inducible genes as the union of 
genes differentially induced by TNFα in each contrast (420 genes, Figure 2A). 
To obtain TNF-inducible genes specifically affected by mutant p53 depletion, we first 
identified genes differentially expressed in the siC_TNF vs sip53_TNF contrast by 
FC>=2, generating two lists: genes downregulated in sip53_TNF samples (275 genes, 
up_siC) and genes upregulated in sip53_TNF samples (148 genes, up_sip53). Next, we 
intersected both lists with the list of TNF-inducible genes (Figure 2A), obtaining TNF-
inducible genes differentially expressed in control or sip53-depleted cells after TNF-
treatment (Table S1). 
 
 
!!
Gene Ontology (GO) term enrichment analysis 
Differentially expressed gene lists were analyzed for functional associations. Data were 
analyzed through DAVID Bioinformatics Resources v6.7 (Dennis et al., 2003; Huang da 
et al., 2009) using standard parameters and the Illumina HumanHT-
12_V3_0_R2_11283641_A gene set as background population (Table S2). 
 
ExPlain analysis 
To analyze enrichment in predicted transcription factor binding sites, we used the ExPlain 
3.1 package of the Biobase suite (Kel et al., 2008). 
We focused on genes differentially expressed by FC >= 2 in siC_TNF vs siC and in 
sip53_TNF vs sip53, and generated three lists: 1) genes induced by TNFα only in control 
cells; 2) genes induced by TNFα only in sip53-transfected cells; 3) genes induced by 
TNFα in both. We analyzed predicted transcription factor binding sites in the genomic 
region spanning -500 to +100 nucleotides of the genes in the three lists. As control 
background population we used a set of 3000 genes showing no change upon TNF-
treatment in our microarrays (-0.02 < logFC > 0.02). 
 
Breast cancer datasets and meta-analysis 
We used a meta-dataset comprising 3254 unique samples from 19 independent studies 
comprising microarray data of breast cancer samples and annotations on patients’ clinical 
outcome. Generation and normalization of the meta-dataset, together with the list of 
datasets included, are described in detail in Rustighi et al. (2013). 
A total of 876 basal/TNBC samples has been defined using Subtype Clustering Model 
and ESR1, ERBB2 and AURKA gene modules as implemented in the scmod2.robust 
function of the genefu Bioconductor package (Wirapati et al., 2008). 
To identify two groups of tumor samples with either high or low levels of a given gene 
signature, we used the classifier described in Adorno et al. (2009). Briefly, we defined a 
classification rule based on summarizing the standardized expression levels of each gene 
in a signature into a combined score with zero mean. Tumors were then classified as 
signature Low if the combined score was negative and as signature High if the combined 
!!
score was positive. This classification was applied to log2 expression values obtained 
using RMA on the meta-dataset described above. 
The same classification was used for analysis of average expression of various signatures 
in the affimetrix meta-dataset as well as in the Uppsala (Miller et al., 2011) and Metabric 
(Curtis et al., 2012) datasets. 
The upsiC10 signature includes the following genes: MMP9, LTB, CXCL10, HLA-DMB, 
CX3CL1, EBI3, CASP1, HLA-F, IDO1, CTSW. 
 
Survival analysis 
To evaluate the prognostic value of genes signatures, we estimated, using the Kaplan-
Meier method (Kalbfleisch and Prentice, 2002), the probabilities that patients would 
remain disease free (DFS). Kaplan-Meier curves were compared using the log-rank test 
(Harrington and Fleming). P-values were calculated according to the standard normal 
asymptotic distribution. Survival analysis and Kaplan-Meier plots were obtained using R 
survcomp package. Kaplan-Meyer curves were compared using the log-rank test of the 
surv_test function (coin R package). 
To evaluate the prognostic value of gene signatures in datasets with known p53 
status, we collected the only available public datasets with known p53 status and reliable 
information on disease-free (or relapse-free) survival: these are the Uppsala (Miller et al., 
2005) and CRCM (Sabatier et al., 2011) studies. 
The Uppsala dataset contains information on p53 sequence. In this dataset, 189 samples 
are annotated as “wt”, and 58 samples as “mutant” p53. Among the latter, 11 samples 
have nonsense or frameshift mutations in the first half of the p53 sequence, and therefore 
are predicted to express no p53 protein: these samples were manually annotated as p53-
null (ko). All other mutants are predicted to encode translatable p53 proteins with various 
structural alterations (37 are missense). The CRCM dataset contains information on the 
immunohistochemical (IHC) detection of p53: a weak or null IHC signal is annotated as 
“wt” and a strong IHC signal is annotated as “mutant” p53. Therefore, CRCM samples 
annotated as “mutant” are conceptually similar to samples annotated as “mutant” in the 
manually edited Uppsala dataset. 
!!
We used the two datasets to analyze disease-free survival by univariate Cox regression 
using the coxph function (survival R library), merging the results to calculate the hazard 
ratio (HR) for expression of various metagenes (Table S3). 
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PART 3: IDENTIFICATION OF microRNA TARGETING DAB2IP 
 
In this part, I describe the results of a project aimed to identify and characterize microRNAs able 
to target and down-regulate DAB2IP in tumor cells. This could represent an important additional 
mechanism counteracting DAB2IP tumor suppressive functions in human malignancies, and 
may set the basis for a potential therapeutic strategy to restore DAB2IP levels and activity in 
cancers in which this protein is down-regulated. 
 
3.1 microRNA 
Currently, there are nearly 2000 annotated microRNA (miRNA) precursor genes in the human 
genome. They are processed into more than 2500 mature miRNA sequences, many of them with 
unknown functions (Adams et al., 2014). miRNAs show a crucial role in the regulation of gene 
expression. Indeed, it has been proposed that at least 50% of mammalian proteins are controlled 
by this kind of small non coding RNA (Krol et al., 2010). They are 20-22 nt –long and appear to 
be involved in the regulation of virtually all biological processes, including development, 
differentiation, apoptosis and proliferation. Notably, changes in their expression have been 
observed in multiple human pathologies, including cancer (Adams et al., 2014; Krol et al., 2010). 
 
3.1.1 microRNA biogenesis 
miRNA genes are transcribed by both RNA polymerase II (RNAPol II) and RNA polymerase III 
(RNAPol III) into a primary transcript (pri-miRNA) (Winter et al., 2009). More than half of 
miRNA loci are transcribed as clusters from polycistronic transcriptional units (Lee et al., 2002). 
They can be localized in intergenic regions, or be located within other genes, in intronic non-
coding regions (40% of human miRNAs) or within exons (10% of human miRNAs).  
While intergenic miRNAs are transcribed autonomously by RNA Pol II from their own specific 
promoter, intronic and exonic miRNAs are presumed to be transcribed with their host gene 
(Tessitore et al., 2014). In mammals, most miRNAs have multiple paralogs, likely derived from 
gene duplications, which share the same seed sequence and presumably target genes. However, 
differences in the 3’ miRNA sequence may affect the miRNA-mRNA affinity, so that paralogous 
miRNAs may exert very distinct roles in vivo (Ventura et al., 2008). 
Expression of miRNAs is under the same kind of control as protein-coding genes (Winter et al., 
2009), and each miRNA located in a given genomic cluster can be transcribed and regulated 
independently (Song and Wang, 2008).  
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It should be considered that pri-miRNAs can be subjected to RNA editing; this process can 
change their sequence, affecting base-paring and structural properties, thus influencing their 
further processing as well as their target recognition abilities (Winter et al., 2009). Notably, 
miRNA editing has been shown to enhance miRNA processing by Drosha (Kawahara et al., 
2008). The pri-miRNA folds into hairpins with two single-stranded flanking regions upstream 
and downstream. The double-stranded stem and the unpaired flanking regions are critical for 
DGCR8 binding and cleavage by the RNase-type III endonuclease Drosha (components of the 
nuclear Microprocessor complex) (Han et al., 2006; Zeng and Cullen, 2005). This cleavage 
occurs co-transcriptionally, preceding intron splicing (Morlando et al., 2008), and generates the 
pre-miRNA (Figure 3.1). After nuclear processing, the pre-miRNA is exported into the 
cytoplasm by Exportin-5 (Yi et al., 2003), in a manner not dependent on miRNA sequence or 
loop structure. 
In the cytoplasm the pre-miRNA is processed by the RISC loading complex (RLC). The RNase-
type III endonuclease Dicer, the double strand RNA-binding domain proteins TRBP (Tar RNA 
binding protein), PACT (protein activator of PKR) and the core component Argonate-2 (Ago-2) 
assemble this protein complex (Winter et al., 2009). Argonaute family contains four AGO 
proteins, AGO1 to AGO4. Their function in miRNA pathway is demonstrated with their ability 
to repress protein synthesis when artificially tethered to the mRNA 3’UTR (Filipowicz et al., 
2008; Pillai et al., 2004). AGO1 is dedicated to the miRNA pathway, and AGO2 is the only one 
that functions in RNA interference processes (Peters and Meister, 2007). TRBP and PACT are 
not essential for the endonuclease activity of Dicer, but they can facilitate it, stabilizing Dicer 
protein (Krol et al., 2010; Winter et al., 2009). Moreover, they are important for the recruitment 
of AGO2 (MacRae et al., 2008). Dicer cleaves the loop of the pre-miRNA and generates a 22-
ntmiRNA duplex with two nucleotides protruding as overhangs at each 3’ end. This cleavage is 
essential for miRNA processing and has been observed in many organisms (Bernstein et al., 
2001; Ketting et al., 2001). Deletion of Dicer decreases or totally abrogates the production of 
mature miRNAs in cells (Grishok et al., 2001; Hutvagner et al., 2001), while in mice, its loss is 
associated with lethality early in development, underlining its crucial role in miRNA processing, 
and the crucial role of miRNAs in embryogenesis (Bernstein et al., 2003). Intriguingly, for pre-
miRNAs that display a high degree of complementary along the hairpin stem, an additional 
endonucleolytic cleavage mediated by Ago2 occurs before the Dicer-mediated one (Bernstein et 
al., 2003).  
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Dicer also participates in loading miRNAs into miRISC (miRNA-induced silencing complexes), 
also known as miRNP (micro-ribonucleoprotein–RNP-complex) (Krol et al., 2010; Winter et al., 
2009). The mature miRISC complex is composed by a single strand RNA and one of the AGO 
proteins that harbors the silencer activity of the complex (Krol et al., 2010) (Winter et al., 2009) 
To form the active RISC complex involved in gene silencing, the functional guide strand, 
Figure 3.1: Biogensesis of miRNAs 
and their assembly into 
microribonucleoproteins. The pri-
miRNAs are transcribed from 
independent miRNA gene or are 
portions of introns of protein-coding 
gene (mirtron). Pri-miRNA folds into 
hairpind structures containing 
imperfectly base-paired stems and are 
processed in two steps, catalysed by 
RNaseIII-type endonucleases Drosha 
and Dicer. These enzymes work 
together with accessory proteins 
containing a dsRNA-binding domain: 
DGR8 for Drosha and TRBP for 
Dicer. After Drosha-mediated 
cleavege, pre-miRNAs are transported 
in the cytoplasm by Exportin-5, where 
they are cleaved by Dicer to yield 
20bp miRNA duplexes. In some cases 
a previous clevaged of pre-miRNA is 
mediated by AGO2. Then, one strand 
is selected to act as a mature miRNA, 
while the other one is generally 
degradeted. Occasionally, both arms 
of the duplex give rise to two guide 
miRNAs. Following their processing, 
miRNAs are assembled into miRNP 
(or miRISC) to mediate miRNA-
specific translational repression. 
Figure taken from (Krol et al., 2010). 
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complementary to the target mRNA, needs to be separated by the other strand in the duplex (the 
passenger strand). Apart from the AGO proteins, miRISC often comprises other proteins, which 
probably drive its assembly or regulation, or act as effectors (Peters and Meister, 2007). 
The thermodynamic stability of the miRNA duplex ends defines which strand, miRNA-3p or 
miRNA-5p, is preferentially loaded on miRISC. Notably, cleavage heterogeneity can affect the 
stability of the hairpin ends, and thus influence strand selection (Krol et al., 2010). In addition, 
the identity of the 5’-terminal nucleotide may directly affect the efficiency of miRNA loading 
into miRISC, independent of duplex end stability (Frank et al., 2010). 
Commonly, most miRNA genes produce one dominant mature miRNA; the passenger strand 
miRNA, also identified as miRNA*, is generally degraded once the guide strand is loaded on the 
RISC complex (Winter et al., 2009). However, passenger strand miRNAs* can also be loaded 
into RISC to function in gene regulation (Ghildiyal et al., 2010; Okamura et al., 2009).  
Notably, the ratio of miRNA to miRNA* production and RISC loading can vary in different 
tissues or developmental stages; this probably depends on specific properties of the pre-miRNA 
duplex, or on the activity of different accessory factors (Krol et al., 2004; Zeng and Cullen, 
2005). Notably, this ratio can be modulated also by the availability of the respective mRNA 
targets, as a results of enhanced destabilization of either miRNA or miRNA* occurring in the 
absence of respective complementary mRNA (Krol et al., 2010). 
 
3.1.2 microRNAs mechanisms of action 
In plants, miRNAs generally bind mRNA target with nearly perfect complementarity and trigger 
endonucleolytic mRNA cleavage by a RNAi-like mechanism (Filipowicz et al., 2008). In rare 
cases, this mechanism it applied also in mammals: perfect pairing of a miRNA with its target 
leads to endonucleolytic cleavage of the mRNA by Argonaute (Figure 3.2, model a) (Llave et al., 
2002). However, most commonly, miRNAs bind imperfectly their targets, inducing a set of 
different processes that support the block of mRNA translation and impair protein synthesis 
(Filipowicz et al., 2008; Pasquinelli, 2012).  
Partial pairing of the miRNA to the target 3’UTR sites can result in the deadenylation of the 
mRNA. The miRISC-associated GW182 protein mediates the recruitment of the CCR4-NOT 
deadenylating complex and the decapping proteins DCP1 and DCP2, which remove the poly(A) 
tail and make the mRNA susceptible to exonucleolytic degradation (Figure 3.2, model b) (Behm-
Ansmant et al., 2006; Braun et al., 2011; Wu et al., 2006).  
Partial pairing of the miRNA to the target 3’UTR sites can also cause reduction of protein, but 
not mRNA levels. This phenomenon can be explained by inhibition of translation initiation and 
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elongation, as well as by direct proteolysis of the peptide that is being synthesized (Behm-
Ansmant et al., 2006; Filipowicz et al., 2008) (Figure 3.2). Factors bound at the 3’UTR of a 
mRNA-miRNA complex exert an inhibitory effect on translational initiation by the recruitment 
of proteins that interfere with the eIF4E and eIF4G interaction (one of the essential steps to 
catalyze initiation of translation) or bind directly to the mRNA cap. Both these mechanisms 
counteract the recruitment of the 40S ribosomal subunit and the formation of 40S initiation 
complex (Figure 3.2, model c). 
The observation that miRNAs are associated with polysomes implies that translation can be 
repressed by the miRISC also after initiation, possibly by promoting ribosome drop-off, 
premature ribosome dissociation, or stimulating proteolysis of the nascent peptide (Filipowicz et 
al., 2008; Pasquinelli, 2012). 
Intriguingly, under certain circumstances miRNAs have also been shown to up-regulate target 
mRNA expression. (Orom et al., 2008; Vasudevan et al., 2007). 
 
 
 
Figure 3.2: Possible mechanisms of microRNA-mediated post-transcriptional gene repression in mammals. A 
schematic representation of the better known mechanisms implicated in miRNA-mediated regulation of translation 
and protein production. Reproduced from (Pasquinelli, 2012). See text for details. 
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3.1.3 microRNAs in cancer 
The first evidence of an association between miRNA deregulation and cancer was published in 
2002: the loss of two miRNAs (miR-15 and miR-16), whose genes are localized into a 
chromosomal region frequently deleted in chronic lymphocytic leukemia (CLL), was correlated 
with the development of an indolent form of CLL (Calin et al., 2002). Progressively, various 
evidences showed how miRNAs are involved in the control of several cancer-relevant processes, 
such as proliferation, apoptosis, DNA damage, regulation of the tumor microenvironment, 
migration and invasion (Baranwal and Alahari, 2010; Chou et al., 2013; Hwang and Mendell, 
2006; Jovanovic and Hengartner, 2006; Tessitore et al., 2014). 
Abnormal expression of miRNAs has been observed in both solid and hematopoietic tumors 
(Calin and Croce, 2006; Lu et al., 2005). Thus, miRNA expression signatures distinguish 
cancerous tissues from normal tissue; these signatures are associated to diagnosis, staging, 
progression, prognosis and response to treatment in many cancer types. For instance, two large 
studies using various solid tumors and leukemias demonstrated that miRNA-expression profiles 
classify human cancers according to developmental lineage and differentiation stage, and that 
patterns of miRNAs expression for each tumor type reflect distinct mechanism of transformation 
(Lu et al., 2005; Volinia et al., 2006). Notably, these studies and other have individuated a group 
of miRNAs whose expression is commonly altered in tumors, involving common impaired 
regulatory pathways. For example miR-21, miR-17-92 cluster, and let-7 are often deregulated 
leading to the activation of important oncogenic pathways (Johnson et al., 2005; Mendell, 2008; 
Volinia et al., 2006). 
miRNAs are not involved only in tumor development, but affect every step of carcinogenesis 
(Acunzo and Croce, 2015; Acunzo et al., 2015). For example, a pro-metastatic role has been 
observed for miR-10b in breast carcinoma. Expression of this miRNA is promoted by the EMT 
inducer Twist; miR-10b inhibits the translation of the homebox D10 (HOXD10) mRNA, 
releasing expression of the pro-metastatic gene RHOC (Ma et al., 2007). Conversely, members 
of the miR-200 family and miR-205 have been shown to decrease cell motility and invasiveness 
by targeting the ZEB transcription factor, a known EMT inducer, and protein kinase PKCγ 
(Gandellini et al., 2009; Gregory et al., 2008). 
The miR-92a family is a group of highly conserved miRNAs, including miR-25, miR-92a-1, 
miR-92a-2, and miR-363, that share an identical seed region, and arise from three different 
paralogous clusters: miR-17-92, miR-106b-25 and miR-106a-363 (Li et al., 2014a). They are all 
known onco-miRNAs able to sustain proliferation, migration, and invasion of tumor cells. For 
example, miR-92a can directly target PHLPP2 (PH domain leucine-rich repeat protein 
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phosphatase), an important negative inhibitor of the PI3K/Akt/mTOR pathways; up-regulation of 
miR-92a can activate this signaling, inhibiting cell apoptosis induced by chemotherapy in mantle 
cell lymphoma (Rao et al., 2012). The family-member miR-25 targets the cell cycle inhibitor 
p21, the pro-apoptotic factor Bim, and the inhibitory Smad 7 directly, resulting in an increased 
level of TGF-β signaling, and TGF-β pathway-mediated tumor growth and invasion (Kan et al., 
2009; Petrocca et al., 2008b; Smith et al., 2012). 
In conclusion, there is now a vast literature in support of the major impact of miRNAs in cancer, 
so the mechanisms of their aberrant expression represent a crucial aspect of oncogenesis.  
miRNA deregulation in cancer could be due to aberrant epigenetic changes in the methylation 
status of miRNA promoters (Fabbri et al., 2013). Notably, half of the known miRNAs reside in 
genomic regions that are reported to be prone to alterations in cancer, including minimal regions 
of amplification, which may contain oncogenes and onco-miRNAs, common breakpoint region 
in or near pro-oncogene or tumor suppressor genes and fragile site (Volinia et al., 2006). 
Another mechanism involved in aberrant miRNA levels expression in cancer is the altered 
functions and/or activities of the enzymes implicated in miRNA biogenesis. For example, the 
expression of Drosha and Dicer is reduced in 39% of patients with ovarian cancer and in lung 
cancer (Karube et al., 2005; Merritt et al., 2008), while frameshift or nonsense mutations of 
Dicer were observed in other tumors, resulting in truncated proteins (Lin and Gregory, 2015). 
Three recurrent inactivating mutations of Exportin 5 were identified in sporadic colon, gastric 
and endometrial tumors, possibly resulting in a global reduction of mature miRNAs (Melo et al., 
2010). 
Clearly, activity of transcription factors is also a major player in the regulation of miRNA 
expression, with multifaceted and opposite roles. A very important example of this is the 
induction of miR-17-92 cluster transcription by the c-myc proto-oncogene (O'Donnell et al., 
2005). 
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3.2 MicroRNA 149-3p (miR-149*) 
In this Thesis, I describe functional studies regarding miR-149, so I summarize here the current 
knowledge about this molecule. 
The human miRNA-149 gene localizes on chromosome 2q37.3, within the first intron of the 
glypican 1 (GPC1) gene, and encodes for two different miRNAs: miR-149-5p (miR-149, guide 
strand) and miR-149-3p (miR-149*, passenger strand). Both miRNAs are highly conserved 
among mammals (Chamorro-Jorganes et al., 2014; Jin et al., 2011). 
There are studies indicating that both miR149 and miR-149* may have a role in tumors; 
however, the available information on their target identity, regulation, and possible involvement 
in oncogenic biological processes is limited and occasionally controversial. Moreover, there are 
very scarce data regarding their transcription and biosynthesis regulation. 
miR-149 is an intronic miRNA, so its expression should be linked to that of its host gene, GPC1. 
Glypicans (GPCs) are glycosyl-phosphatidylinositol-anchored (GPI-anchored) heparan sulphate 
proteoglycans (HSPGs) (Fico et al., 2011). Together with syndecans, they are the major cell 
membrane HSPGs; their presence in extracellular matrix and in cell surface is crucial for the 
regulation of various biological processes, including cell proliferation, development and 
differentiation, blood coagulation, angiogenesis and tumor metastasis (Iozzo and Sanderson, 
2011). Intriguingly, GPC1 is involved in angiogenesis and tumorigenesis; indeed, it is frequently 
overexpressed in multiple malignances, such as pancreatic carcinoma, breast cancer and glioma 
(Aikawa et al., 2008; Kleeff et al., 1998; Kleeff et al., 1999; Matsuda et al., 2001; Su et al., 
2006). GPC1 has been shown to act as a co-receptor for FGF, enhancing FGF signaling, 
especially in endothelial cells, sustaining cell cycle progression and cell proliferation (Chamorro-
Jorganes et al., 2014). 
In contrast to what expected for an intronic miRNA, Chamorro-Jorganes and colleagues 
observed poor correlation in the expression pattern of miR-149 (including mature and primary 
miRNA analysis) and GPC1 in a panel of human tissues and cell lines. They concluded that this 
observation is indicative of independent transcriptional regulation (Chamorro-Jorganes et al., 
2014). In support of their hypothesis, they identified a predicted transcription start site (TSS) 
located 3,1kb upstream of the miR-149 gene sequence. Looking for evidences of a putative 
promoter, they recognized three distinctive regions with various chromatin states in endothelial 
cells (EC). Notably, in other cell types the chromatin state of these regions were different, 
possibly justifying the differences in miR-149 expression among various cell lines (Chamorro-
Jorganes et al., 2014). Treating endothelial cells with FGF2, the authors observed increased 
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levels of pri-miRNA and both mature miRNAs, suggesting that this growth factor may be 
involved in the regulation of the expression of miR-149 and miR-149*, at least in endothelial 
cells (Chamorro-Jorganes et al., 2014). 
 
Notably, TNF signaling has been observed to negatively modulate miR-149 expression. TNFα 
treatment in endothelial cells down-regulates miR-149 levels specifically through p38MAPK 
signaling activation; no effect is mediated by TNF-induced JNK and Akt pathways (Palmieri et 
al., 2014). This study did not consider miR-149* expression. 
Recently, Li et al. have observed that miR-149 is dramatically down-regulated in fibrosis and in 
gastric cancer associated fibroblasts (CAFs). Intriguingly, they observed that such down-
regulation could be associated with hypermethylation of an H3K27ac-enriched area in a GC-rich 
region within -2.500 to 1500 base pair upstream of the putative miR-149 transcriptional star site 
(Li et al., 2015). They found that PGE2 (prostaglandin E2) treatment strongly induces DNA 
methylation of miR-149 gene and down-regulates miRNA-149 expression, while treatment with 
an inhibitor of DNA methylation abolishes this effect (Li et al., 2015). In normal fibroblasts, 
miR-149 down-regulates IL6-expression, maintaining these cells in an inactive state. Notably, 
the authors describe this regulatory circuit in the interaction between H. pylori-infected gastric 
epithelial cells and gastric CAFs: H. pylori infection induces the secretion of PGE2 by gastric 
epithelial cells; PGE2 silences miR-149 by hypermethylation of miR-149 gene, removing the 
suppression on IL-6 and EP2; the elevated levels of IL-6 stimulates the tumor-promoting ability 
of fibroblasts, which enhances EMT transition and stem-like properties of gastric cancer cells (Li 
et al., 2015). This work is a good example of a how miRNAs can modulate the behavior of 
immune cells in the tumor microenvironment, and how modification in their regulation and 
synthesis can affect tumor development and progression. However, as in previous work, this 
study did not consider miR-149* expression. It is tempting to speculate that TNF-mediated 
p38MAPK signaling, as well PGE2-mediated hypermethylation, could regulate miR-149* levels 
in cells, as has been observed for miR-149. 
Interestingly, in one study focused on miR-149*, Jin et al. identified a putative p53-responsive 
element located 1.592 to 1.572 base pair upstream of the GPC1 translational star site. The p53 
binding region is transcriptionally responsive to treatment with tunicamycin (TM), a drug that 
induces Endoplasmic Reticulum (ER) stress. They found that treatment with TM increases levels 
and transcriptional activity of p53, and augments miR-149* levels in melanoma cells. Notably, 
an increase of miR-149-5p has also been measured, although to less extent (Jin et al., 2011).  
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One interesting aspect that emerges from literature regarding miR-149/miR-149* is the 
involvement of both strands in the regulation of translation, so that this gene actually encodes 
two functional miRNAs. Chamorro-Jorganes and colleagues observed that the two miR-149 
strands showed an overall different pattern of expression, which is in agreement with the idea of 
tissue-dependent mechanisms of strand selection (Chamorro-Jorganes et al., 2014). 
Notably, in some cases they functionally cooperate; for instance, both miR-149 strands target the 
GPC1 and FGFR1 mRNAs, to control a complex signaling network in endothelial cells that have 
a role in proliferation, cell motility and angiogenesis (Chamorro-Jorganes et al., 2014).  
Indeed, even though miR-149 and miR-149* do not have the same seed sequence, they share 
many predicted targets involved in multiple aspects of tumorigenesis, including angiogenesis, 
inflammation, proliferation, migration and invasion, as inferred by bioinformatics analysis 
(Chamorro-Jorganes et al., 2014). When both miRNAs are co-expressed in cells, this is likely to 
promote cooperative silencing, therefore reinforcing their activity. 
In addition to common targets, miR-149 and miR-149* display also many different putative and 
validated targets, and are involved in the regulation of different biological processes, often with 
opposite results. 
While miR-149 almost exclusively acts as a tumor suppressor miRNA (Bischoff et al., 2014; 
Chamorro-Jorganes et al., 2014; Chan et al., 2014; Fujii et al., 2015; Ke et al., 2013; Li et al., 
2015; Luo et al., 2015; Palmieri et al., 2014; Wang et al., 2012; Xu et al., 2015a; Xue et al., 
2015), two works indicate that miR-149* exerts mainly a pro-tumoral activity (Fan et al., 2016; 
Jin et al., 2011). 
In particular, miR-149 has been observed to counteract EMT and cell migration and invasion in 
hepatocellular carcinoma and in breast, endothelial cell, colorectal, and non-small cell lung 
cancer (Palmieri et al., 2014) (Bischoff et al., 2014; Chan et al., 2014; Ke et al., 2013; Luo et al., 
2015; Xu et al., 2015a). miR-149 was also reported to block cell proliferation and cell cycle 
progression in gastric and prostate cancer and glioma (Fujii et al., 2015; Wang et al., 2012; Xue 
et al., 2015). In these studies, miR-149 was shown to down-regulate various signaling proteins, 
growth factors, and cytokines, including IL-6, MMP9, IL-8, ZBTB2, FOXM1, actin–regulatory 
protein PPM1F, small GTPases Rap1a and Rap1b, and the kinase Akt. 
On the contrary, miR-149* seems to be able to promote cell proliferation and suppress apoptosis 
in liquid ad solid tumors. In melanoma cells, under ER stress, p53 mediates a pro-survival 
pathway by up-regulation of miR-149*, that in turn targets glycogen synthase kinase-3α 
(GSK3α), eventually leading to stabilization of Mcl-1, an anti-apoptotic protein belonging to the 
Bcl-2 family (Jin et al., 2011). Inhibition of miR-149* results in marked retardation of tumor 
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initiation and growth in xenografts mouse models; this reduced tumor growth correlates with 
high GSK3α and low Mcl-1 levels, and increased caspase3/7 activity (Jin et al., 2011). 
A recent work has shown that miR-149* is highly expressed in T-ALL lymphoblastic leukemia 
cell lines (Molt-4 and Jurkat) and in bone marrow cells from T-ALL patients (Fan et al., 2016). 
In this cell context miR-149* overexpression down-regulates JunB, a transcription factor 
downstream of JNK signaling, influencing cell cycle progression and survival (Fan et al., 2016). 
Interestingly, the authors have also observed that miR-149* overexpression down-regulates p21, 
cyclin D1, and downstream effectors of mTOR signaling (4EBP1 and p70s6k), extended the list 
of putative means through which miR-149* could sustain the development and the progression 
of T-ALL (Fan et al., 2016). 
 
However, miR-149* has also been shown to act as a tumor suppressor miRNA in HeLa and 
BeC2 neuroblastoma cell lines. In these cells, miR-149* overexpression leads to down-
regulation of Akt and E2F1 protein levels, and induction of apoptosis. The silencing of Akt and 
E2F1 recapitulate this phenotype, suggesting that the pro-apoptotic effects of miR-149* are 
exerted by repressing these two proteins (Lin et al., 2010). 
 
To conclude, while the role of miR-149 is relatively well understood in tumorigenesis, and data 
indicate it is tumor suppressive in almost all condition studied, much less is known about miR-
149*, its possible targets, and its role in tumorigenesis. Moreover, our knowledge about the 
mechanisms that control expression of the miR-149 gene in tumors is still very limited, and in 
particular we have absolutely no clues about the cellular processes or biological stimuli that 
dictate expression of the miR-149 or miR-149* strands in cancer cells. 
Nevertheless, both microRNAs seem to be important in carcinogenesis, both because they 
control pathways and processes important in tumor development, such as cell migration and 
invasion, cell proliferation and apoptosis, and because their expression may be regulated by 
stress conditions, and by extracellular stimuli such as cytokines and growth factors from the 
tumor microenvironment.  
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3.3 RESULTS 
 
3.3.1 Identification and validation of microRNAs targeting DAB2IP 
To discover additional DAB2IP-targeting miRNAs, we employed a functional approach. In 
collaboration with dr. Miguel Mano (ICGEB, Trieste), using an automated high-throughput 
screening facility, we screened a collection of 879 human miRNA mimics using dual-Luciferase-
based report gene system (psiCHECK). The 3’UTR of human DAB2IP was cloned downstream 
of Renilla Luciferase reporter gene in psiCHECK vector. This vector expresses another reporter 
gene, Firefly Luciferase, used to normalize the efficiency of transfection. We co-transfected 
psiCHECK-DAB2IP 3’UTR, or psiCHECK empty vector, together with a library of miRNA 
mimics in HeLa cells. After 48 hours we read the Renilla/Firefly luciferase activity ratio. The 
graph in Figure 3.3A reports the list of top miRNAs able to down-regulate the reporter, resulting 
after two rounds of primary screening. Among them, we identified miR-338-3p, previously 
reported to target DAB2IP 3’UTR (Barik, 2008), confirming the reliability of the assay. 
Interestingly, our functional screening identified several miRNAs that specifically up-regulate 
the DAB2IP 3’UTR reporter, suggesting the existence of molecular circuits that could enhance 
DAB2IP mRNA translation or stability (Figure 3.3B). 
Our experimental approach allowed the identification of miRNAs that are not detected by 
prediction algorithms (Target Scan, miRanda, miRDB, mirWalk, RNA22), or have a very low 
probability score. Below are Venn diagrams showing the overlap between miRNAs identified 
through high-throughput screening (Exp) and miRNAs suggested by at least one (Pred 1) or at 
least three (Pred 3) prediction programs. 
                                                            
 
We next performed a secondary screening using the psiCHECK empty vector to expunge false 
positives. At the end of the screening, we identified 81 miRNAs that specifically target the 
miRNAs down-regulating DAB2IP 3’UTR reporter 
 
miRNAs up-regulating DAB2IP 3’UTR reporter 
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DAB2IP 3’UTR reporter with high confidence. 
We focused on 41 miRNAs that repress DAB2IP 3’UTR reporter. Having a substantial number 
of hits, we selected the best candidates based on efficiency of inhibition on the DAB2IP 3’UTR 
reporter. Then, we performed a process of validation by measuring their effects on endogenous 
DAB2IP in multiple cell lines (HeLa, MCF-10A, SKOV-3, H1299, HCT-116, HePG2, PC-3 and 
LNCaP). We transfected miRNA mimics for 48 hours, and then did Western blots to evaluate 
DAB2IP protein levels. Representative blots relative to non-transformed mammary epithelial 
(MCF-10A) and prostate (PC-3) cancer cells are shown in Figure 3.3C. As can be seen, the 
majority of tested miRNAs reduced the protein levels of DAB2IP, at least in one cell line. 
We next analyzed expression of positive miRNAs in these cell lines by RT-PCR (data not 
shown). We found that two top-scoring miRNAs were not expressed in our model cell lines: 
miR-555 and miR-582-5p. These were excluded from further study. 
A heat map in Figure 3.3D summarizes the activity of 8 miRNAs tested in multiple cell lines. 
Some miRNAs exert different effects depending on the cell line. Notably, miR-744, miR-92a 
and miR-96 induced strong reduction of DAB2IP levels in at least four out of seven cell lines 
(Figure 3.3D). Intriguingly, among top hits there are two miRNAs that originate from the same 
precursor. miR-149 (miR-149-5p) is the guide strand, and has tumor suppressive functions in 
multiple human malignancies (Bischoff et al., 2014; Chamorro-Jorganes et al., 2014; Chan et al., 
2014; Fujii et al., 2015; Ke et al., 2013; Li et al., 2015; Luo et al., 2015; Palmieri et al., 2014; 
Wang et al., 2012; Xu et al., 2015a; Xue et al., 2015). miR-149* (miR-149-3p) is the passenger 
strand, and its role in tumor progression is still unclear. Notably, miR-149* is able to induce 
robust DAB2IP reduction in all cell lines, while miR-149 has a weaker effect, although still 
detectable.  
We therefore focused on miR-744, miR-92a, miR-96 and miR-149* in order to examine their 
ability to sustain oncogenic pathways activation, and promote and/or enhance the acquisition of 
aggressive phenotypes, possibly through the inhibition of DAB2IP translation. 
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Figure 3.3: Identification of microRNAs targeting DAB2IP by high-throughput functional screening. 
A-B) Results of the primary screening. A) HeLa cells were reverse-transfected with miRNA mimics; after 24 hours 
cells were transfected with psiCHECK2 DAB2IP 3’UTR vector. Dual-Luciferase assay was performed 48 hours 
later. The graph summarizes the results of two rounds of primary screen. The Y axis reports RLuc/FLuc ratio for 
each miRNA, normalized to the average of negative controls. Cel-miR-231 and cel-miR-67 were used as negative 
controls, while miR-338-3p mimic and a DAB2IP siRNA were transfected as positive controls (mean ± SD, n=2). In 
green, miR-338-3p, previously reported to target DAB2IP (Barik, 2008). B) The plot describes, for each microRNA, 
the reporter fold expression normalized to the average of all samples, in two independent screens. Values lower than 
1 indicate specific repression; a significant number of samples have values greater than 2, corresponding to 
induction of the reporter. C-D) Top scoring miRNAs are able to reduce endogenous DAB2IP protein levels. C) A 
representative western blot of MCF-10A and PC-3 cells transfected with indicated miRNA mimics for 48 hours. 
DAB2IP siRNA (siDAB2IP) was used as positive control. Actin was used as loading control. D) The heat map 
summarizes the effects of the indicated miRNA mimics on endogenous DAB2IP protein levels in the indicated cell 
lines. Cells were treated as described in C. For quantitative evaluation, gel bands were quantified by densitometry 
on autoradiography films and normalized to control siRNA-transfected samples. 
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3.3.2 DAB2IP depletion strongly increases tumor cells motility 
The choice of experimental assay and cellular context in which to perform the functional 
characterization of validated miRNAs should be based on the characteristic of each miRNA, its 
biological role (if known), and the kind of tumors in which it is mostly expressed. Finally, also 
the biological processes in which DAB2IP is involved must be considered. 
Since DAB2IP is a powerful inhibitor of EMT induction, cell migration, and invasion, we 
evaluated the impact of DAB2IP knockdown on cell motility. We performed invasion and 
migration assays with several cell lines: PC-3, MCF-10A, SKOV-3 (ovarian cancer), HepG2 
(hepatocellular carcinoma).  
We found that DAB2IP silencing strongly increases matrigel invasion in PC-3, HepG2 and 
SKOV-3 cell lines (Figure 3.4A-C), and cell migration in MCF-10A (Figure 3.4D). We thus 
confirmed that cell migration/invasion is a cell phenotype linked to DAB2IP depletion. 
Consistently, we observed that stable DAB2IP overexpression in PC-3 cells reduces vimentin 
(mesenchymal marker) expression, and matrigel invasion. We infected PC-3 cells with retroviral 
vectors encoding the two major DAB2IP isoforms (DAB2IP-long and DAB2IP-short); the 
encoded proteins differ at the N-terminus, where DAB2IP-long has additional 96 amino acids, 
allowing for a putative larger PH domain (Figure 1.1, Chapter 1.2). Notably, both isoforms 
reduced the expression of vimentin (Figure 3.4E), suggesting they are both involved in the 
regulation of pathways that control EMT. Curiously, we noticed that the short isoform of 
DAB2IP significantly reduced the motility of PC-3 cells (Figure 3.8B), in agreement with its 
ability to reduce vimentin expression. In contrast, the long DAB2IP isoform had a lesser impact 
on basal PC-3 invasion. We don’t know the reason for the different effect exerted by the two 
isoforms. Immunoblotting and immunofluorescence confirmed high expression levels and 
cytoplasmic and membrane localization of both isoforms (Figure 3.4E). 
In collaboration with dr. Luigi Marchionni at Johns Hopkins University of Baltimore (USA), we 
analyzed the correlation between DAB2IP mRNA levels and clinical parameters in public gene 
expression datasets. We focused on prostate cancer, a tumor in which the loss of DAB2IP often 
correlates with aggressive phenotype and metastasis formation (Kong et al., 2010; Min et al., 
2010; Xie et al., 2010; Zhou et al., 2015). We analyzed the GSE21032 dataset, referring to a 
patient cohort in which data relative to mRNAs and miRNAs expression in primary tumors and 
metastases are available, along with clinical parameters (Taylor et al., 2010). In line with 
previous studies, DAB2IP levels are significantly reduced in primary tumors and metastasis, 
compared to normal tissue (Figure 3.4F). 
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Together, these observations suggest that DAB2IP inhibits cell invasion in various tumor 
contexts, especially in prostate cancer, and therefore migration/invasion is a cell phenotype that 
could be linked to DAB2IP depletion. 
 
 
 
Figure 3.4: DAB2IP depletion increases cell motility and metastasis. A-D) DAB2IP silencing increases tumor 
cell invasion and migration. A-C) Indicated cells were transfected with DAB2IP (siDAB2IP) or control siRNAs 
(siC). After 48 hours, invasion assays were performed using matrigel-coated transwell filters under low serum 
conditions; the lower chamber was filled with high serum medium (10%FBS). Where indicated, two different 
DAB2IP siRNAs were used. Graphs summarize migrated cells per area (mean ± SD; n=3; ***P<0.001; **P<0.01; 
*P<0.05). DAB2IP depletion was checked by western blot, with actin as loading control. D) MCF-10A cells were 
infected with a lentivirus expressing an inducible shRNA targeting DAB2IP 3’UTR sequence (shDAB2IP). After 96 
hours of doxycycline (dox) treatment (50ng/ml) to induce the expression of shRNA, migration assays were 
performed using transwell filters in low serum; the low chamber was filled with high serum medium. Graph 
summarizes migrated cells per area (mean ± SD; n=3; **P<0.01). Efficiency of DAB2IP depletion was confirmed 
by western blot of the same cells. E) Stable DAB2IP overexpression reduces vimentin expression. PC-3 cells were 
infected with retroviral constructs expressing two isoforms of DAB2IP (pLPC DAB2IP-long and pLPC DAB2IP-
short). pLPC empty vector was used as control. Immunofluorescence and immunoblotting confirm DAB2IP 
overexpression and cytoplasmic localization. F) DAB2IP expression is significantly reduced in primary tumors and 
metastasis. Boxplot showing DAB2IP expression levels across normal prostate, primary cancers, and metastatic 
lesions from GSE21032 dataset (Taylor et al., 2010). Significance was calculated by Anova test (***P<0.001). 
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3.3.3 miR-96 and miR-149* enhance cancer cell invasivity 
To infer the potential cancer relevance of positive miRNA hits, and in particular their impact on 
metastasis formation, we analyzed their expression in the GSE21032 prostate cancer dataset 
(Taylor et al., 2010). 
As shown in Figure 3.5A, miR-96 is strongly expressed in primary tumors and metastases. This 
is in line with its known oncogenic role in various cancers. For example, in prostate carcinomas 
it has been observed that miR-96 targets FOXO1 to inhibit apoptosis and enhance proliferation 
(Fendler et al., 2013; Yu et al., 2014). This miRNA has been shown to sustain cell migration and 
invasion in breast, hepatocellular, non-small cell lung cancer, and tongue squamous cell 
carcinoma by the regulation of various proteins (Guo et al., 2014; Guo et al., 2015; Leung et al., 
2015; Li et al., 2014b; Siu et al., 2015). Finally, in prostate cancer TGF-β can increase miR-96 
levels that in turn sustains invasion through the up-regulation of mTOR signaling (Siu et al., 
2015).  
Also miR-92a is strongly expressed in metastatic lesions (data not shown).  miR-92a belong to 
miR-17-92 cluster, and is a well known onco-miRNA. Its expression promotes cell proliferation, 
suppresses apoptosis of cancer cell and induces tumor angiogenesis and metastasis (Hayashita et 
al., 2005; Li et al., 2014a; Mendell, 2008; Rao et al., 2012). Both E2F1 and E2F3 can directly 
activate transcription of this miRNA, establishing a negative feedback loop (Petrocca et al., 
2008a).  
On the contrary, miR-744 is not differentially expressed in this dataset (not shown). In literature 
its role is still controversial. Some works describe it as an onco-miRNA whose serum levels have 
been proposed as non-invasive biomarkers for the detection of gastric cancer (Fang et al., 2015; 
Song et al., 2012; Tan et al., 2015). However, it has been also demonstrated that miR-744 targets 
and down-regulates oncogenes such as c-Myc in hepatocellular carcinoma, where reduced miR-
744 expression increases cell proliferation (Lin et al., 2014). 
Finally, miR-149* is strongly expressed in prostate tumor tissue, with even higher levels in 
metastatic lesions (Figure 3.5A).  
For their strong correlation with metastasis in prostate cancer patients, we decided to further 
analyze the role of miR-149* and miR-96 in cell invasion mediated by DAB2IP down-
regulation. To this aim, we transfected miR-149* and miR-96 mimics in PC-3 cells and 
performed invasion assays. Knockdown of DAB2IP by siRNAs provided a positive control. As 
shown in Figure 3.5B, both miRNAs are able to increase the invasive properties of this 
metastatic cell line, with similar, if not better, efficiency as DAB2IP depletion.  
While miR-96 has known pro-oncogenic and pro-invasive activity in various malignances, 
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supported by multiple publications, the role miR-149* in tumorigenesis is not completely 
understood. In particular, evidences for miR-149* functions in migration and metastasis of 
cancer cells have not been reported yet. For this reason we decided to focus our attention on 
miR-149*, and tested if the observed phenotype could be extended to other cell models. 
Overexpression of miR-149* clearly increased invasivity of metastatic prostate LNCaP and 
ovarian SKOV-3 cancer cell lines (Figure 3.5C-D). We then turned to MCF-7 breast cancer 
cells, which are not invasive and migrate poorly in trans-well assays. As shown in Figure 3.6C, 
DAB2IP depletion enhances the motility of these cells. Notably, miR-149* overexpression also 
efficiently increased MCF-7 cell migration, confirming that cell migration/invasion is a robust 
property of this miRNA (Figure 3.6C).  
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Figure 3.5: miR-149* and miR-96 increase tumor cells motility and metastasis. 
A) miRNA-96 and miR-149* expression is significantly increased in primary tumor and metastasis. Boxplot 
showing miRNA expression levels across normal prostate, primary cancers, and metastatic lesions from GSE21032 
data set (Taylor et al., 2010). Significance was calculated by Anova test. (***P<0,001; *P<0,05). B) miR-96 and 
miR-149* increase prostate cancer cells invasion. PC-3 cells were transfected with a mix of two DAB2IP siRNAs 
(siDAB2IP), with a control siRNA (siC), or with miRNA mimics (miR-96 and miR-149*) as indicated for 48 hours. 
Invasion assay was performed as in Figure 3.4A. Graph summarizes migrated cells per area (mean ± SD; n=3; 
***P<0,001; **P<0,01; *P<0,05). DAB2IP depletion was checked by western blot, with actin as loading control. 
Representative images of migrated cells are shown. C-D) miR-149* increases invasion of LNCaP and SKOV-3 
cells. Cells were transfected as indicated for 48 hours. Invasion assay was performed as in Figure 3.4A. Graph 
summarizes migrated cells per area (mean ± SD; n=3; **P<0,01; *P<0,05). DAB2IP depletion was checked by 
western blot. 
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3.3.4 miR-149* and miR-149, two sides of the same coin? 
Our screening identified, among the validated hits, also miR-149 (miR-149-5p), encoded by the 
same precursor as miR-149*, but with a different seed sequence. Prediction analysis confirmed 
that target sites for miR-149 and miR-149* are present within the 3’UTR of human DAB2IP and 
indeed, at least in some cell types, miR-149 down-regulates DAB2IP protein levels (Figure 
3.3C-D). We therefore analyzed expression and activity of miR-149 as described above for miR-
149*. Interestingly, we found no evidence of differential miR-149 expression in prostate cancer 
samples from GSE21032 (Figure 3.6A), and we observed no relevant effects of its 
overexpression in cell invasion/migration assays in PC3 or MCF-7 cells, an effect correlated to a 
much less efficient depletion of endogenous DAB2IP protein (Figure 3.6B-C). Together, these 
data strongly suggest that the two miRNAs encoded by the miR-149 gene, despite sharing the 
potential to target DAB2IP, may have significantly different activities. 
We used RT-qPCR to measure miR-149* and miR-149 levels in a panel of tumor and non-
transformed cell lines (Figure 3.6D). The expression of miR-149* appears to be very similar in 
all cell lines, with comparable levels both in cancer (PC-3, LNCaP, MCF-7, MDA-231, MDA-
468, SKOV-3, OVCAR-3, TOV112D, H1299, HCT116) and in non-transformed cell lines 
(PWRE, RWPE, MCF-10A). Instead, miR-149 shows a more variable pattern of expression, 
with lower levels in tumor than in non-transformed or less aggressive cell lines. For example, 
miR-149 is more expressed in non-transformed prostate epithelial cells (i.e. PWRE and RWPE), 
than in prostate cancer (PC-3 and LNCaP). This is in line with its described tumor suppressive 
activity (Bischoff et al., 2014; Chamorro-Jorganes et al., 2014; Chan et al., 2014; Fujii et al., 
2015; Ke et al., 2013; Li et al., 2015; Luo et al., 2015; Palmieri et al., 2014; Wang et al., 2012; 
Xu et al., 2015a; Xue et al., 2015). 
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Figure 3.6: miR-149 and miR-149* sharing the potential to target DAB2IP, but with different effect on cell 
motility.  
A) miRNA-149 is not differentially expressed in prostate cancer. Boxplot showing miRNA expression levels across 
normal prostate, primary cancers, and metastatic lesions from GSE21032 data set (Taylor et al., 2010). Significance 
was calculated by Anova test (ns = non significant). B) miR-149 does not induce a significant increase of cell 
invasion. PC-3 cells were transfected with miR-149 for 48 hours. Invasion assay was performed as in Figure 3.4A. 
Graph summarizes migrated cells per area (mean ± SD; n=3). DAB2IP depletion was checked by western blot, with 
actin as loading control. C) miR-149*, but not miR-149, increases migration of breast cancer cells. MCF-7 was 
transfected with mix of two DAB2IP siRNAs (siDAB2IP), control siRNAs (siC) or miRNA mimics as indicated for 
48 hours. Migration assay was performed as described in Figure 3.4D. Graph summarizes migrated cells per area 
(mean ± SD; n=3; ***P<0,001; **P<0,01). DAB2IP depletion was checked by western blot. D) miR-149* and miR-
149 are expressed in tumor and in non-transformed cell lines. The graphs summarize the expression of both 
miRNAs detected by RT-qPCR. The Y axis reports measured Ct of both miRNAs in each cell line. Error bars 
indicate standard deviation (n=3). 
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3.3.5 miR-149* inhibition increases DAB2IP protein levels and reduces prostate cancer 
cells invasion 
miR-149* seems to be a potential onco-miRNA in prostate cancer, given its ability to sustain 
invasion (Figure 3.5B-C) and its increased expression in metastasis of prostate cancer patients 
(Figure 3.5A). To further validate the role of miR-149* in promoting invasion, we counteracted 
endogenous miR-149* activity using a specific miRNA inhibitor. We transfected miR-149* (inh 
149*) or control inhibitors (inh C) in PC-3 and LNCaP cells, and performed matrigel invasion 
assays. The miR-149* inhibitor strongly reduced invasive capability of both PC-3 and LNCaP 
cells, simultaneously increasing DAB2IP protein levels (Figure 3.7A). This observation 
convince us of a powerful role of miR-149* in sustaining tumor cells invasion, at least in 
prostate cancer. 
 
 
 
Figure 3.7: Endogenous miR-149* inhibition reduces prostate cancer cells invasion. A) Inhibition of 
endogenous miR-149* reduces tumor cells invasion and increases DAB2IP protein levels. PC-3 and LNCaP cells 
were transfected with miR-149* (inh miR-149*) or control hairpin inhibitors (inh C) for 24 or 48 hours, 
respectively. Invasion assay was performed as in Figure 3.4A. Graphs summarize migrated cells per area (mean ± 
SD; n=3; **P<0,01; *P<0,05). Western blot confirms increased expression of DAB2IP protein. Actin was used as 
loading control. Representative images of migrated PC-3 cells are shown. 
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3.3.6 miR-149* increases the invasive behavior of cancer cells through DAB2IP protein 
down-regulation 
To asses if DAB2IP down-regulation mediated by miR-149* is the main driver for increased 
invasion in prostate cancer cells, we tested whether DAB2IP depletion might have additional 
effects on the pro-invasive phenotype induced by miR-149* overexpression. To this aim we co-
transfected DAB2IP siRNAs with miR-149* mimic for 48 hours in PC-3 cells, and performed 
matrigel invasion assays. As shown in Figure 3.8A, overexpression of miR-149*, depletion of 
DAB2IP by siRNA, or co-transfection of both reagents gave a similar increase in cell invasion, 
supporting the notion that the impact of miR-149* on this specific phenotype is largely mediated 
by DAB2IP depletion. 
To further confirm the epistasis between miR-149* and DAB2IP, we tested whether 
overexpression of DAB2IP could rescue the effects of miR-149* in our cell models. We 
transfected miR-149* or control siRNA in PC-3 cells overexpressing DAB2IP isoforms encoded 
by cDNA constructs lacking the 3’UTR sequences recognized by miR-149* (Figure 3.4E). As 
expected, miR-149* overexpression increased invasion of vector transfected PC-3 cells, but 
could not increase invasivity of DAB2IP overexpressing cells (Figure 3.8B). In other words, 
DAB2IP blocked miR-149* induced prostate cancer cell invasion, confirming their functional 
epistasis. 
To confirm that miR-149*-induced invasion depends on its binding to the 3’UTR of DAB2IP 
mRNA, we used miRNA Target Protector technology. Target Protectors (TP) are innovative 
tools, designed to protect the miRNA-binding site of a specific target gene, blocking the access 
of a specific miRNA to its target site, and thus preventing protein down-regulation. The 
important advantage of these molecules is their ability to counteract the effects of a given 
miRNA on a specific target gene, without affecting its action on other cellular genes. 
We designed target protectors for three putative miR-149* binding sites on human DAB2IP 
3’UTR, as predicted by miRDB (www.mirdb.org/miRDB/) (Figure 3.8C). 
The transfection of target protectors significantly increased DAB2IP protein levels in PC-3, 
similar to what observed with miR-149* inhibitor, thus confirming that endogenous miR-149* is 
active in these cells (Figure 3.8D). Quite robust results were obtained by combined transfection 
of the three target protectors (TPmix). Importantly, all three TPs could protect to some extent 
DAB2IP from downregulation by a miR-149* mimic (Figure 3.8D). This experiment confirms 
that miR-149* reduces DAB2IP protein levels by targeting its 3’UTR, and indicates that all three 
predicted binding sites on DAB2IP mRNA are functional targets of this microRNA. 
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We next investigated the effects of TPs on invasivity of prostate cancer cells, with or without 
miR-149* overexpression. We transfected PC-3 cells with miR-149*, with or without target 
protectors (TPmix), and performed matrigel invasion assays. In these conditions, target 
protectors increased DAB2IP protein levels and reduced invasion of PC-3 cells (Figure 3.8E), 
suggesting they counteract the activity of endogenous miR-149* in these cells. Moreover, TPmix 
reduced the invasivity of cells overexpressing the miR-149* mimic, partially protecting DAB2IP 
protein from miR-149* induced down-regulation (Figure 3.8E). 
We conclude that miR-149* ability to increase invasion of prostate cancer cells is largely 
mediated by its ability to bind the 3’UTR of DAB2IP mRNA, and reduce expression of DAB2IP 
protein, and its tumor suppressive functions. 
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Figure 3.8: Functional interaction between miR-149* and DAB2IP in prostate cancer cells. 
A) PC-3 cells were transfected with DAB2IP siRNAs (siDAB2IP), control siRNA (siC) or miR-149* mimic as 
indicated for 48 hours. Invasion assays were performed as in Figure 3.4A. Graph summarizes migrated cells per area 
(mean ± SD; n=3). Western blot confirmed DAB2IP silencing. B) PC-3 cells infected with retroviruses expressing 
DAB2IP-long or -short isoforms were transfected with miR-149* mimic (miR-149*) or control siRNA (siC) for 48 
hours. Invasion assay was performed as in A. Graph summarizes migrated cells per area (mean ± SD; n=3; 
***P<0,001; **P<0,01; *P<0,05). A control western blot of endogenous and exogenous DAB2IP proteins is shown. 
C) Schematic representation of the three putative miR-149* target sites on DAB2IP 3’UTR; in red miR-149* seed 
sequence. We designed three Target Protectors that bind specifically site 1 (TP1), site 2 (TP2) and site 3 (TP3). D) 
Target Protectors increase DAB2IP protein levels in untreated cells, and in cells transfected with miR-149*. PC-3 
were co-transfected with three different target protectors (TP1, TP2, TP3) alone or in combination, with a non-
targeting control (TPc), and either control siRNA (siC) or miR-149* mimic for 48 hours. DAB2IP protein levels 
were measured by western blot. Bottom: graph summarizes the fold increase over control (siC+TPc transfected 
sample) measured by densitometry of autoradiography films. E) Target protectors significantly reduce prostate 
cancer cells invasion. PC-3 cells were transfected with control siRNA (siC), miR-149* and target protectors mix 
(TPmix) or negative control (TPc) as indicated for 48 hours. Invasion assay was performed as in Figure 3.4A. Graph 
summarizes migrated cells per area (mean ± SD; n=3; **P<0,01). Control western blot was performed to detect 
endogenous DAB2IP protein levels. Actin was used as loading control. 
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3.3.7 miR-149*-mediated DAB2IP depletion induces an inflammatory, immunogenic, NF-
κB-related gene expression program 
To gain a molecular insight on the invasive phenotype, we used microarrays to analyze the 
transcriptional profile of PC-3 cells transfected with miR-149* mimic, or with DAB2IP specific 
siRNAs. We observed that overexpression of miR-149* had a much broader impact on 
transcription than DAB2IP knockdown, probably reflecting its nature of pleiotropic modulator of 
translation. Gene Set Enrichment Analysis (GSEA) revealed that genes down-regulated by miR-
149* or DAB2IP siRNA are not involved in the modulation of cell motility and/or EMT, and in 
general are not associated to biological processes that could be linked to the phenotypes under 
analysis (data not shown). On the contrary, genes up-regulated by miR-149* or DAB2IP siRNA 
(miR-149*_UP and siDAB2IP_UP) revealed enrichment for relevant biological functions, 
including hypoxia, inflammatory and immune response, apoptosis, and EMT. Moreover, up-
regulated genes were enriched in hallmarks of relevant signaling pathways such as TNF via NF-
κB, mTORC1, and IL6-STAT3 (Figure 3.9A-B). Not surprisingly, miR-149* up-regulated genes 
are also enriched for additional biological processes, including glycolysis, response to estrogen, 
and Heme metabolism, that are not detected in genes up-regulated by DAB2IP depletion (Figure 
3.9A). These could be connected to biological functions mediated by miR-149* in a DAB2IP-
independent mechanism. Notably, one of the hallmarks with strongest enrichment in both 
conditions was “TNF signaling via NF-κB”, a pathway which is related to EMT and cell motility 
(Figure 3.9C). 
To define pathways and processes activated by miR-149* in a manner strictly dependent on 
DAB2IP inhibition, we focused on common genes up-regulated by DAB2IP siRNA and by miR-
149* mimics transfection (Figure 3.9D); GSEA confirmed a specific enrichment for hallmarks of 
NF-κB signaling. Among NF-κB target genes common in the miR-149*_UP and siDAB2IP_UP 
genesets, we identified some chemokines and cytokines, including CCL20, IL8 (CXCL8), and 
CSF2 (GM-CSF). These inflammatory factors are involved in the regulation of immune cells 
recruitment and activity; however, studies in vitro and in vivo demonstrated that they are also 
fundamental regulators of EMT and cell motility in tumor microenvironment (Cheng et al., 
2014; Gales et al., 2013; Park et al., 2007; Roberti et al., 2012; Rudisch et al., 2015; Zeng et al., 
2014).  
We conclude that miR-149*-mediated reduction of DAB2IP sustains a transcription program 
that supports cell motility and inflammatory response, and defines NF-κB signaling activation. 
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Microarrays were validated by RT-qPCR on a selection of genes belonging to the intersection of 
miR-149*_UP and siDAB2IP_UP genesets, confirming their regulation (Figure 3.9E). 
To further validate these results, we transfected PC-3 cells with a miR-149* inhibitor, and 
performed RT-qPCR of selected target genes. The inhibition of miR-149* significantly reduced 
CCL20, CSF2 and PTX3 expression, confirming their positive regulation by miR-149*, possibly 
through inhibition of DAB2IP (Figure 3.9F). 
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Figure 3.9: miR-149*-mediated DAB2IP reduction modulates prostate cancer cells transcription program.  
A-B) PC-3 cells were transfected with DAB2IP siRNA mix (siDAB2IP), control siRNA (siC) and miRNA-149* 
mimic for 48 hours and analyzed by Illumina microarray. Up-regulated genes were selected and analyzed by Gene 
Set Enrichment Analysis (GSEA) tool. Top GSEA hallmarks specifically enriched in miR-149*_UP or 
siDAB2IP_UP are shown. (MSigDB= Molecular Signature Data Base). C) GSEA enrichment plots for the “TNF 
signaling via NF-κB” hallmark. D) Venn diagram shows the intersection of miR-149*_UP and siDAB2IP_UP gene 
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sets. Graph summarizes the top enriched hallmarks in common up-regulated genes. E) Expression of selected genes 
identified in miR-149*_UP and siDAB2IP_UP was validated by RT-qPCR. Values are normalized to histone H3 
and compared to siC samples (mean ± SD; n=4). A control western blot is shown on the right. F) Basal expression 
of validated common genes depends on miR-149*. miR-149* or control inhibitors were transfected in PC-3 cells for 
48 hours. Expression of indicated genes was measured by RT-qPCR. Values are normalized to histone H3 and 
compared to inh C samples (mean ± SD; n=3). A control western blot is shown on the right. 
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3.3.8 miR-149* sustains cell invasion through increased activation of NF-κB signaling 
The hallmark most enriched upon DAB2IP depletion and miR-149* overexpression is TNF 
signaling via NF-κB, and many validated genes are NF-κB targets (CCL20, IL8, CSF2, BIRC3 
and PTX3). Several studies indicate that DAB2IP is a fundamental inhibitor of NF-κB signaling, 
and demonstrate that this inhibitory activity reduces EMT and restrains cell motility in various 
cancer models (Min et al., 2015; Min et al., 2010). We therefore evaluated the nuclear 
localization of transcription factor NF-κB by immunoblotting on purified nuclear and 
cytoplasmic fractions of transfected PC-3 cells. An increased nuclear localization of p65 RelA 
was observed in cells transfected with miR-149* mimic, or DAB2IP siRNA as a positive control 
(Figure 3.10A). 
We used a specific siRNA against p65 RelA to evaluate the relevance of NF-κB activation in the 
increased invasion observed upon miR-149* overexpression. As shown in Figure 3.10B, the 
transient knockdown of p65 RelA totally blocked the invasiveness of PC-3 cells induced by 
miR-149* overexpression, or by DAB2IP depletion. Curiously, depletion of NF-κB does not 
affect the basal invasive behavior of this metastatic cell line (Figure 3.10B). This observation 
suggests that NF-κB signaling is fundamental for the increase in invasivity triggered by miR-
149* overexpression; it is possible that other pathways (i.e. PI3K/Akt or Wnt/βcatenin) are 
involved in the maintenance of basal invasive features of PC-3 cells. 
These experiments demonstrate that NF-κB signaling is the main pathway involved in the 
invasive phenotype observed in prostate cancer cells upon miR-149*-dependent DAB2IP 
reduction. 
 
 
Figure 3.10: NF-κB pathway activation mediates miR-149* induced cell invasion. A) Overexpression of miR-
149* or siRNA-mediated DAB2IP depletion increase nuclear localization of p65 RelA. PC-3 cells were transfected 
as described in Figure 3.5 and subjected to biochemical fractionation to purify nuclei from cytoplasm. Tubulin 
(cytoplasmic) and Lamin A/C (nuclear) were blotted as controls. DAB2IP depletion was checked by western blot of 
total samples (left panel). B) Depletion of p65 RelA blocks miR-149*-induced cell invasion. PC-3 cells were co-
transfected with a DAB2IP siRNAs mix (siDAB2IP), miR-149* mimic, a siRNA to p65 RelA (sip65) or a control 
siRNA (siC), as indicated. After 48 hours, invasion assay was performed as in Figure 3.4A (mean ± SD; n=3; 
***P<0,001; *P<0,05). Western blot confirmed DAB2IP and p65 RelA silencing. Actin was used as loading 
control. 
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3.3.9 miR-149* affects TNF-induced transcription  
Many genes up-regulated upon miR-149* overexpression, or DAB2IP depletion, are cytokines 
and chemokines downstream of TNFα signaling via NF-κB (Figure 3.9A-C). To evaluate the 
role of miR-149* in the response to TNFα, we transfected PC-3 cells with a miR-149* inhibitor 
for 48 hours, and then treated cells with this cytokine for 20 hours. TNFα up-regulated the 
expression of CCL20 and IL8, while transfection of a miR-149* inhibitor counteracted this 
phenotype (Figure 3.11A). This preliminary observation suggests that miR-149* - likely by 
reducing DAB2IP levels – can modulate NF-κB signaling upon inflammatory stimuli, in 
particular TNFα, with implications for oncogenic behavior of tumor cells exposed to 
inflammation. By affecting TNFα signaling, therefore, miR-149* can control inflammation-
induced invasion, proliferation, or survival of tumor cells. Further experiments are needed to 
better characterize this aspect. 
 
 
Figure 3.11: miR-149* inhibition modulates TNF-induced transcription. A) PC-3 cells were transfected with 
miR-149* or control inhibitors as described in Figure 3.9F. Cells were serum starved and treated with TNFα (10 
ng/ml) for 20 hours. Expression of CCL20 and IL8 was measured by RT-qPCR. Values are normalized to histone 
H3 and compared to inh C samples (mean ± SD; n=3; **P<0,01; *P<0,05). A control western blot is shown on the 
right. 
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3.3.10 Implications of miR-149* in cancer: analysis of TCGA dataset 
To explore the potential clinical impact of this molecular axis, with the help of Denis Torre 
(University of Trieste) we analyzed the expression of both miR-149 (miR-149-5p) and miR-149* 
in public gene expression datasets from TCGA (The Cancer Genome Atlas). In particular, we 
analyzed miR-149 expression levels in breast cancer (BRCA), prostate adenocarcinoma (PRAD), 
and lung squamous cell carcinoma (LUSC). We performed two different analyses, comparing 
paired samples (tumor versus normal tissues of the same patient) and unpaired samples (all 
tumors versus all normal). 
Notably, miR-149 (hsa-miR-149, mature) is easily and better detected in tumors and normal 
tissues with respect to the passenger strand (hsa-miR-149, star), suggesting it is expressed at 
higher levels. However, miR-149* is clearly overexpressed in breast cancer samples with respect 
to their corresponding paired normal tissues (Figure 3.12A), in line with its oncogenic effect in 
tissue culture experiments. 
In unpaired analyses, both miR-149 and miR-149* resulted to be overexpressed in breast, 
prostate, and lung squamous cell carcinomas (Figure 3.12B), with absolute miR-149 expression 
levels consistently higher than those of miR-149*. The higher expression of miR-149* in breast, 
prostate and lung cancer correlates with its pro-metastatic role described previously (Figure 3.5). 
In contrast, cancer overexpression of miR-149-5p appears in conflict with its reported tumor 
suppressive activity. However, it should be considered that miRNA activity does not depend 
only on expression levels in cells and tissues, but also on the biological context, abundance of 
mRNA target, and regulation of its biogenesis and function. 
Together, these preliminary analyses suggest that miR-149* is overexpressed in prostate, breast, 
and lung squamous cell cancers, in agreement with is oncogenic ability to sustain invasion 
through the reduction of DAB2IP levels and the increase of NF-κB activity, most likely in 
response to inflammatory stimuli, including TNF. 
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Figure 3.12: miR-149* is differentially expressed in breast, prostate, and squamous cell lung carcinoma. 
A) Expression of miR-149 (miR-149, mature) and miR-149* (miR-149, star) in 84 paired breast tissue samples 
(tumor versus normal tissue of the same patient) from TCGA. Significance was calculated with Wilcoxon test (p= 
FDR). B) Expression of miR-149 (miR-149, mature) and miR-149* (miR-149, star) in unpaired breast, prostate, and 
lung cancers from TCGA. Significance was calculated with non-parametric Mann-Whitney test (p= FDR). 
BRCA= breast cancer; PRAD= prostate adenocarcinoma; LUSC= lung squamous cell carcinoma. 
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3.4 DISCUSSION 
The tumor suppressor DAB2IP is emerging as a fundamental factor to maintain physiological 
control of signaling pathways, to counteract acquisition of oncogenic properties, and to modulate 
the crosstalk with immune and stromal cells in the microenvironment. For this reason DAB2IP 
tumor suppressive activities are disabled in human malignancies through multiple mechanisms, 
including the inhibitory binding with the oncogenic mutant p53 protein, as described in Part 2 of 
this Thesis. Since DAB2IP has a rather long 3’UTR, it is a good candidate miRNA target. Three 
miRNAs have been described to down-regulate DAB2IP in various tissue or cancer types (Barik, 
2008; Liao et al., 2015; Xu et al., 2015b). We performed a high-throughput screening and 
identified 81 additional miRNAs able to target and modulate - either negatively or positively - a 
reporter with the DAB2IP 3’UTR (Figure 3.3). 
 
Importantly, this screen identified miRNAs that escaped available prediction algorithms. For 
example, miR-555 was not identified by these tools, and miR-17-3p and miR-96 are predicted 
only by a few engines, and with a very low score. However, we confirmed by western blot that 
miR-555, miR-17-3p and miR-96 significantly down-regulate DAB2IP endogenous proteins in 
various cell lines (Figure 3.3C- D). 
Intriguingly, this screen also identified a consistent number of miRNAs that can up-regulate the 
DAB2IP 3’UTR reporter. We have not studied these miRNAs, but the robustness of the effect 
suggests that at least some of them can actually increase DAB2IP mRNA stability or translation. 
Examples of miRNAs able to up-regulate target mRNA translation have been reported (Orom et 
al., 2008; Vasudevan et al., 2007). For example, miRNA-369-3 directs the association between 
Ago and fragile X mental retardation-related protein 1 (FXR1) with AU-rich elements (AREs) to 
activate translation of its target mRNA (Vasudevan et al., 2007). AREs have been shown to bind 
specific proteins to regulate mRNA stability or translation in response to external and internal 
stimuli. An analogous process was observed for miR-let-7, and for a synthetic microRNA called 
miRcxc-4 (Vasudevan et al., 2007). It is therefore possible that similar mechanisms may be 
involved in positive regulation of DAB2IP translation by some of these miRNAs. It is also 
possible that miRNAs can up-regulate the DAB2IP 3’UTR reporter through indirect 
mechanisms; for example they may down-regulate proteins that bind the 3’ UTR to inhibit 
translation or stability, or they may block expression or activity of other microRNAs targeting 
DAB2IP. Characterization of the identified miRNAs potentially able to up-regulate DAB2IP 
may represent an interesting future development of this project. 
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Focusing on miRNAs that down-regulate DAB2IP, we found some known onco-miRNAs, 
including miR-96 (Chen et al., 2015; Fendler et al., 2013; Guo et al., 2014; Guo et al., 2015; 
Leung et al., 2015; Li et al., 2014b; Siu et al., 2015; Wu et al., 2015b; Xia et al., 2014; Yu et al., 
2014), and members of the miR-17-92 cluster and its paralogs, such as miR-25 and miR-92a 
(Kan et al., 2009; Li et al., 2014a; Petrocca et al., 2008b; Smith et al., 2012). Down-regulation of 
DAB2IP could thus represent an additional means through which these oncogenic miRNAs 
promote proliferation, survival, and especially motility of cancer cells. Indeed, we 
experimentally confirmed that overexpression of miR-96 down-regulates DAB2IP and increases 
prostate cancer cells invasion (Figure 3.5). 
However, we also identified tumor suppressor miRNAs; for instance miR-29c (Ding et al., 2011; 
Liu et al., 2013; Wang et al., 2011), miR-744 (Fang et al., 2015; Song et al., 2012; Tan et al., 
2015), miR-154 (Xin et al., 2014; Zhu et al., 2013a; Zhu et al., 2014), and miR-149 (Bischoff et 
al., 2014; Chamorro-Jorganes et al., 2014; Chan et al., 2014; Fujii et al., 2015; Ke et al., 2013; Li 
et al., 2015; Luo et al., 2015; Palmieri et al., 2014; Wang et al., 2012; Xu et al., 2015a; Xue et 
al., 2015). Our data suggest that by targeting DAB2IP these miRNAs can potentially exert also 
pro-oncogenic functions; therefore, their contribution to tumor progression may depend on 
biological context and availability of targets. 
 
In this Thesis, we validated and functionally characterized miR-149*. We demonstrated that this 
miRNA can significantly reduce DAB2IP protein levels by binding three specific regions in the 
3’UTR (Figure 3.8C-D). According to our experiments, site 1 is the more important for miR-
149* function; however, also sites 2 and 3 are involved in the process, indicative of functional 
redundancy. 
We used miRNA inhibitor and target protectors (TPs) to inhibit miR-149* activity, and observed 
DAB2IP protein accumulation in prostate cancer cells (Figure 3.7A and 3.8D). Importantly, 
these approaches also strongly reduced matrigel invasion, indicating that endogenous miR-149* 
contributes to DAB2IP inactivation in PC-3 cells (Figure 3.7A and 3.8E). 
Notably, our data do not demonstrate if miR-149* may have a driving role in cell transformation. 
To define its oncogenic potential, it will be necessary to overexpress miR-149* in non-
transformed prostate and mammary epithelial cells. Our prediction is that forced miR-149* 
expression would promote, or facilitate, cancer development and progression. At the same time, 
stable expression of a “miRNA sponge” construct could be used to stably inhibit miR-149* in 
tumor cells. Long-term overexpression or inhibition of miR-149* could be used to investigate its 
role in the acquisition of mesenchymal features, in three-dimensional growth of prostate cancer 
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cells in vitro (prostate spheres), and eventually in tumor growth and dissemination in vivo, 
performing xenograft experiments in nude mice. 
 
To infer oncogenic pathways or biological processes linked to miR-149*-induced invasive 
phenotype, we analyzed the transcriptional program of PC-3 cells overexpressing miR-149* or 
depleted for DAB2IP. A key involvement of NF-κB activity was predicted by this analysis 
(Figure 3.9). We experimentally confirmed that NF-κB is an essential player in increased 
invasion induced by miR-149* overexpression - or DAB2IP depletion (Figure 3.10). 
Notably, the analysis of the transcriptional landscape of cells transfected with DAB2IP siRNA 
allowed us to identify other biological processes implicated in the acquisition of oncogenic 
features upon DAB2IP inactivation. This is the first study to examine the transcriptional program 
of tumor cells depleted for DAB2IP; we observed up-regulation of genes involved in the 
unfolded protein response (UPR), epithelial to mesenchymal transition (EMT), apoptosis, K-Ras, 
p38MAP kinase, and STAT signaling. Notably, these biological processes and pathways are 
known to be somehow regulated by DAB2IP (as described in Chapter 1.2). Interestingly, we also 
observed enrichment for genes implicated in hypoxia, inflammation, and immune system 
regulation; these are possibly liked to the already mentioned pathways, or may suggest DAB2IP 
implication in additional yet undefined molecular circuits. Importantly, these hallmarks are also 
enriched in the set of genes up-regulated by miR-149* overexpression, suggesting that miR-149* 
can affect these processes through inhibition of DAB2IP.  
The role of DAB2IP in the modulation of cell response to inflammation has been described in 
endothelial cells (Huang et al., 2013; Wan et al., 2010; Yu et al., 2011), but not completely 
explored in the context of tumor development and progression. We have demonstrated that 
inhibition of DAB2IP by interaction with mutant p53 reprograms TNF-induced transcription, 
shifting the spectrum of cytokines and chemokines expressed by cancer cells from a tumor-
promoting to a pro-inflammatory and anti-tumorigenic program (Part 2 of this Thesis). Another 
recent work described the effects of DAB2IP depletion on tumor microenvironment: DAB2IP 
loss in vascular endothelial cells subverts the secretion of EMT-promoting factors in the tumor 
niche, enhancing tumor vascularization, pre-metastatic niche formation, and augmenting tumor 
growth and metastasis in mouse models of breast cancer and melanoma (Ji et al., 2015). 
Based on our data, we speculate that DAB2IP reduction mediated by miR-149* can also affect 
the inflammatory and immunogenic transcriptional program of tumor cells, in particular in 
response to inflammatory signals. We obtained results in line with this concept: expression of 
some inflammatory cytokines and chemokines (CCL20, IL8, PTX3 and CSF2) was induced in 
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PC-3 cells treated with miR-149*, both in basal conditions and after TNF-treatment (Figure 3.9 
and Figure 3.11). These secreted factors are important inducer of tumor cells invasion, and often 
predict worst survival (Cheng et al., 2014; Frick et al., 2016; Gales et al., 2013; Park et al., 2007; 
Roberti et al., 2012; Rudisch et al., 2015; Zeng et al., 2014). In the tumor microenvironment, 
these secreted factors are principally pro-metastatic, pro-angiogenic, and pro-inflammatory. 
More importantly, these factors can affect tumor recruitment and activity of immune cells. For 
example, CCL20 is known to increase the recruitment of regulatory T cells (Treg), Th17, and 
immature dendritic cells in various tumors, including hepatocellular carcinoma, cervical and 
breast cancer, sustaining escape of immune control and tumor progression (Chen et al., 2011b; 
Treilleux et al., 2004; Walch-Ruckheim et al., 2015). 
If this model is true, we predict a positive correlation between expression of this group of genes 
(a molecular signature including CCL20, CSF2, PTX3, IL8, BIRC3) and levels of miR-149* in 
tumor samples; if this is confirmed, it would be interesting to correlate this pattern of expression 
with quantity and quality of the inflammatory infiltrate, and with patients’ clinical survival. This 
model also predicts that prostate cancer cells expressing high miR-149* would secrete factors 
capable of affecting the recruitment of immune cells and modulation of their activity. Co-culture 
experiments and transwell migration assays to evaluate lymphocyte chemotaxis can be 
performed to test this hypothesis. 
 
An important open question regards the mechanisms involved in miR-149* regulation. The 
evidence of p53-dependent regulation of miR-149* upon ER stress induction in melanoma cells 
has been described (Jin et al., 2011), as well as FGF2 dependent regulation of miR-149* in 
endothelial cells (Chamorro-Jorganes et al., 2014). We performed some experiments and 
observed that FGF2 treatment does not induce miR-149* expression in our cell models (data not 
shown), indicating that these circuits might be cell-type specific. We have not tested ER-stress in 
our cells yet. 
miRNA-149 gene localizes within the very large first intron of the human glyplican-1 (GPC1) 
gene, in the same orientation. Interestingly, it is also within in the first intron of a long non-
coding RNA that overlaps the GPC1 gene in the opposite orientation; no information is available 
on this lncRNA (LOC100130449) and on its possible regulatory interaction with its antisense 
overlapping host gene – or miRNA. I anticipate that this complex gene arrangement will 
eventually prove to have some important regulatory functions, at least in some tissues or 
conditions. 
One study reported that miR-149 and miR-149* transcription is uncoupled from that of the host 
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GPC1 gene, and suggested the existence of a transcription start site (TSS) located within 3,1kb 
upstream of the miR-149 gene, also identifying three regions with various chromatin states 
indicative of gene regulatory regions (Chamorro-Jorganes et al., 2014). I think that additional 
specific studies are necessary to better characterize these regions, to confirm the existence of a 
miR-149 gene promoter within the GPC1 intron, and eventually to identify transcription factors 
potentially involved in its regulation. 
Other works identified molecular circuits involved in the regulation of miR-149 transcription. 
TNF treatment negatively modulates miR-149 transcription in a P38 MAPK dependent 
mechanism (Palmieri et al., 2014). Hypermethylation of miR-149 promoter induced by PGE2 
has been recently observed in gastric cancer associated fibroblast (Li et al., 2015). Finally a 
positive correlation between syndecan-1 and miR-149 has been detected in androgen-
independent prostate cancer cell lines (i.e. PC-3) (Fujii et al., 2015). 
Clearly, mechanisms controlling miR-149* expression, in particular in prostate cancer cells, are 
of great interest to understand its potential impact in cancer. I am particularly intrigued by the 
possibility of a negative feedback loop between TNFα and miR-149*, and DAB2IP, as this could 
strongly impact cell-autonomous and non-autonomous responses of cancer cells to inflammatory 
tumor microenvironment. Also PGE2 could be involved in this regulatory circuit, with strong 
impact on the crosstalk between tumor and stromal cells. 
 
An intriguing aspect emerging from this study is the opposite effect observed for miR-149 and 
miR-149* in tumor cells. While miR-149 has tumor suppressive functions in multiple human 
malignancies, our work revealed novel tumorigenic properties for miR-149*. Notably, although 
both of the miRNAs can target DAB2IP, they have significantly different effects on cell motility. 
Indeed, miR-149 expression did not affect prostate and breast cancer cell invasion (Figure 3.6A-
C) This may be explained by the fact that this miRNA has a weaker effect on DAB2IP levels 
reduction than miR-149* (Figure 3.3C-D and 3.6B-C). However, we should also consider that 
miR-149 can down-regulate various proteins controlling cell-migration in tumors (Bischoff et 
al., 2014; Chan et al., 2014; Ke et al., 2013; Luo et al., 2015; Xu et al., 2015a), and this could 
potentially counteract the metastatic phenotype triggered by DAB2IP depletion. 
Together, these observations suggest that the miR-149 gene encodes two miRNAs that can have 
an opposite impact on cell behavior, potentially affecting tumor progression and aggressiveness.  
Notably, the miR-149* levels in primary tumors and normal tissue is very low, if compared with 
the guide strand, which seems to be easily detected and highly expressed (Figure 3.12).  
However, miR-149* is differentially expressed between normal and tumor tissue in prostate, 
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breast and lung squamous cell carcinoma (Figure 3.12). Data from the GSE21032 study (Taylor 
et al., 2010) confirmed these observations. In particular, the expression of miR-149* is strongly 
increased in metastatic lesions, at least in prostate cancer (Figure 3.5A). These data suggest that, 
where its expression and stability are augmented, miR-149* may promote acquisition of a more 
aggressive phenotype, increasing the metastatic potential of tumor cells - probably even better 
than miR-149 silencing or genetic deletion. This is an interesting hypothesis that will require 
further consideration, initially through the scrutiny of additional public gene expression datasets. 
The molecular parameters controlling pri- and pre- miRNA processing, as well as co-
factors involved in the assembly on miRISC, can deeply impinge on the choice between one 
strand and the other. It is possible that deregulation of these factors in human tumors can 
increase the stability of the oncogenic miR-149*, facilitating its loading on miRISC, while 
increasing the degradation of tumor-suppressive miR-149, dictating the acquisition of oncogenic 
features. A molecular understanding of the parameters involved in this aspect could significantly 
increase our comprehension of the role of miR-149/miR-149* on carcinogenesis. 
 
To conclude, in this part of my PhD I identified and validated novel microRNAs able to target 
DAB2IP and modulate its expression levels in tumor cells. I collected convincing evidences for 
an oncogenic role of miR-149* in prostate cancer; I found that its overexpression in tumor and 
metastatic cells strongly augments invasive ability through the reduction of DAB2IP levels and 
the sustained activation of a specific NF-κB transcriptional program. 
Importantly, I found that inhibition of endogenous miR-149* activity restores DAB2IP protein 
functions and counteracts invasivity in a prostate cancer cell line model, suggesting possible 
applications of this strategy in tumor therapy. Intriguingly, miR-149*-mediated DAB2IP 
reduction seems to be involved in the regulation of an inflammatory transcriptional program, 
which includes pro-angiogenic, pro-metastatic, and immunogenic factors. Expression and 
secretion of these inflammatory factors in the tumor microenvironment, sustained by miR-149*, 
could significantly affect the crosstalk between tumor and immune cells, with a possible relevant 
impact on tumor progressions and patient survival. 
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3.5 EXPERIMENTAL PROCEDURES 
Cell Culture, Transfections, Retroviral Transductions and treatments 
Cell Culture. PC-3, LNCaP, OVCAR-3, TOV112 and H1299 were cultured in RPMI medium 
(Sigma) supplemented with 10% FBS (ECS0180L, Euroclone), and antibiotics (ECB3001D, 
Euroclone). HeLa, SKOV-3, HCT116, MDA-MB-231, MDA-MB-468, were cultured in DMEM 
medium (Sigma) supplemented with 10% FBS, and antibiotics. HepG2 and MCF-7 were 
cultured in EMEM (Sigma) supplemented with MEM Non-essential Amino Acid Solution 
(Sigma), 10% FBS, and antibiotics. MCF10A cells were maintained in DMEM:F12 Ham’s 
medium 1:1, supplemented with 5% horse serum (HS), insulin (10 µg/ml), hydrocortisone (0.5 
µg/ml) and epidermal growth factor (EGF 20 ng/ml). PWRE and RWPE were cultured in 
Keratinocyte Serum Free Medium (K-SFM) (Invitrogen), supplemented with bovine pituitary 
extract (BPE 0.05 mg/ml) and epidermal growth factor (EGF 5 ng/ml).	  All human cell lines were 
subjected to STR genotyping with PowerPlex 18D System and confirmed in their identity 
comparing the results to reference cell databases (DMSZ, ATCC, and JCRB databases). 
Transfections. For the high-throughput screening, miRIDIAN microRNA Library packaged in 
96-well plates was purchased from Dharmacon. HeLa cells were plated in these 96-well plates; 
the day after they were transfected with Fugene (Promega), following manufacturer’s 
instructions.  
For siRNA, miRNAs, miRNA inhibitors and Target Protectors transfections, cells were plated 
and transfected the day after with 50 nM siRNA oligonucleotides, 3nM miRNAs mimics, 20nM 
miRNAs hairpin inhibitors and Target protectors, using Lipofectamine RNAiMax (Invitrogen), 
following manufacturer’s instructions. After 48 hours of silencing, cells were processed.  
siRNAs, used in this work are listed in the following table: 
 
 
 
 
 
 
 
 
siRNA Sequence Purchase from/  
Reference 
Control siRNA  (siC) Unknown All star negative control 
(1027281,Qiagen) 
siDAB2IP A GGAGCGCAACAGUUACCUG Eurofins MWG 
siDAB2IP B GGUGAAGGACUUCCUGACA Eurofins MWG 
siDAB2IP 3’UTR GUAAUGUAACUAUCUCACC Eurofins MWG 
sip65 GCCCUAUCCCUUUACGUCA Eurofins MWG 
	 138	
Human miRNA mimics and Hairpin Inhibitors were purchased from Dharmacon. 
 
Catalog Number Mature Accession Mature Name Mature Sequence 
C-301151-01 MIMAT0004609 hsa-miR-149-3p AGGGAGGGACGGGGGCUGUGC 
C-300486-05 MIMAT0000071 hsa-miR-17-3p ACUGCAGUGAAGGCACUUGUAG 
C-300498-05 MIMAT0000081 hsa-miR-25-3p CAUUGCACUUGUCUCGGUCUGA 
C-301089-01 MIMAT0004748 hsa-miR-423-5p UGAGGGGCAGAGAGCGAGACUUU 
C-300873-01 MIMAT0003219 hsa-miR-555 AGGGUAAGCUGAACCUCUGAU 
C-300901-01 MIMAT0003247 hsa-miR-582-5p UUACAGUUGUUCAACCAGUUACU 
C-301251-01 MIMAT0004957 hsa-miR-760 CGGCUCUGGGUCUGUGGGGA 
C-300510-05 MIMAT0000092 hsa-miR-92a-3p UAUUGCACUUGUCCCGGCCUGU 
C-300872-03 MIMAT0003218 hsa-miR-92b-3p UAUUGCACUCGUCCCGGCCUCC 
C-300514-07 MIMAT0000095 hsa-miR-96-5p UUUGGCACUAGCACAUUUUUGCU 
C-300631-07 MIMAT0000450 hsa-miR-149 UCUGGCUCCGUGUCUUCACUCCC 
C-300633-03 MIMAT0000452 hsa-miR-154 UAGGUUAUCCGUGUUGCCUUCG 
IH-301151-02-
0002 
MIMAT0004609 hsa-miR-149-3p Unknown 
IN-001005-01-05 Hairpin Inhibitor Negative Control Unknown 
 
miScript Target Protectors and negative control Target Protector  were purchased from Qiagen.  
 
Assay Name Catalog Number Target binding site sequence provide/Sequence: 
Neg. Control Target 
Protector 
MTP0000002 Unknown 
Target Protector DAB2IP 1 MTP0076757 5’TGCTGGAGAAAGCCACGCCCTCCCTGCTAG
3’ 
Target Protector DAB2IP 2 MTP0076750 5’CTCTTCTCTCCCCAGCCCCCTCCCACCGCT3’ 
Target Protector DAB2IP 3 MTP0076743 5’TTCTGTAGCTTATCTGCCCCTCCCCCACTT3’ 
 
 
Retroviral Transductions. For retrovirus production, low confluence (≈20%) 293GP packaging 
cells, stably expressing retroviral gag and pol proteins, were transfected by calcium-phosphate 
precipitation. Briefly, cells were plated the day before the transfection in 10 cm2 dishes in 
exactly 10 ml of medium. Each different virus was produced by co-transfection of 10 µg of the 
vector of interest and 5 µg of pEnv encoding vector. After 8 hours, medium was changed and 
cells were incubated at 37°C. After 48-72 hours the virus-containing medium was filtered (0.45 
µm filter) and supplemented with 10% FBS and polybrene (8 ug/ml). The culture medium of 
target cells growing at low confluence (≈30-40%) was replaced by the appropriate viral 
supernatant and incubated at 37°C for 24 hours. Cells were selected with puromycin (0.5 µg/ml) 
and kept under selection for the entire experiment. 
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Lentiviral Transductions. For Lentivirus production HEK-293T cells were transfected with the 
packaging plasmids and the plasmid construct of interest, using standard calcium-phosphate 
method. After 8 hours, medium was changed and cells were incubated at 37°C. After 48 hours, 
the supernatants containing viral particles were filtered (0.45 µm filter), supplemented with 10% 
FBS and polybrene (8ug/ml). The culture medium of target cells growing at low confluence 
(≈30-40%) was replaced by the appropriate viral supernatant and incubated at 37°C for 24 hours. 
Cells were selected with puromycin (0.5 µg/ml) and kept under selection for the entire 
experiment. 50 ng/ml of Doxycycline has been used to induce shRNA expression and DAB2IP 
protein knockdown. 
 
Treatments. Human TNFα was purchased from Invitrogen (PHC3015). Cells were treated with 
recombinant TNFα (10ng/ml) in low serum (0.1% FBS) for 20 hours. 
 
Plasmids 
psiCHECK2 DAB2IP 3’UTR was generated by amplifying DAB2IP 3’UTR (NM_032552.2) 
from genomic DNA extracted from H1299 cells and subsequently cloning it into psiCHECK2 
(Promega) downstream of Renilla Luciferase reporter gene, between NotI and XhoI restriction 
sites.  
pLKO-shDAB2IP plasmid was generated by cloning in the pLKO lentiviral vector a double 
stranded oligonucleotide corresponding to the sequence of siDAB2IP 3’UTR. 
pLPC-DAB2IP-long was obtained by cloning mouse DAB2IP (mDAB2IP) transcript variant 1 
(NM_001114125.1) into pLPC empty vector. pLPC-DAB2IP-short was generated by amplifying 
DAB2IP-long coding region using specific primers starting from nucleotide 404 of mDAB2IP 
transcript variant 1 sequence, and cloning it into pLPC empty vector. 
 
Cell manipulation and Western blot analysis 
Total cell extracts were prepared in RIPA buffer without SDS (150mM NaCl, 50mM Tris-HCl 
pH8, 1mM EDTA, 1% NP-40, 0.5% Na-deoxycholate) supplemented with 1 mM PMSF, 5 mM 
NaF, 1 mM Na3VO4, 10µg/ml CLAP, 1µM TSA and 5µM nicotinamide. Protein concentration 
was determined with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Lysates were 
resolved by SDS/PAGE and transferred to nitrocellulose (Millipore). 
Western blot analysis was performed according to standard procedures using the following 
primary antibodies: 
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Anti-goat, anti-mouse and anti-rabbit HRPO-conjugated (Sigma), were used as secondary 
antibodies. 
 
Nucleus-cytoplasm fractionation  
Cells were washed two times in PBS and scraped in Cytoplasmic-buffer (10mM HEPES pH7.9, 
1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.1% NP-40) supplemented with inhibitors (1mM 
PMSF, 5mM NaF, 10mg/ml CLAP, 1mM Na3VO4); lysis was obtained gently pipetting a 
couple of times. After 3 minutes in ice, lysates were centrifuged at 2500g for 5 minutes at 4°C; 
the supernatant was collected as the cytoplasmic fraction. The pellet was washed twice in Wash-
buffer (10mM HEPES pH7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT) and then Nuclei in the 
pellet were resuspended in Nuclear-buffer (20mM HEPES pH7.9, 1.5mM MgCl2, 420mM NaCl, 
0.2mM EGTA, 0.5mM DTT, 25% glycerol) supplemented with inhibitors (1mM PMSF, 5mM 
NaF, 10mg/ml CLAP, 1mM Na3VO4); after 30 minutes of incubation in ice, nuclear extract was 
recovered by centrifugation at 15000g for 15 minutes at 4°C. 
 
Immunofluorescence 
Cells were washed two times with PBS and fixed in 4% paraformaldehyde at room temperature 
for 20 minutes. The fixed cells were then permeabilized in PBS plus 0.1% Triton X-100 at room 
temperature for 5 minutes. Permeabilized cells were incubated with primary antibodies for 1 
hour at room temperature. The coverslip was then washed three times PBS before incubation 
with secondary antibodies (Alexa Fluor® 568, 488 conjugated secondary antibodies - Life 
Technologies) for 1 hour, and then incubated 5 minutes with Hoecst. Each coverslip was 
prepared for microscopic examination by applying mounting medium (ProLong Gold antifade 
reagent, Life Technologies). Images were captured using a Leica DM4000B epifluorescence 
microscope. 
 
RNA extraction and RT-qPCR  
Total RNA was extracted with QIAzol (Qiagen) following manufacturer’s instructions.  
For mRNA expression analysis, 1µg of total RNA was reverse-transcribed with QuantiTect 
Target Antibody 
Actin #A9718 (Sigma) 
DAB2IP  A302-440A (Bethyl) 
Tubulin T5168 (Sigma) 
p65 RelA sc-372X (Santa Cruz) 
Lamin A/C sc-6215 (Santa Cruz) 
Vimentin ab8069 ( (Abcam) 
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Reverse Transcription (Qiagen). DAB2IP, CCL20, IL8, PTX3, BIRC3, CSF2 and the 
housekeeping gene control H3 were amplified SsoAdvancedTMSYBR® Green Master Mix 
(Biorad) on a CFX96™ Real-Time PCR System (Biorad).  
For microRNAs expression analysis, 1ug of RNA was retro-transcribed with miScript PCR 
System (Qiagen). miR-149*, miR-149, the other microRNAs studied  and the housekeeping gene 
control U6B and SNORD25 small nuclear RNAs were amplified with miScript SYBR Green 
PCR kits (Qiagen), following manufacturer’s instructions on a CFX96™ Real-Time PCR 
System (Biorad).  
 
List of primers used: 
Target Sequence 
DAB2IP Fw: 5’CACATCACCAACCACTAC3’ 
Rev: 5’TCCACCTCTGACATCATC3’ 
CCL20 Fw: 5’	  CAGTGCTGCTACTCCACCTC3’ 
Rev: 5’	  AAAGTTGCTTGCTGCTTCTGA3’ 
CSF2 Fw: 5’AATGTTTGACCTCCAGGAGCC3’ 
Rev: 5’TCTGGGTTGCACAGGAAGTT3’ 
IL8 Fw: 5’GGCAGCCTTCCTGATTTCTG3’ 
Rev: 5’CTTGCCAAAACTGCACCTTCA3’ 
PTX3 Fw: 5’ GCGGTGCTAGAGGAGCTG3’ 
Rev: 5’ GCCTCATTGGTCTCACTGGA3’ 
BIRC3 Fw: 5’ AGCTGAAGCTGTGTTATATGAGC3’ 
Rev: 5’ ACTGTACCCTTGATTGTACTCCT3’ 
H3 Fw: 5’GAAGAAACCTCATCGTTACAGGCCTGGT3’ 
Rev: 5’CTGCAAAGCACCAATAGCTGCACTCTGGAA 3’ 
 
Assay Name Official Symbol Catalog Number Purchase from 
Hs_SNORD25_11 SNORD25 MS00014007 Qiagen 
Hs_RNU6B_13 RNU6B MS00014000 Qiagen 
Hs_miR-149_1 MIR149 MS00003570 Qiagen 
Hs_miR-149*_3 MIR149 MS00037702 Qiagen 
Hs_miR-1282 MIR1282 MS00014462 Qiagen 
Hs_miR-92b MIR92B MS00032144 Qiagen 
Hs_miR-92_1 MIR92A1 MS00006594 Qiagen 
Hs_miR-154_1 MIR154 MS00003598 Qiagen 
Hs_miR-744 MIR744 MS00010549 Qiagen 
Hs_miR-96_1 MIR96 MS00003360 Qiagen 
Hs_miR-25_1 MIR25 MS00003227 Qiagen 
Hs_ miR-555_1 MIR555 MS00004655 Qiagen 
Hs_ miR-582_1 MIR582 MS00004844 Qiagen 
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Migration and invasion assays 
 For transwell migration assays, cells (1x105) were plated on 24 well PET inserts (8.0 µm pore 
size, Falcon). After 18 hours, cells that passed through the filter were fixed in 4% PFA, stained 
with 0.05% crystal violet and counted. 
For invasion assays, cells (0.5-1x105) were plated on 24 well PET inserts (8.0 µm pore size, 
Falcon) coated with BD MatrigelTM (BD Bioscience). Cells that passed through the matrigel-
coated filter were fixed, stained, and counted after 20 hours. Specifically, for both invasion and 
transwell migration assays, cells were seeded on filters in low serum (0.1% FBS); the lower 
chamber was filled with high serum medium (10% FBS). MCF-10A cells were seeded on filter 
in low serum (0.05% HS), with the addiction of insulin (10 µg/ml), hydrocortisone (0.5 µg/ml) 
and epidermal growth factor (EGF 20 ng/ml); the lower chamber was filled with high serum 
medium (5% HS), with the addiction of insulin (10 µg/ml), hydrocortisone (0.5 µg/ml) and 
epidermal growth factor (EGF 20 ng/ml). 
 
Statistical Analysis 
In all graphs data are expressed as mean ± SD of three independent experiments, except when 
otherwise indicated. Differences were analyzed by Student’s t test using Prism 6 (GraphPad), 
except when otherwise indicated. P-values < 0.05 were considered significant. 
 
Microarray Hybridization and Analysis 
For gene profiling, we used the Illumina HumanHT-12-v4-BeadChip (Illumina), which includes 
a bead pool of more than 48,000 unique bead types corresponding to 40,876 transcripts. Total 
RNA (2µg) isolated from PC-3 cells expressing control siRNA (siC), siRNA for DAB2IP 
(siDAB2IP), or miR-149* mimic were reverse transcribed and amplified according to standard 
protocols and in vitro transcription was then carried out to generate cRNA. cRNA was 
hybridized onto each array (three replicates for each condition) and then labeled with Cy3-
streptavidin (Amersham Biosciences). The array was then scanned using a BeadStation 500 
system (Illumina). The probe intensities were calculated and normalized using GenomeStudio 
Data Analysis Software’s Gene Expression Module (GSGX) Version 1.9 (Illumina). Further data 
processing was performed in the R computing environment (http://www.r-project.org/) version 
3.2.2, with BioConductor packages (http://www.bioconductor.org/). Statistical analysis for 
differentially expressed genes was performed with limma (Smyth, 2004). P-values were adjusted 
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for multiple testing using Benjamini and Hochberg's method to control the false discovery rate 
(Hochberg and Benjamini, 1990). 
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